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With the increasing life expectancy, the global aging population is expanding 
rapidly in the last few decades. In some cases, aging is accompanied by 
neurodegenerative diseases, such as Alzheimer’s Disease (AD) and dementia. 
Early clinical intervention is crucial for the management and prognosis of AD 
patients as there is no cure for the disease thus far. However, the lack of specific 
and accurate biomarkers for its accurate diagnosis hinders the early clinical 
diagnosis and intervention of AD. In addition, the discovery and development of 
novel effective therapies for AD necessitate the use of reliable efficacy biomarker 
to facilitate and accelerate the clinical studies. Mass spectrometry (MS)-based 
metabonomics provides an important platform for the metabolic profiling of 
complex biological samples, which may lead to the discovery of biomarkers for the 
diagnosis of diseases.  
In this thesis, both non-targeted metabolic and targeted steroidal biomarker 
profiling of aging and AD were investigated using in vivo and in vitro models. The 
first objective was to characterize the global metabolic fluxes associated with aging 
and AD using GC/MS-based metabonomics and multivariate data analysis. Lister 
Hooded (LH) rat (2-month vs 2-year) and C57BL/6J mouse (1-month vs 5-month) 
models were analyzed using GC/MS to identify the small molecule metabolite 
markers of aging. In addition, both young and aged LH rats were treated with α-
lipoic acid, and their metabolic profiles were investigated and compared. To 
identify the metabolite markers of AD, the metabolic profiles of two transgenic AD 
mouse models, TASTPM and p25-induced mice, were examined and compared to 
those of wild type C57BL/6J mice. Moreover, an in vitro cortical neuron cell 
 x 
model was involved to investigate the changes in metabolic profiles associated 
with aging and glutamate-treatment, which may be implicated in the pathogenesis 
of AD.  
As endogenous steroid levels were found to be associated with aging and AD, the 
brain and plasma samples obtained from our animal models were further 
investigated for endogenous steroids using enzyme immunoassay. In addition, MS-
based analytical techniques for the profiling of endogenous steroids in biological 
samples were investigated and compared.  
Our study demonstrated clear differences in metabolic profiles associated with 
aging and AD in both in vivo and in vitro models. A number of metabolites were 
found to be associated with the aging process and AD, with different markers 
being observed between different aging and AD animal models. In addition, the 
levels of endogenous steroids in brain and plasma of the animal models were found 
to be modified with aging and AD. While interesting and pertinent data were 
generated based on the MS-based assays for steroid analysis, none of the 
investigated methods was found to be suitable for the endogenous steroid profiling 
in complex biological samples. Our results suggested collectively that small 
molecule metabolites and steroids are promising biomarkers for the future study of 
aging and diagnosis of AD.  
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CHAPTER 1 GENERAL INTRODUCTION 
In this chapter, an overview on aging and neurodegenerative diseases is provided. 
Alzheimer’s disease (AD), including its etiology, pathology, diagnosis and clinical 
interventions are also discussed. In addition, the scopes of biomarker discovery, 
particularly the metabonomic profiling techniques, are presented. Finally, the 
clinical roles of endogenous steroids in neurodegeneration and the associated 
analytical methods for their detection are discussed. 
1.1 AGING AND NEURODEGENERATIVE DISEASES 
The world’s population continues to age, characterized by growth in both the 
number and proportion of older people. Currently, 10% of the world’s population 
is 60 years or above, and it is predicted that this number will increase to 20% by 
2050. In some developed countries, the proportion of older people is already 25%, 
and will be close to 50% by 2050 [1, 2]. In the United States, there will be 71 
million older adults by 2030, accounting for roughly 20% of the population [3]. In 
Singapore, currently 7% of the population is over the age of 65, however, it will 
increase to 19% by 2030 [4].  
Aging is a progressive, inevitable process partially related to the accumulation of 
oxidative damage of biomolecules, such as nucleic acids, lipids, proteins or 
carbohydrates, due to the disturbance of the prooxidant-antioxidant balance of the 
biological system [5]. Brain aging has become an area of intense research, as 
oxidative stress in brain is emerging as a potential causal factor in aging and age-
associated neurodegenerative diseases [6-11].  
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Neurodegenerative diseases are amongst the most common and most disabling of 
all diseases. Resulted from premature progressive degeneration of specific neurons, 
neurodegenerative diseases are characterized by progressive dysfunction and death 
of specific populations of neurons, and manifest as syndromes with varied 
combinations of cognitive, motor, sensory and autonomic dysfunctions [12]. The 
most common of these age-associated chronic illnesses are AD, Lewy body 
diseases such as Parkinson’s disease (PD), Huntington’s disease (HD), Prion 
disease and amyotrophic lateral sclerosis (ALS) [12]. Although several factors 
appear to underlie the pathological depositions, the cause of neuronal death in each 
disease appears to be multifactorial. Current therapies provide only symptomatic 
relief, while none significantly alter the course of disease [12].  
1.2 AD 
Following the general briefing of aging and neurodegenerative diseases, a specific 
introduction on AD including its prevalence, etiology and pathology, diagnosis and 
treatment will be presented here. In addition, biomarkers for the diagnosis and 
progress monitoring of AD will be highlighted.  
AD is a degenerative brain syndrome, characterized by loss of neurons and 
synapses resulting in cognitive impairment and a progressive decline in memory, 
thinking, comprehension, calculation, language, learning capacity and judgment 
leading to dementia and finally death [13, 14]. In 1906, Alois Alzheimer presented 
a hallmark paper at a meeting, describing the clinical and neuropathological 
characteristics of the disease in a 51-year-old woman that was subsequently named 
after him [15]. One hundred years later, AD is the most common 
neurodegenerative disease and cause of dementia in old population. It accounts for 
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at least two thirds of all dementias, more than dementia with Lewy bodies and 
vascular dementia combined [16].  
1.2.1 Prevalence of AD  
The prevalence of AD is increasing with the highest rate in the advanced age 
population over 75-years old. A recent study clearly illustrated the importance of 
age on cognitive impairment and development of AD [17]. The results suggested 
that both cognitive impairment and AD developed dramatically with age after 85, 
even if the subject is considered in optimal health. In addition, patients with AD 
are predicted to increase markedly as the proportion of people surviving well into 
old age continues to rise. It is estimated by World Health Organization (WHO) that 
there are currently about 18 million people worldwide with AD, and this figure is 
projected to nearly double to 34 million by 2025 due to the aging population. In the 
United States, approximately 4.5 million people are suffering from AD [3, 18] 
now, while the prevalence grows exponentially [19]. The number of people with 
AD is estimated to reach 7.7 million in 2030, and 11-16 million by 2050, unless 
science finds a way to prevent or effectively treat the disease [18, 20].  
1.2.2 Etiology and pathology of AD 
AD is characterized by two pathological features: regional accumulation of 
extracellular deposits of senile plaque (SP) largely made up of β-amyloid (Aβ) 
peptide in the cerebral cortex and intracellular neurofibrillary tangle (NFT) mainly 
deriving from hyperphosphorylated cytoskeletal protein tau (P-tau) [21-23]. Both 
of the two features are caused by the misfolding and gradual conversion of highly 
soluble proteins into insoluble filamentous polymers [24, 25]. In addition, the 
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brains of AD patients develop significant synapse loss and neuronal cell death 
particularly affecting associative cortical areas [26-30]. Recent studies indicate that 
loss of synaptic function resulting in cognitive impairment may actually precede 
the more oblivious brain pathology of plagues and tangles [31, 32]. Two genes 
have been implicated in this form of AD: the amyloid precursor protein (APP) 
gene [33], which encodes the Aβ peptide; and the presenilin (PS) protein genes, 
which encode transmembrane proteins [34, 35].  
1.2.2.1 Amyloid protein hypothesis  
The observations in early pathological and genetic studies have led to the 
prevailing amyloid cascade hypothesis that AD is initiated by Aβ-peptide 
accumulation leading to neuronal toxicity [36-41]. Genetic evidence from cases of 
familial AD indicates that Aβ metabolism is linked to the disease [42, 43]. AD is 
characterized by the deposition of amyloid plaques, the major constituent being the 
Aβ that is cleaved from the membrane-bound APP [44-46]. Aβ, a 40- to 42-amino 
acid peptide, is derived from β- and δ-secretase-mediated cleavage of the longer 
APP [46]. Metabolism of APP generates a variety of Aβ species, predominantly a 
40-amino acid peptide, Aβ 1-40, with a smaller amount of a 42-amino acid peptide, 
Aβ 1-42. This latter form of the peptide is more prone to forming amyloid deposits. 
Mutations in all the pathogenic genes alter the processing of APP such that a more 
amyloidogenic species of Aβ is produced [47]. According to the amyloid cascade 
hypothesis, the process of Aβ deposition is intimately connected to the initiation of 
AD pathogenesis, and all the other features, the tangles and the cell and synapse 
loss, are secondary to this initiation [48]. The gene confirmed to confer increased 
risk for typical, late-onset AD is the apolipoprotein E4 (ApoE4) allele [49]. ApoE 
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gene knockouts have been shown to prevent Aβ deposition [50], consistent with 
the amyloid cascade hypothesis. ApoE4 is more susceptible than ApoE3 to 
proteolytic cleavage and is thus more likely to cause detrimental effects in the 
central nervous system (CNS). It is predictable that ApoE4 acts through various 
pathways to cause cognitive decline and neurodegeneration [51]. Other genes 
predisposing to AD are being sought, and it seems most likely that they also act by 
alteration of Aβ metabolism [52, 53]. These findings suggest that Aβ metabolism is 
the key pathway to be targeted for therapy, and there has been much progress in 
this arena with transgenic mice that develop plaque pathology [54]. Immunization 
of these transgenic mice with Aβ results in a reduction in pathology and better 
performance in behavioral tests, providing evidence that Aβ-directed therapy may 
be clinically relevant [55]. Immunization may not turn out to be a practical 
approach to therapy, but the results of these animal studies have been an important 
proof of principle [56]. In addition, Aβ 1-42 has been shown to induce oxidative 
stress and neurotoxicity [57-62]. Genetic mutations that result in increased 
production of Aβ 1-42 from APP are associated with an early onset and accelerated 
pathology of AD. Consequently, Aβ 1-42 has been proposed to play a central role in 
the pathogenesis of AD as a mediator of oxidative stress [63].  
Although Aβ cascade hypothesis is prevailing, some studies proposed opposite 
view that Aβ represents an initiator of disease pathogenesis. Lee et al. argued that 
Aβ occurs secondary to neuronal stress. Moreover, Aβ functions as a protective 
adaptation to the disease rather than causing cell death [64].  
1.2.2.2 NFT hypothesis 
 6 
NFT is one of the neuropathological hallmarks of AD, described early as part of 
the pathological criteria of the disease [65-69]. In 1963, the paired helical filament 
(PHF) was identified as the major component of the neurofibrillary pathology of 
AD [70]. In 1988, its molecular composition was proven that tau protein is an 
integral component of the PHF [71]. By the early 1990s, it was clear that tau 
protein is the major component of the PHF and that the latter comprises all six tau 
isoforms, each full-length and hyperphosphorylated [72]. Further studies were 
devoted to the analysis of tau post-translational modifications in the affected 
tissues and in cellular and animal models [73]. 
1.2.2.3 Risk factors of AD 
The dominant risk factor associated with the neurodegenerative diseases is 
increasing age. Although the above described factors appear to underlie the 
pathological dispositions, the causes of AD are reported to be multifactorial.  
Glutamate 
Glutamate is the most ubiquitous and major excitatory neurotransmitter of the 
cerebral cortex and hippocampus and it appears to have an important role in 
learning and memory. In addition to its transmitter function, glutamate is a 
neurotoxin that has been implicated in the pathogenesis of a variety of 
neurodegenerative disorders including AD as a key factor [74]. It has been shown 
that, glutamate induces different types of neuronal death including necrosis and 
apoptosis in vitro [75], which are known to occur during the course of 
neurodegeneration observed in AD [76]. Glutamate binds to post-synaptic 
ionotropic receptors, stimulating an influx of cations to depolarize the post-
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synaptic cell. Glutamate must then be quickly and efficiently removed from the 
synaptic cleft by high-affinity transporters to prevent receptor over-stimulation. 
Perturbations of glutamate neurotransmission have severe consequences. 
Prolonged elevation of the extracellular glutamate level tonically activates 
glutamate receptors, causing sustained local depolarization of neurons, which in 
turn triggers a sequence of intracellular events that culminate in Na+ and Ca2+ 
influx and further exocytosis of glutamate. Ca2+ influx leads to delayed necrosis of 
the neuron, and to a lesser extent activation of apoptotic pathways. Continuing 
release of glutamate leads to a spreading of the process [77], which is termed 
excitotoxicity. Excitotoxicity resulting from excessive activation of N-methyl-D-
aspartate (NMDA) receptors may enhance the localized vulnerability of neurons in 
a manner consistent with AD neuropathology and may be involved in neuronal loss 
in AD [78]. Glutamate was found to be elevated in the cerebrospinal fluid (CSF) of 
AD patients [79]. In summary, the capacity of glutamate to be highly toxic, yet 
necessary for neurotransmission, sets a fine balance between plasticity and 
pathology. Glutamate toxicity and glutamatergic dysfunction play important roles 
in the pathogenesis of AD. 
Glycogen synthase kinase-3 (GSK-3) 
GSK-3 is a pivotal molecule in the development of AD [80]. GSK-3β is involved 
in the formation of PHF-tau, which is an integral component of the NFT deposits 
that disrupt neuronal function, and a marker of neurodegeneration in AD [81]. 
These results strongly suggest that GSK-3 activation is a critical step in brain aging 
and the cascade of detrimental events in AD, preceding both the NFT and neuronal 
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death pathways. Therefore, therapeutics targeted to inhibiting GSK-3 may be 
beneficial in the treatment of this devastating disease [82]. 
Cholesterol  
Cholesterol and its oxidative derivatives such as 24S-hydroxycholesterol have been 
reported to be relevant to the development of AD [83]. A high cholesterol levels in 
mid-life is a risk for AD [84-86]. In addition, plasma 24S-hydroxycholesterol 
(cerebrosterol) is increased in AD and vascular dementia patients [87, 88].  
Inflammation 
Inflammation has been reported in numerous neurodegenerative disorders 
including AD [89-92]. In AD, the inflammatory response is mainly located to the 
vicinity of amyloid plaques. Cytokines, such as interleukin-1 (IL-1), interleukin-6 
(IL-6), tumor necrosis factor α (TNF-α) and transforming growth factor β (TGF-β) 
have been clearly involved in this inflammatory process. Although their expression 
is induced by the presence of Aβ, these cytokines are also able to promote the 
accumulation of Aβ peptide. Altogether, IL-1, IL-6, TNF-α and TGF-β should be 
considered as key players of a vicious cycle leading to the progression of the 
disease [90, 93].  
Cardiovascular diseases 
Recently, several studies demonstrated the associations between cardiovascular 
disease and its risk factors and the incidence of AD [94-97]. Previous study 
examined the evidence linking chronic brain hypoperfusion (CBH) produced by 
several types of heart disease and stroke on the development of AD. The evidence 
suggested that CBH is responsible for protein synthesis defects that later result in 
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the classic AD neurodegenerative lesions such as the formation of excess beta-
amyloid plaques and NFT [98]. In addition, several studies reported that blood 
pressure is increased in victims of AD decades before the onset of the disease [99-
102].  
Diabetes 
Currently, the existence of links between AD and diabetes is an important topic 
under active debate. AD is associated with peripheral and central insulin 
abnormalities, while cognitive capacities are often impaired in patients with 
diabetes [103-107]. The increased occurrence of insulin resistance in AD suggests 
that improving insulin effectiveness may have therapeutic value in AD patients and 
therefore is worth intensive investigation [103]. A novel hypothesis was proposed 
that the impaired glucose uptake/metabolism contributes to AD by facilitating 
abnormal hyperphosphorylation of tau [108].  
Glutathione (GSH) 
Furthermore, the concentration of GSH, the most abundant intracellular nonprotein 
thiol and important antioxidant, declines with age and in some age-related diseases, 
and the decreased GSH content may be involved in AD pathology in humans 
[109].  
Vitamin E and C 
As oxidative stress plays an important role in the pathogenesis of AD, the high 
levels of oxidizable lipids in the brain must be protected by antioxidants. Vitamin 
E is one of the major lipophilic antioxidants in the brain. Recently, the combination 
use of vitamin E and C supplements was found to reduce the prevalence and 
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incidence of AD in elderly population [110], as well as the susceptibility of CSF 
lipoproteins to in vitro oxidation [111]. In addition, vitamin E reduced lipid 
peroxidation and amyloid deposition in a transgenic mouse model of AD [112]. 
These data suggested that vitamin E may be effective against in vivo oxidation of 
CSF lipoproteins and brain lipids, and offer new perspectives in the treatment of 
AD and other neurodegenerative disorders [111].  
Metal ions  
Several studies in mice have shown that one of the consequences of normal aging 
is a rise in the levels of copper and iron in brain tissue [113-115]. The brain is an 
organ that concentrates metal ions and recent evidence suggests that a breakdown 
in metal homeostasis is a key factor in a variety of age-related neurodegenerative 
diseases [116]. 
1.2.3 Diagnosis of AD 
There are no proven treatments that delay the onset or prevent the progression of 
AD, although a few promising candidates are under development. Thus, it is 
critical to identify individuals with “preclinical AD” prior to the development of 
clinical symptoms and concomitant neuronal loss, so that therapies will have the 
greatest clinical impact. Unfortunately, there is hitherto no single satisfactory 
biological marker for preclinical AD, which is difficult to diagnose in its early 
stages. Definitive diagnosis of AD can only be performed by examining the 
neuropathological features of the disease-amyloid plaques and NFT at autopsy 
[117]. Additionally, there is a considerable overlap in the phenotypes of disease 
between AD and other pathologic conditions.  
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Currently, the clinical diagnosis rates of AD are generally low, averaging around 
60% in developed nations, but vary widely according to healthcare policies and 
guidelines in different countries. A diagnosis of AD can be made with reasonably 
high accuracy using a combination of clinical criteria, neuropsychologic testing, 
and conventional neuroimaging.  
1.2.3.1 Cognitive test 
In developed countries, primary care is the point of initial diagnosis. Individuals 
may subsequently be referred to a neurologist to confirm diagnosis and for 
treatment. Patients will be assessed against standard clinical criteria that take into 
account patient age, cognitive testing [such as the Mini-Mental State Exam 
(MMSE) or Mini-Cog], and functional and behavioral testing (such as the 
Dementia Severity Rating Scale). The National Institute of Neurological and 
Communicative Diseases and Stroke/Alzheimer’s Disease and Related Disorders 
Association criteria use this information to give a diagnosis of “probable” or 
“possible” AD, with definitive diagnosis requiring pathologic confirmation. 
Criteria from the Fourth Edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV) can also be used. Both criteria require that other causes of 
dementia are excluded. In clinical trials, it is often the MMSE that is used as a 
primary endpoint, although it is arguable whether this endpoint is sensitive or 
robust enough, as the test was not designed for repeated use.  
Prospective studies of people with amnestic mild cognitive impairment (MCI) have 
shown that episodic memory (such as delayed recall of word lists [118] and paired-
associates learning [119]), semantic memory [119, 120], attention processing 
[121], and mental speed can consistently predict which patients will develop 
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dementia [119, 122-125]. Similarly, in a retrospective study of people with MCI 
who had developed AD, verbal and visual memory, associative learning, 
vocabulary, executive function and other verbal tests of general intelligence were 
impaired at baseline [126].  
1.2.3.2 Neuroimaging 
Imaging modalities such as computed tomography (CT scan), magnetic resonance 
imaging (MRI), positive emission tomography (PET), and single-photon emission 
computerized tomography (SPECT) have the potential to contribute to both the 
diagnosis of AD, as well as assist in the search for more effective treatments. A 
number of AD-related biomarkers have been proposed and evaluated, and have 
been shown to correlate with the progression of AD [127]. 
Structural MRI 
Longitudinal studies have shown that decreased entorhinal cortex [122] and 
hippocampal volumes [128] can predict which patients with MCI will develop AD. 
Entorhinal-cortex atrophy might be a better predictor of AD progression than 
hippocampal volume loss [123],  although result of other studies were less clear-
cut [129]. In a more qualitative manner, medial-temporal-lobe atrophy assessed 
with a standardized visual rating scale [130] also identifies patients who will 
develop AD. Whole-brain, hippocampal, and entorhinal-cortex atrophy assessed by 
MRI were more common among patients with amnestic MCI who went on to 
develop AD than among non-converters [131]. Measurement of hippocampal 
apparent diffusion coefficient with diffusion weighted imaging improved the 
prediction of development of AD [132].  
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Functional imaging 
Although the usefulness of functional imaging techniques has been established in 
AD, findings were inconsistent in preclinical disease [119]. Patients with MCI who 
went on to develop AD were identified by using a combination of regional cerebral 
blood flow at the cingulate, the hippocampus-amygdaloid complex, and the 
thalamus on single-photon emission CT [119]. Other studies showed decreased 
regional cerebral blood flow in the left frontal regions [133] and left posterior 
cingulate gyrus [119] to be similarly predictive. Studies with PET have shown that 
cerebral hypometabolism in the left temporoparietal region [134] and right superior 
temporal region [135] are predictive of progression to AD in people with MCI. A 
recent study with functional MRI showed that people with MCI who would go on 
to develop AD recruited a larger extent of the right parahippocampal gyrus upon 
the encoding phase of memory testing [124], which reflects a compensatory 
response to accumulating AD pathology. 
1.2.3.3 Biological markers of AD 
Biomarkers for AD can be used to facilitate clinical diagnosis, particularly early 
and possibly pre-symptomatic diagnosis. In evaluating treatment aimed at 
modifying the course of AD, biomarkers can help to assess the response to drug 
treatment. It will be particularly useful during the dose-finding stage. In definitive 
clinical trials, biomarkers can be used as surrogate outcome measures. Progress has 
been made in investigating candidate biomarkers in CSF and plasma. At present, 
CSF levels of Aβ, total tau and P-tau come closest to meeting the criteria proposed 
for useful biomarkers for diagnosis. There is clear evidence that CSF levels of Aβ 
1-42 are significantly reduced, while total tau and P-tau are increased in AD patients 
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as compared with senile controls [136-138]. Other biomarkers can provide insight 
into processes such as inflammation and oxidative damage. An increasing number 
of unbiased and broad-based searches for novel biomarkers suggest that 
supplementary use of biomarkers preferably in combination will help to improve 
the accuracy of AD diagnosis [139]. As efforts to diagnose and treat AD move 
towards earlier intervention and even towards prevention, biomarkers are 
important as tools to aid research and ultimately clinical practice [140]. 
In this section, the extensively studied biomarkers for AD in blood or CSF will be 
summarized and discussed. These biomarkers include the most prevailing Aβ, total 
tau, and P-tau, alone or in combination. Moreover, the less popular biomarkers 
such as inflammatory markers (IL-1 and IL-6 etc.), oxidative stress markers 
(isoprostanes and plasma antioxidants etc.), cholesterol and 24S-
hydroxycholesterol in the diagnostic process or prediction of AD will also be 
described.  
Aβ 
The most extensively evaluated markers of sporadic AD are Aβ proteins and levels 
of both total and hyperphosphorylated microtubule-associated protein tau [141]. 
Motter et al. were the first to demonstrate a selective reduction of CSF Aβ 1-42 
[142]. The statistically significant decrease of Aβ 1-42 concentrations in the CSF of 
AD patients has been confirmed later in over 30 studies [143-146]. The decrease in 
the CSF Aβ 1-42 has also been observed as early as in the stage of MCI, the earliest 
clinical manifestation of AD in some of the subjects [138, 147, 148], suggesting 
that low levels of the CSF Aβ 1-42 might be useful even before the diagnosis of 
clinical dementia might be established. The plasma Aβ 1-42 levels is not useful as a 
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biomarker of AD, while might constitute a biological risk factor for this illness 
[149]. Mayeux et al. reported that the risk of AD in the highest quartile of plasma 
Aβ 1-42 was increased more than twice in comparison with the lowest quartile 
[149]. Moreover, plasma Aβ 1-42 was highest in individuals non-demented at 
baseline, who developed AD during follow-up. With dementia becoming obvious, 
plasma Aβ 1-42 levels declined [149].  
Total tau and P-tau 
Both tau and P-tau can be detected in the CSF. Extensive studies have 
unequivocally reported increased CSF tau levels in AD [143, 144, 146, 150-152] 
and the stage of MCI [138, 147, 148]. CSF tau levels effectively discriminated 
patients who progressed from MCI to AD or had a progressive MCI from those 
with stable MCI [138]. 
A significant elevation of P-tau in the CSF of AD subjects has consistently been 
observed in previous studies [153-156]. In clear contrast to total tau, the CSF P-tau 
is hardly a marker of neuronal damage, but rather of an AD-specific increase in tau 
protein phosphorylation. Therefore, the main advantage of this measurement 
compared to all other biomarkers of AD is an improved specificity towards AD, an 
observation that has frequently been replicated. P-tau concentrations in the CSF 
have been similar to control groups, or just marginally elevated in dementia with 
Lewy bodies, frontotemporal dementia or vascular dementia [153-155], suggesting 
a higher diagnostic accuracy than Aβ 1-42 or total tau.  
Potential inflammatory cytokines 
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Proinflammatory cytokines, in particular IL-1 or IL-6, drive a cascade of 
neurotoxic changes that are important for the development and progression of both 
the neuritic plaques and NFTs characteristic of AD. Epidemiological investigations 
revealed a decreased incidence of AD in subjects protractedly using non-steroidal 
anti-inflammatory drugs [157, 158], indirectly confirming the importance of 
inflammation in the pathogenesis of AD. However, the potential for using blood 
levels of proinflammatory cytokines as biomarkers of AD progression remains 
unrealized. The interpretation of cytokine levels in the blood is complicated by the 
fact, for example, that the overexpression of IL-1 in AD brain may act to increase 
adrenal cortisol production through the hypothalamic-pituitary-adrenal axis, which 
acts to limit macrophage activation and peripheral cytokine production [159]. 
Therefore, the studied inflammatory parameters in either plasma or CSF should not 
be considered diagnostic markers for AD [160].  
Oxidative stress markers 
F2-Isoprostanes (F2-IsoPs), one group of lipid peroxidation products derived from 
arachidonic acid, are especially useful as in vivo biomarkers of oxidative damage. 
There is broad agreement that increased CSF levels of F2-IsoPs also are present in 
patients with early AD [161]. Increased levels of F2-IsoPs have systematically been 
confirmed in the CSF of AD patients compared to controls (158-161).  
Measurement of CSF F2-IsoPs can increase the accuracy of laboratory-based 
classification of geriatric dementias, and have been used to assess objectively the 
response to anti-oxidant interventions in AD [162].  
In contrast, quantification of F2-IsoPs in plasma and urine of AD patients has 
produced conflicting results. Some authors did not observe any statistically 
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significant changes [163-166] while others reported an increase [164, 167]. A 
positive correlation between F2-IsoPs CSF, plasma and urine levels was also 
shown in the latter, followed by correlations between F2-IsoPs concentrations and 
cognitive decline, ApoE genotype and other biomarkers of AD pathology like Aβ 1-
42 [164]. Furthermore, F2-IsoPs levels have been increased in the CSF, plasma and 
urine of subjects with MCI compared to age matched controls [167], suggesting 
feasibility for an early diagnosis. 
Plasma Antioxidants 
The non-enzymatic antioxidants have usually been reported to be significantly 
lower in AD subjects compared to age matched controls [168-170]. The depletion 
of antioxidants could be observed as early as in the stage of MCI, with a degree 
comparable to AD [169], possibly allowing the assessment of efficacy of 
antioxidant supplementation in MCI. Similar to cytokines, high levels of plasma 
antioxidants have been shown to correlate with a subsequent cognitive decline in 
healthy subjects [171], suggesting their potential (in combination with other 
predictors) in anticipating deterioration of cognitive functions. 
Cholesterol and 24S-hydroxycholesterol 
There is increasing evidence that AD is closely linked with cholesterol 
metabolism. In the course of the AD-associated neuronal degeneration, cell 
membrane degradation occurs releasing cholesterol [172]. The association between 
cholesterol levels and cognitive function is controversial. Epidemiological studies 
have provided evidence of a significant reduction in the prevalence of AD in 
patients taking statins [173, 174]. While prospective, population based studies have 
reported an association between elevated midlife total cholesterol and late-life AD 
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[175]. Midlife serum cholesterol level has also been significantly positively 
correlated with the risk of developing MCI [176]. In a large Framingham Study 
cohort, baseline and long-term average serum total cholesterol levels were not 
associated with the risk for incident AD [177].  
The enzyme mediating this conversion was recently identified as cholesterol 24-
hydroxylase, representing a new cytochrome P450 (CYP) subfamily, CYP46 
[178]. As most of the circulating 24S-hydroxycholesterol in the human body 
originates in the brain [179], its plasma concentration could be putative 
biochemical marker for an altered cholesterol homeostasis in the brain of AD 
patients and other neurological diseases. 
24S-hydroxycholesterol (24-hydroxycholesterol), also known as cerebrosterol, is 
formed after enzymatic oxidation of cholesterol by 24-hydroxylase. In humans, 24-
hydroxylase is almost exclusively located in the brain. The enzymatic conversion 
of CNS cholesterol to its polar oxidized product 24S-hydroxycholesterol, which 
readily crosses the blood-brain barrier, is the major pathway for the elimination of 
brain-derived cholesterol and the maintenance of brain cholesterol homeostasis 
[178-182]. 
CSF 24S-hydroxycholesterol levels have been found to be elevated in patients with 
AD compared to age-matched controls [87, 183, 184]. This increase has been 
independent of both plasma total cholesterol and plasma 24S-hydroxycholesterol 
levels [183], and could be observed as early as in the MCI stage [184]. Some 
studies showed decreased plasma 24S-hydroxycholesterol in severely affected AD 
patients [88, 185, 186], while others did not report any differences in plasma 24S-
hydroxycholesterol in AD patients and controls [183, 184]. The results suggested 
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that CSF 24S-hydroxycholesterol might be a useful diagnostic marker for 
monitoring the onset and progression of AD, while serum cholesterol deserves 
further studies as a putative predictor of cognitive decline. Due to the effectiveness 
and relative safety of the pharmacological treatment of hypercholesterolemia, 
identification of this association may be of great importance in the prevention and 
slowing down of AD progression. 24S-hydroxycholesterol, contrary to total 
cholesterol, should be considered a potential state marker of AD. Further research 
is necessary for precise estimation of its sensitivity and specificity, both in plasma 
and CSF.  
Summary 
Of all the presented potential biochemical markers of AD, only decreased CSF Aβ 
1-42 and increased tau and P-tau have consistently been proven satisfactorily 
sensitive and specific. Plasma Aβ 1-42, inflammatory and oxidative stress markers 
might be useful for isolating patients clinically predisposed to cognitive 
impairment, therefore constituting biochemical risk factors rather than diagnostic 
markers. The promising results of studies on oxidative stress markers, particularly 
F2-IsoPs, 24S-hydroxycholesterol deserved further studies. Until then, their 
potential in the differential diagnosis of neurodegenerative disorders cannot be 
precisely evaluated. At present, a desired diagnostic accuracy can be obtained only 
with both precise clinical assessment and data acquired from neuroimaging 
techniques, apart from biochemical markers. As CSF is not a matrix that can be 
easily used for diagnostic purposes, let alone for screening population on risk 
factors, special stress should be put on the profiling of peripheral biomarkers of 
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AD, with the use of non-invasively derived matrices such as plasma, serum or 
urine. 
1.2.3.4 Combinations of different biomarkers 
Given the complex pathology of AD, simultaneous analysis of markers related to 
several disease mechanisms might improve their discriminative power. A 
combination of neuropsychological testing and neuroimaging improved the 
diagnostic accuracy of predicting cognitive decline in people with MCI from that 
achieved with either modality alone [128, 134]. Likewise, single-photon emission 
CT and MRI volumetry in combination showed better discriminative performance 
in detecting MCI progression than either test used alone [187]. Okamura and 
colleagues [188] showed high ratios between CSF tau and posterior cingulate 
perfusion on SPECT to be useful in identifying MCI-converters.  
Currently, there are two important classes of drugs approved for the treatment of 
symptoms of late-onset or sporadic AD. Acetylcholinesterase (AChE) inhibitors 
are widely considered to be first-line treatment for the cognitive symptoms of 
dementia associated with AD and are indicated for the mild and moderate stages. 
AChE inhibitors prolong the action of acetylcholine in the synapse by preventing 
its breakdown, resulting in improvements of cognitive decline, mood and behavior 
in mild to moderate AD, even if the improvement is not permanent.  
NMDA receptor antagonists are believed to work by helping to regulate levels of 
the neurotransmitter glutamate. Memantine (Namanda®, Forest Laboratories) 
blocks glutamate gated NMDA channels, thereby blocking pathological activation 
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and preserving physiological activation. Other currently available promising 
strategies are summarized in Table 1-1. 
Table 1-1 Currently available strategies for the medical intervention of AD 
Therapies  Representative drugs Pathogenic mechanisms References 





Johnson & Johnson) 
 
Symptomatic relief of 
early and intermediate 
stages of AD; slows 
disease progression  
[117, 189, 
190] 




Blocking of glutamate 
gated NMDA channels 
and excitotoxicity; for 
advanced stages of AD 
 
[191] 
β or γ-secretase 
inhibitors 













Aβ immunotherapy Immunogen AN-1792 [Aβ 1-42 
with adjuvant (QS-21)] 
(Elan/Wyeth);  
Monoclonal antibody 
Bapineuzumab (AAB-001) and 
ACC-001(Elan/Wyeth) 
 
Reduces brain Aβ load [195-197] 
Nonsteroidal anti-
inflammatory drugs 
Acetylsalicylic acid (Aspirin); 
Diclofenac;  





microglia, and astrocytes; 
reduce risk of AD by 











Prevents atrophy of 
cholinergic neurons; 
reduces oxidative stress; 
modulates the effects of 
nerve growth factors; 
reduces neuronal injury by 




Antioxidants Vitamin E; 
Vitamin C; 
 α-LA 
Modulates brain metal 
metabolism and attenuates 
oxidative stress 
[204-207] 
In addition, a variety of pharmaceutical approaches targeting at several disease 
hypotheses are now under investigation or are ready to be introduced into the 
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therapy of AD [208]. Notably, α-lipoic acid (LA) has been widely investigated on 
the possibility for the treatment of AD due to its multiple properties that can 
interfere with pathogenic principles of AD [209]. 
1.3 METABONOMICS 
Hypothesis-driven research has been the bedrock of the scientific method since the 
time of Francis Bacon, in which experiments are designed to test specific ideas 
[210]. Over the past two decades, the advent of “-omics”-level biology, i.e., studies 
involving the generation and analysis of very large data sets that simultaneously 
measure multiple variables, has begun to provide a complementary data-driven 
approach, with varied but increasing levels of acceptance [210].  
Since the 1990s and particularly the determination of the human and other 
genomes, automated micro-array methods have been used for detecting changes in 
gene expression, leading to the new discipline of “genomics” and 
“transcriptomics”. Subsequently, the expanded ability in analyzing and identifying 
the proteins in a biological system has led to the term “proteomics” being coined. 
However, now it has been recognized that understanding of complex interactions 
between genetic and environmental factors are impossible at the transcriptomic 
level and difficult at the proteomic level. The “metabolome” is the complete set of 
small (typically less than 1 kDa) molecules (metabolites) present in a biology 
system involving in biochemical processes. Therefore, the metabolome provides a 
great deal of information for our understanding of the intricate biochemical and 
biological status and functioning of a living system. The analysis of these 
metabolites leads to term “metabonomics”.  
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While metabonomics is the newest “-omics” in the field of system biology, it 
derived from earlier work using nuclear magnetic resonance (NMR) spectroscopy 
of biofluids that could be dated back to the mid-1980s. Metabonomics was 
subsequently combined with the use of pattern recognition and multivariate 
statistics investigation of the complex data sets. The term was formally coined in 
1999 by Professor Jeremy Nicholson and his colleagues at the Imperial College 
London as “the quantitative measurement of the dynamic multiparametric 
metabolic response of living systems to pathophysiological stimuli or genetic 
modification” [211]. In 2001, the term “metabolomics” was introduced by other 
researchers and defined somewhat differently as “a comprehensive and 
quantitative analysis of all metabolites” in a system [212]. Although there remain 
some differences in concept, there is now a great deal of overlap in the 
philosophies and methodologies, and these two terms are often used 
interchangeably. In this thesis, “metabonomics” will be used throughout the 
following sections.  
Metabonomics is a rapidly growing field that emphasizes the global (non-targeted) 
holistic analysis of multiple low-molecular-weight metabolites (MW < 1000) in a 
given biological sample. Metabonomics encompasses the comprehensive and 
simultaneous systematic profiling of multiple metabolite levels and their systemic 
and temporal changes in biological systems caused by factors such as diet, 
lifestyle, environment, genetic effect and pharmaceutical effect (efficacy and 
toxicity) [211]. This is achieved by the study of biofluids and tissues with the data 
being interpreted using chemometrics techniques. The biochemical level of the 
metabolome is closest to that of the function of a cell (the phenotype), which 
represents the downstream effect of enzyme catalysis and other biotransformations. 
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Therefore, the study of metabolome is key in understanding biological functioning 
and metabolites are obvious candidates for biomarker screening. In conjunction 
with other “-omics” approaches, metabonomics offers a complimentary approach 
in the system biology, especially for the untargeted profiling of potential 
biomarkers [213].  
All metabonomic studies result in complex multivariate data sets that require 
visualization software and chemometric and bioinformatic methods for 
interpretation. The aim of these procedures is to produce biochemically based 
fingerprints that are of diagnostic or other classification value. A second stage, 
crucial in such studies, is to identify the marker metabolites causing the 
classification. These metabolites become the combination of biomarkers that 
define the biological or clinical context. Statistical pattern recognition methods, 
when combined with either NMR spectroscopy or mass spectrometry (MS), create 
enormous opportunities for metabonomic research beyond simple data reduction 
methods. Among a variety of statistical methods employed, principal component 
analysis (PCA) has proven to be suitable for differentiating sample groups on the 
basis of metabolite composition. As an unsupervised method, PCA requires no 
knowledge of the nature of samples prior to the data analysis, and any significant 
difference between the groups of samples will be detected, whether or not this 
difference is important to the study. Other methods are described as “supervised” 
because classes of samples are identified before the mathematical analysis begins. 
These include partial least squares discriminant analysis (PLS-DA) and soft 
independent modeling of class analogies (SIMCA). These methods have been used 
for the classification of spectroscopic results, and are especially useful for 
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detecting biomarkers that differentiate the pre-identified classes of samples, such 
as diseased and undiseased.  
1.3.1 Biomarker and “-omics” 
Biomarkers are biological parameters assessed by a wide array of analytical tools 
to achieve more expeditious and informative therapeutic research. Biomarker is 
broadly defined, according to National Institute of Health (NIH) Biomarker 
Definitions Working Group, as “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathological processes, 
or pharmacologic responses to a therapeutic intervention” [214]. The NIH 
documents and other literatures [215, 216] further categorized biomarkers into 
distinct subsets: drug activity biomarker, nature history biomarker, surrogate 
endpoint and clinical endpoint [217]. Recently, biomarkers attract substantial 
attentions for their potential to diagnose human diseases [218, 219], assess drug 
efficacy and safety [220-223], develop and evaluate novel therapies [224], select 
patients having the highest probability of benefiting from a particular drug 
treatment [225] and limit adverse events [226]. 
The “-omics” including genomics (gene analysis), transcriptomics (gene 
expression analysis), proteomics (protein expression analysis) and metabonomics 
(metabolite profiling) have been widely used in the biomarker discovery [227-
230]. Researchers have increasingly turned to the analysis of small endogenous 
molecules using metabonomics in the search for novel biomarkers, as it is uniquely 
suited to biomarker discovery. Compared to proteomics, metabonomics has a 
number of logistical advantages, especially the more finite set of analytes that tend 
to be structurally conserved across species. It has been estimated that the human 
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metabolome consists of less than 3000 small molecule metabolites [231], although 
some estimates put the potential list at a much higher number [232]. By 
comparison, the number of proteins in the human proteome has been estimated at 
over one million. In addition, many metabolites have known functions and 
participate in well-characterized pathways. Furthermore, metabolites are the last 
step in the molecular response to various factors. Unlike gene and protein 
expression that can be altered and regulated by homeostatic mechanisms, 
metabolite levels respond to the gross effect of differences in gene and protein 
expression and represent a more holistic response [233]. Metabonomics has shown 
the ability to quickly assess changes in the abundance of large numbers of 
endogenous metabolites representing multiple compound classes [234]. Moreover, 
metabolism is conserved during evolution; metabolic networks are essentially very 
similar in rodents and humans.  Therefore, a further advantage of metabonomics over 
other “-omics” is that the data may be transferable from one species to another. Thus, 
it suits a major requirement for becoming an ideal tool for translational research; 
metabolic patterns associated to pathology or therapeutic responses in animal models 
could be directly transferred to the clinical setting [235]. 
1.3.2 Metabonomic platforms 
A variety of analytical methods can be used to generate metabonomic datasets on 
complex biological samples. The rapidly expanding field of metabonomics has 
been driven in recent years by advances in the analytical methods of high-
resolution NMR spectroscopy and MS, and their combination with multivariate 
statistics [236-238]. MS technique requires a pre-separation of the metabolic 
components using either gas chromatography (GC) after chemical derivatization, 
or liquid chromatography (LC), with the newer method of ultra-performance LC 
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(UPLC) being increasingly used. The used of capillary electrophoresis (CE) 
coupled to MS has also been reported [239]. Other more specialized techniques 
such as fourier transform infra-red (FTIR) spectroscopy and arrayed 
electrochemical detection have been used in some cases [240]. It is clear that NMR 
and MS-based approaches are complementary, giving information on different sets 
of biomarkers [238]. Therefore, the combination of NMR and MS will create more 
comprehensive metabolic profiling data, allow improved identification of unknown 
analytes, and create an opportunity to expand the scope of metabonomics research. 
Recently, the integration of both technologies to provide more comprehensive 
classification and biomarker information had been reported [241-243], which 
indicated exciting potential for the metabonomic study. A statistical correlation 
tool has also been developed to interrelate the metabolites from NMR and 
UPLC/MS [243]. Different metabolites, including some possible biomarkers, 
measured with NMR and UPLC/MS individually were linked by their mutual 
correlation values and then illustrated by a corresponding contour plot.  
Analytical methods used for metabonomics should be sensitive, quantitative and 
robust. The development of a generic analytical method fulfilling these 
requirements is very challenging, especially in view of the wide range of 
compound classes and large range of metabolite concentrations present in the 
samples. In the biomedical sciences, most samples are blood, urine, or cell cultures 
or tissues taken from the site of pathology. Blood and urine are the samples most 
frequently used to explore systematic fluctuations in endogenous metabolites. 
Urine is commonly used because it allows continuous noninvasive monitoring and 
facilitates the investigation of kidney-related toxicity or diseases. Although 
metabonomics emerged initially using NMR spectroscopic profiling, MS has 
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evolved as a powerful complementary technique for the comprehensive profiling 
of the metabolome in biological samples [213]. The power of MS in metabonomics 
arises from its sensitivity, speed, and ability to interface directly with 
chromatography. To date, many MS techniques coupled to GC, LC or CE are 
applied to metabonomic analysis. GC/MS has been used widely and considered as 
one of the most effective tools in metabonomic study due to its powerful separation 
and sensitivity [242, 244-250]. GC/MS using electron impact (EI) ionization 
combines very high separation power and reproducible retention times with a 
versatile, sensitive, and selective mass detection. As the full scan response of the 
EI ionization mode for quadrupole instruments is approximately proportional to the 
amount of compound injected, i.e., more or less independently of the compound, 
all compounds suitable for GC analysis are detected non-discriminatively. This 
makes the technique very suitable for comprehensive non-target analysis, i.e., the 
analysis of a wide range of metabolites. In addition, the assignment of the identity 
of peaks detected with GC/EI/MS via a database of mass spectra is straightforward, 
due to the extensive and reproducible fragmentation patterns obtained. However, 
GC/MS usually needs derivatization step in the sample preparation, as metabolites 
contain polar functional groups may be thermally labile at the temperatures 
required for their separation or are not volatile at all.  
1.3.2.1 NMR 
The studies involving NMR spectroscopy for the composition investigations of 
biofluids dates back to the mid-1980s. High resolution 1H NMR spectroscopy has 
shown to be one of the most powerful technologies for biofluids. It is cost-
effective, unbiased, rapid, robust and reproducible, quantitative, nonselective and 
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nondestructive, and generates useful data from samples. NMR is essentially the 
only one capable of studying intact tissues, producing a comprehensive profile of 
metabolite signals without the need for pre-selection of measurement parameters or 
the use of separation or derivatization procedures [251]. NMR spectroscopy is an 
acclaimed technique for providing detailed structural information of small organic 
molecules and, as such, enables a large number of biofluid constituents to be 
identified [252]. While NMR spectroscopy yields relatively low-sensitivity 
measurements when compared with MS, it is highly quantitative and reproducible, 
which is especially important when metabonomic data are analyzed by multivariate 
statistical methods [251]. This feature compensates for its limited sensitivity. 
Furthermore, variable detection responses, such as differential volatilization or 
ionization effects as in MS, are not an issue for NMR spectroscopy. NMR is an 
excellent choice for broad-based analyses, and suitable for samples in different 
conditions [253-257]. In addition, progress has been made to improve the 
resolution [258] and sensitivity of NMR spectroscopy by means of the J-resolved 
experiment [259] and other 2-D methods. The assistance of flow-injection probes 
and automated liquid handlers, and microcoil probes enable high-throughput NMR 
methodology and much lower detection limit [260].  
1.3.2.2 MS 
MS has been a key part of biomarker discovery and evaluation owing to several 
important attributes, including high sensitivity (typically pg level) and selectivity, 
multi-analyte analysis, and the ability to provide structural information. Because of 
these capabilities over NMR [261], MS has been widely deployed in search for 
new markers  both through the analysis of large molecules (proteomics) and small 
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molecules (metabonomics). In addition, MS is increasingly being used to support 
quantitative measurement to assist in the evaluation and validation of biomarker 
leads. 
GC/MS 
GC and more recently GC × GC combined with MS detection provide an excellent 
system for metabonomic study, and they have been widely used in metabolic 
profiling not only in plants and microorganisms [262], but also in mammals 
including human [244-250, 263-265]. The high resolution of GC, combined with 
MS detection using either EI or chemical ionization (CI) provides a good starting 
point for the identification of putative biomarkers. The availability of commercial 
structure databases further adds value to this metabonomic approach. GC/MS using 
EI ionization combines very high separation power and reproducible retention 
times with a versatile, sensitive, and selective mass detection. As the full scan 
response of the EI ionization mode for quadrupole instruments is approximately 
proportional to the amount of compound injected, i.e., more or less independently 
of the compound, all compounds suitable for GC analysis are detected non-
discriminatively. This makes the technique very suitable for comprehensive non-
target analysis, i.e., the analysis of a wide range of metabolites. To date, GC/MS, 
including quadrupole and time-of-flight (TOF) MS, has been extensively used for 
metabolite profiling [266-269], especially in microbial applications [250]. 
Recently, a significant enhancement in the resolving power of GC for complex 
mixture analysis was achieved using multidimensional GC, usually described as 
GC × GC [270, 271]. An advantage of GC-based strategies for metabonomics lies 
in the area of identification, where a number of databases exist that can be 
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interrogated in an effort to identify unknown metabolites. As many biomolecules 
are not yet included in the databases, they are not the perfect source of information 
for metabolite identification. Nonetheless, the availability of this information 
represents a valuable resource that will become more comprehensive with time. 
The most obvious practical limitation of GC/MS-based metabolite profiling is that 
many interesting classes of compounds cannot be analyzed directly due to their 
polarity and lack of volatility. The extraction and chemical derivatization prior to 
analysis are essential prerequisites, and it is possible to introduce variability and 
losses in the process of sample preparation. The absolute requirement for fairly 
extensive sample preparation prior to chromatography and the long 
chromatographic run times result in a relatively low throughput technique. 
However, GC/MS, particularly GC × GC/MS possesses many advantages 
including very high resolution, good sensitivity and robustness. 
LC/MS 
The increasing chromatographic resolution of LC/MS has resulted in a rapid and 
continuing increase in the number of publications using this technique for 
metabolic profiling [272-277]. Apart from conventional LC, some recently 
introduced LC techniques such as capillary LC [278, 279] and UPLC [273, 275, 
276] have been reported to achieve increased resolution, decreased sample size, 
higher sensitivity [278, 279] and faster separations [275], but at the cost of long 
analysis times (capillary LC) and high operating pressures [278].  
In many ways, LC/MS is ideal for metabolite profiling as biofluids such as urine 
can be directly injected whereas samples such as plasma need minimal 
pretreatment (protein precipitation). LC/MS is also amenable for moderate to high 
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throughput analysis, has a reasonable dynamic range combined with good potential 
for biomarker identification (based on the spectral data generated), is not specific 
to particular classes of compounds and can be extremely sensitive. However, 
unlike 1H NMR spectroscopy, LC/MS is not equally sensitive to all types of 
metabolites, which makes the comparison of metabolite more challenging. In 
general, separations for LC/MS have been performed using reversed-phase 
gradient chromatography and electrospray ionization (ESI) in both positive and 
negative mode in order to obtain the most comprehensive profile possible. 
However, LC/MS may be susceptible to the phenomenon known as “ion 
suppression”. These effects result when co-eluting compound(s) changes the 
degree of ionization of a particular analyte causing its signal to be reduced (or 
increased). This problem is particularly difficult to control in complex multi-
component samples of unknown composition and care has to be taken in 
interpreting metabolite profiling data. Indeed, it is arguable that biomarkers 
identified in this way should be treated as provisional until confirmed using a 
validated, compound specific method [280].  
CE/MS 
CE/MS has shown considerable potential in metabonomics, especially in the area 
of bacterial metabolic profiling [239, 281]. Like LC/MS, CE/MS is well suited for 
the analysis of endogenous metabolites with minimal sample pretreatment. In 
addition, CE/MS requires only very small amounts of sample, and it well suited to 
polar and ionizable molecules. Therefore, CE is likely to be a highly 
complementary alternative to separation techniques such as HPLC and GC.   
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In summary, the developments in GC/MS, LC/MS and CE/MS have significantly 
broadened the applicability of MS-based metabonomics, although the need to 
resolve the metabolites prior to MS detection can make the assay time-consuming. 
Tandem MS [274, 277, 282-284] and TOF methods [241, 275, 284-286] are often 
used to validate the identities of unknown analytes. Current challenges for MS-
based metabonomics include the development of more robust methods for 
chromatographic separation, data reduction methods to deal with the enormous file 
sizes, as well as the reduction of matrix effects that can cause widely varying 
signal intensities.  
Others 
In addition to these popular techniques, some other analytical methods, such as 
fourier transform ion cyclotron resonance (FT-ICR) MS [287, 288], direct infusion 
[289, 290], desorption electrospray ionization (DESI) MS [291] have also been 
reported in metabonomic studies.  
1.3.3 Applications of metabonomics 
Widespread application of metabonomics has been achieved in the areas of disease 
diagnosis [238, 292, 293], drug discovery and pharmaceutical research [238, 292, 
294], toxicology assessment [238, 295, 296], food and nutrition science [297] and 
others [285, 298]. In the following sections, only the most popular applications 
such as disease diagnosis, drug safety assessment and clinical pharmaceutical R&D 
will be discussed.   
1.3.3.1 Disease diagnosis 
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Metabonomics using both NMR spectroscopy and MS-based techniques have been 
explored for the diagnosis of diseases [293, 299-301]. Extensive studies have been 
reported on the use of metabolic profiling to aid  human disease diagnosis [302], 
such as coronary heart diseases [299], diabetes [266], PD [303], human 
hepatocellular carcinoma [304], liver cancer [300] and breast cancer [301].   
1.3.3.2 Preclinical drug candidate safety assessment 
Metabonomics has been widely used for the toxicity evaluation of drug candidates 
to assist in the preclinical drug R&D [294, 296, 305, 306]. This potential of 
metabonomics has been comprehensively explored by the Consortium for 
Metabonomic Toxicology (COMET) [307, 308]. The consortium has shown that it 
is possible to construct predictive and informative models of toxicity using NMR-
based metabonomic data, delineating the whole time course of toxicity [307]. In 
addition, extensive studies have been reported on the use of metabonomic 
evaluation of xenobiotics toxicities such as nephrotoxicity [241, 309] and 
hepatotoxicity [310-312]. Moreover, the species differences between rat and mouse 
in the toxicity of one compound have also been reported [313]. 
1.3.3.3 Clinical pharmaceutical R&D 
The availability of predictive biomarkers for drug safety and efficacy, obtained 
from metabonomics and other technologies such as genomics, proteomics and bio-
imaging is very valuable to pharmaceutical R&D (reviewed in [314]). It is 
predicted that molecular profiling by metabonomic, proteomic and transcriptomic 
methods could revolutionize the effectiveness of drug discovery and development 
in the future [315]. Recently, an approach which is termed as “pharmaco-
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metabonomics” has been developed to aid the personalization of drug treatments 
and personalized drug therapy [316-318]. Based on the analysis and modeling of a 
pre-dose metabolic profile, the method tried to understand the inter-subject 
variability in response to drug treatment using a combination of multivariate 
metabolic profiling and chemometrics to predict the metabolism and toxicity of a 
dosed substance [316]. Compared to pharmaco-genomics, this approach is 
sensitive to both the genetic and the modifying environmental influences that 
determine the basal metabolic fingerprint of an individual, as these also influence 
the outcome of a chemical intervention. 
1.3.3.4 Plant and microbial sciences  
Metabolite profiling has been used in the plant and microbial sciences for a long 
history [319]. Indeed, as mentioned earlier, a specific term “metabolomics” has 
been coined for the metabolic profiling in plant and microbial sciences [261], and 
substantial studies have been reported [320]. Whilst NMR is a traditional analytical 
technique used [321, 322], MS has now overtaken NMR in metabolomics 
primarily due to its high sensitivity. Herein, we would not like to cover this area in 
details.   
1.3.3.5 Other applications 
Several studies have used metabonomics to identify metabolic differences in 
experimental animals, such as mice and rats, caused by a range of inherent and 
external factors [323]. Such differences, including gender differences, age-related 
changes, diet and interspecies differences and similarities, may help to explain 
differential toxicity of drugs between strains and inter-animal variation within a 
 36 
study. Some preliminary results have been obtained using an UPLC/MS profiling 
method comparing normal and obese Zucker rats [273]. More importantly, 
metabonomics may be used for the phenotyping of mutant and transgenic animals 
and the investigation of the consequences of transgenesis [324]. Metabonomics has 
also been applied in the large-scale population phenotyping for molecular 
epidemiological studies in human [325, 326].  
1.4 STEROIDS 
Steroids include 3β-hydroxy-Δ5-compounds, such as pregnenolone (PREG) and 
dehydroepiandrosterone (DHEA), their sulfate esters (PREGS and DHEAS), and 
compounds known as reduced metabolites of steroids, such as the 
tetrahydroderivative of progesterone (PROG) and 3α-hydroxy-5α-pregnan-20-one.  
Table 1-2 Principle enzymes involved in steroid biosynthesis and metabolism 
Common name “Old” abbreviation Current abbreviation 
Cholesterol side-chain cleavage enzyme P450scc CYP11A1 
17α-hydroxylase/17,20-lyase P450c17 CYP17 
21-hydroxylase P450c21 CYP21A2 
11β-hydroxylase P450c11β CYP11B1 
Aldosterone synthase P450c11AS CYP11B2 
Aromatase P450 aro CYP19 
7α-hydroxylase P450c7A P450c7A 
3β-hydroxysteroid dehydrogenase 3β-HSD 3β-HSD 
17β-hydroxysteroid dehydrogenase 17β-HSD 17β-HSD 
3α-hydroxysteroid oxidoreductase 3α-HOR 3α-HOR 
17β-hydroxysteroid oxidoreductase 17β-HOR 17β-HOR 
11β-hydroxysteroid oxidoreductase 11β-HOR 11β-HOR 
18-HSD/5-4 isomerase 18HSOR 18HSOR 
Sulfotransferase  HST HST 
Sulfatase STS STS 
Neuroactive steroids (neurosteroids) belong to the subfamily of endogenous 
steroids de novo synthesized, in the central and peripheral nervous system (PNS), 
glial cells and neurons, from cholesterol or steroidal precursors imported from 
peripheral sources by a series of steroidogenic enzymes [327, 328]. These enzymes 
include the mitochondrial and microsomal P450s and non-P450s, enzymes found 
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within glial cells, Purkinje neurons and other neurons [329, 330] as listed in Table 
1-2 and Figure 1-1. The biosynthesis and metabolism of steroids have been 
extensively studied as described in Figure 1-1. In 1987, Baulieu et al. firstly 
synthesized neurosteroids in primary cell [329, 330]. Then, local synthesis of these 
steroids were proven in various models like C6 glial cell [331] and brain [330, 
332].   
1.4.1 Physiological roles of endogenous steroids  
Extensive studies proved that endogenous steroids play important roles in the 
modulation of GABAA receptors [333-336], NMDA receptors [337] and Sigma 
type 1 receptors [338, 339]. The endogenous concentrations of steroids in brain 
and PNS have been shown to relate to a variety of physiological, cognitive and 
pathological processes [340-342], such as the neurodevelopment, protection and 
regeneration of nervous system [340, 343-346] and the onset and progress of AD 
and PD [347]. Furthermore, circulating levels of steroids were found to decline 
with an increase in age and in patients suffering from neurodegenerative disorders 
[341, 348-351]. In patients suffering from major depression, steroid concentrations 
in plasma and CSF differ from control subjects and these concentrations appear to 
normalize after successful treatment with antidepressants [352-355]. Available data 
indicate that steroids are also involved in premenstrual dysphoric disorder [356], 
eating disorders [357], attention deficit and hyperactivity disorder [358], post-
traumatic stress disorder [359], generalized anxiety disorder [360], panic disorder 






































































































































































Figure 1-1 Biosynthesis and metabolism of steroids and metabolizing enzymes involved in the pathways 
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1.4.2 Clinical significances of endogenous steroids 
A number of studies have been reported on the aging or AD-associated 
modulations of steroid levels. In a circadian study on total and unbound cortisol, no 
major changes in plasma steroids were observed between elderly demented 
patients (mainly women) and healthy elderly women. The phasing of total and 
unbound cortisol showed no major modifications with age, sex or senile dementia 
[366]. PROG and its derivatives were found to be promising neuroprotective 
agents in several models of neurodegeneration, including experimental diabetic 
neuropathy [367]. The PROG plasma levels was markedly lowered in male rats 
within  months of diabetes induced by streptozotocin, while chronic treatment with 
PROG restored them, with protective effects on peripheral nerves. Recent studies 
suggest that alloprognanolone is a promising agent for promoting neurogenesis in 
aged brain and potential restoration of neuronal populations in brains recovering 
from neurodegenerative disease or injury in vitro and in transgenic mouse model of 
AD [368, 369]. It was found that allopregnanolone induced, in a dose dependent 
manner, a significant increase in the proliferation of neuroprogenitor cells derived 
from the rat hippocampus and human neural stem cells derived from the cerebral 
cortex. A study on the postmortem brain tissue showed the increased levels of 
PREG and its neuroactive metabolite allopregnanolone in autopsied brain tissue 
from cirrhotic patients who died in hepatic coma [370]. In another study, 
allopregnanolone was found to be reduced in prefrontal cortex in AD [371]. A 
clinical study found that the 5α-pregnan-3α-ol-20-one (3α,5α-THP) levels in 
dementia patients was much lower compared with controls, but further work is 
needed to establish its sensitivity and specificity in AD patients [372]. The phasing 
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of total and unbound cortisol showed no major modifications with age, sex or 
senile dementia [366]. In addition, AD is associated with significantly higher 
DHEA and lower DHEAS levels in CSF, and the increased DHEA levels are not 
neuroprotective [347]. Such changes may be due to the 7α-, 7β-, and 16α-
hydroxylations of DHEA, which are either present at lower levels or transformed 
through natural polymorphism into less-efficient enzymes [347]. Plasma DHEAS 
and the DHEAS/cortisol ratio were also reported to be significantly lower in AD 
than in controls [373]. 
As early as 1969, Chynoweth and Foley reported a study on pre-senile dementia 
responding to steroid therapy [374]. However, the reports on the estrogen 
replacement therapy (ERT) were quite conflicting. Many biological mechanisms 
support the hypothesis that estrogens might protect against AD by influencing 
neurotransmission, increasing cerebral blood flow, modulating growth proteins 
associated with axonal elongation and blunting the neurotoxic effects of Aβ. On 
the contrary, clinical studies of ERT and cognitive function have reported 
controversial results, indicating a lack of efficacy of estrogens on cognition in post-
menopausal women aged older than 65 years [375]. 
1.4.3 Quantitative analysis of endogenous steroids 
As described in section 1.4.1 and 1.4.2, steroids play important roles in 
neuroscience, especially the changes of circulating levels in aging and 
neurodegenerative disorders including AD [340, 346, 348, 350, 371, 372]. 
Analysis of endogenous steroids in biofluids may provide a potential means in the 
diagnosis of neurological disorders and shed new insights of possible treatment 
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strategies. Therefore, the analytical methods used for the analysis of steroids are 
very important in brain research.  
Due to the low levels (pg-ng/g or pg-ng/mL) of the steroids in complex biological 
matrices, such as plasma (pg-ng/mL) and brain tissue (pg-ng/g), highly sensitive 
and selective analytical methods are necessary. Several methods have been 
developed for the analysis of steroids, with the suitability of the method depending 
on the characteristics of the compound group. During the early stage, several 
different methods have been utilized for the detection of steroids, such as 
electrochemical [376, 377], fluorescence [378] and UV detection [379]. 
Radioimmunoassay (RIA) [380-383] and enzyme immunoassay (EIA) [373, 384, 
385] have also been widely used. In particular, MS combined with GC or LC has 
been extensively used for the determination of steroids in biological samples. 
1.4.3.1 RIA and EIA 
RIA [381, 386, 387] and EIA [383, 388, 389] have been widely used for the 
analysis of steroids due to the high sensitivity. However, RIA and EIA may suffer 
from the generally poor specificity and accuracy due to interference from other 
endogenous steroids and structurally related lipids. Hence, RIA and EIA may 
demand extensive sample purification schemes, including preparative HPLC (prep-
HPLC) [385, 390, 391]. Recently, many commercially available RIA or EIA kits 
do not require the tedious sample preparation steps. A comparison study showed 
that although absolute concentrations may differ for some hormones, RIA and MS 
can yield similar estimates of between-subject differences in serum concentrations 
of most steroids commonly measured in population studies, including estradiol, 
estrone, androstenedione, testosterone, and DHEAS etc.     
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1.4.3.2 GC/MS 
Among the methods developed for the determination of steroids, GC/MS has been 
widely used, especially GC electron capture negative chemical ionization MS 
(GC/ECNCI/MS) has afforded higher sensitivity of the steroids [392]. In the SIM 
mode of GC/MS, only the selected m/z values will be monitored, thus maximizes 
sensitivity as it avoids scanning over the entire mass range. However, extensive 
sample purification procedures [393] and time-consuming derivatization steps 
[394, 395] are required for these GC/MS methods. In addition, GC/MS analysis of 
steroids requires removal of any conjugating groups (e.g. sulphate esters) and 
derivatization of the remaining polar functional groups to provide thermal stability 
and volatility to the analyte. To retain information with respect to conjugating 
groups, separation procedures can be incorporated prior to de-conjugation so as to 
separate neutral steroids from steroid sulphates [394]. 
Various derivatization methods have been reported for the determination of 
steroids using GC/EI/MS, including N,O-bis(trimethylsilyl)trifluoroacetamide 
(BSTFA) + trimethylchlorosilane (TMCS) [396-398], N-methyl-N-
trimethylsilyltrifluoroacetamide (MSTFA) [398, 399], N-Methyl-N- (Tert-
Butyldimethylsilyl) trifluoroacetamide (MTBSTFA) [398, 400] which lead to the 
formation of trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS) derivatives. In 
addition, another derivatizing reagent heptafluorobutyric anhydride (HFBA) has 
been successfully used for the determination of steroids using GC/EI/MS [401]. 
Using this method, the authors achieved the on column detection limits of 1 pg for 
PREG, DHEA and their sulfate esters (PREG-S and DHEAS), 2 pg for PROG and 
5 pg for 3α,5α-THP. This reagent has been widely used in determination of 
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steroids using GC/MS in the biological samples such as plasma and brains [350, 
371]. In some studies, even much better detection limits were reported, ranging 
from 2-120 pg/g brain [402] or 1-2000 pg/g brain or mL plasma [403] for different 
steroids. However, many steroids were still undetectable due to the trace amount in 
the biological samples.  
Negative chemical ionization (NCI) GC/MS was reported to offer better sensitivity 
than GC/EI/MS [392, 394]. The major advantage of GC/NCI/MS is that ionization 
is specific to compounds containing the electron capturing tag, and it provides 
excellent sensitivity in terms of signal-to-noise ratio (S/N). Using this method, Kim 
et al. achieved instrumental detection limits for steroids in the pg range, and 
quantified androsterone (~50 pg/mL), testosterone (~200 pg/mL), 
allopregnanolone (~50 pg/mL) and PREG (~40 pg/mL) in human CSF [392]. 
Vallee et al. determined the levels of allopregnanolone, epiallopregnanolone, 
PREG, testosterone and DHEA in frontal cortex of rat brain to be near or below the 
limits of quantification (2.5 ng/g) [394]. 
Steroid sulphates have been shown to have pharmacological properties [404], and 
were indirectly identified by GC/EI/MS following hydrolysis of the steroid 
sulphate fraction isolated from rat brain [405, 406]. However, intact steroid 
sulphates have been difficult to observe in rat brain [393, 407], as the endogenous 
levels were below the detection limit of 0.1 ng/g  even with GC/NCI/MS [407].  
1.4.3.3 LC/MS 
While GC/MS has proven to be the “gold” standard for steroid analysis due to its 
unsurpassed chromatographic resolution, high sensitivity and informative first 
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dimension MS spectra, the technique is unable to directly analyze polar and 
thermally labile steroids, such as the sulphated steroids. Moreover, GC/MS 
methods require extensive sample purification procedures [393] and time-
consuming derivatization of unvolatile steroids [394, 398, 401].   
Recently, the advantages provided by LC/MS are being exploited for steroidal 
analysis and have gained it popularity [393, 408, 409]. LC coupled with ESI [410, 
411], nano-electrospray ionization (nanoESI) [408], atmospheric pressure chemical 
ionization (APCI) [409] or atmospheric pressure photoionization (APPI) [409, 
411-413] has been studied rigorously for the determination of steroids. A 
comparison study [411] was reported for the analysis of free anabolic steroid 
fraction in human urine using different LC/MS/MS ionization source, including 
ESI, APCI and APPI. The results suggested that LC-ESI/MS/MS was the best 
method for the analysis of steroids.   
A number of groups have investigated the analysis of steroids by LC/MS and 
LC/MS/MS [393, 414-416]. Liu et al. developed a nano-LC/ESI/MS method for 
steroid sulphate analysis [393]. They validated the method on plasma and extended 
it to the identification of steroid sulphates in rat brain. This method provides both 
sensitivity and specificity, and when used in the multiple reaction monitoring 
(MRM) mode, where both the precursor and product-ion masses are predefined in 
the MS/MS experiment, the on-column detection limit was as low as 0.1 pg. 
However, only cholesterol sulphate (1.2 μg/g) was detected in the analyzed 
sulphate fraction from rat brain, no evidence was obtained for any endogenous 
steroid sulphates including PREGS or DHEAS above the detection limit of 
0.3 ng/g. This result agreed with LC/ESI/MS data presented by Mitamura et al. 
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[417], and enzyme-linked immunosorbent assay (ELISA) data of Higashi et al. 
[418], who found levels of PREGS (500 pg/g by LC/MS, 50-500 pg/g by ELISA) 
in rat brain to be much lower than that determined by GC/EI/MS (~10 ng/g) [406].  
As conventional LC/MS methods do not offer favorable sensitivity due to the poor 
ionization efficiencies of unconjugated steroids, steroids have also been 
extensively analyzed by LC/MS/MS using various chemoselective derivatization 
schemes suitable for each ionization method to enhance sensitivity [419-421]. Liu 
et al. derivatized the oxo groups of steroids with hydroxylamine so as to give 
steroid oximes [393]. Steroid oximes are more readily protonated in the 
electrospray process than underivatized analogues and give an enhancement in 
sensitivity of at least 20-fold [419]. Detection limits for testosterone, DHEA, 
PREG and PROG oximes in LC/ESI/MRM experiments ranged from 0.1 to 0.5 pg 
[393]. Analysis of the neutral steroid fraction from rat brain gave levels ranging 
from 0.1-38 ng/g for various steroids, which are comparable to those studies 
determined using GC/NCI/MS [394]. Mitamura et al. used a reversed-phase LC 
negative ESI method which involved derivatization of the oxo group of PREGS 
with 4-(N,N-dimethylaminosulphonyl)-7-hydrazino-2,1,3-benzoxadiazole [417]. 
The derivative enhanced sensitivity by an order of magnitude giving an on-column 
detection limit of ~100 pg [417]. Higashi and colleagues have also used an LC/MS 
approach incorporating derivatization to enhance ionization in the analysis of 
neutral steroids in rat brain [422]. They found that by derivatizing the oxo group of 
steroids with 2-nitro-4-trifluoromethylphenylhydrazine to the corresponding 
hydrazone and performing LC/electron capture atmospheric pressure ionization 
(ECAPI)/MS, they were able to enhance sensitivity by 20-fold, leading to an on-
column detection limit of 1-6 pg. In another derivatization method [423], 
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derivatization of 5α-dihydrotestosterone with 2-hydrazino-1-methylpyridine 
provided a 70 to 1600-fold higher sensitivity compared to intact steroids using 
LC/ESI/MS. Griffiths et al. derivatized steroids possessing an oxo group using 
Girard’s reagent P (GirP) to give a GirP-hydrazone [424, 425]. Steroid-GirP 
hydrazones can be detected at the subpg level in mass spectra and give informative 
MS/MS spectra at the 50 pg level.  
1.5 RATIONALES AND OBJECTIVES OF THE THESIS 
The three major research objectives of the thesis will be concisely presented in this 
section. A more detailed discussion on these objectives would be presented in the 
introduction section of each chapter that follows.  
1.5.1 Metabonomic profiling in aging and AD models 
The difficulties in the diagnosis of AD, especially at its early stages, render timely 
intervention very challenging. Meanwhile, the lack of biomarker for the 
pharmacodynamic evaluation of drug candidates in cognition enhancement hinders 
the research and development of more effective medicines. Despite great interest in 
the novel diagnostic technology and a large amount of effort put into such 
investigation, reliable and accurate biomarkers are still needed to allow the early 
diagnosis of AD in the clinical setting and optimized pharmacodynamic evaluation 
of drug candidates in drug development. Metabonomics, an increasingly used 
technique, for biomarker discovery, is a promising tool for profiling the biomarkers 
related to aging and AD.  
A number of metabonomic studies in aging research have been reported. In a study 
of aging in Sprague-Dawley rats [426] using NMR and UPLC/MS, the data 
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showed decreased concentrations of many Krebs cycle intermediates along with 
increased levels of oxidized antioxidants in urine of older rats, which is consistent 
with current theories on aging and its association with diminishing mitochondrial 
function and increasing levels of reactive oxygen species. In another study [285], 
the effect of aging and development in male Wistar rats on the profiles of urinary 
endogenous metabolites was investigated using both 1H NMR spectroscopy and 
HPLC/TOFMS. Markers detected by 1H NMR spectroscopy included creatinine, 
taurine, hippurate and amino acids/fatty acids, which increased with age, whilst 
resonances related to citrate and glucose/myo-inositol declined. Nicolson et al. 
[298] used 1H NMR-based metabonomic strategy to monitor urinary metabolic 
profiles throughout the lifetimes of control-fed and diet-restricted dogs. They 
found that urinary excretion of creatinine increased with age, reaching a maximum 
between ages 5 and 9 years and declining thereafter. Excretion of mixed 
glycoproteins was noted at earlier ages, which may be a reflection of growth 
patterns. In addition, consistent metabolic variation related to diet was also 
characterized, and energy-associated metabolites, such as creatine, 1-
methylnicotinamide, lactate, acetate, and succinate, were depleted in urine from 
diet-restricted dogs.  
As AD is an age-related neurodegenerative disease, it is imperative to profile, 
compare and differentiate the marker metabolites related to natural aging and 
pathological neurodegeneration. The identification of metabolites related to aging 
and neurodegeneration will help to distinguish unique metabolic characteristic of 
AD and provide valuable information for future AD biomarker research. In 
addition, the indentified specific biomarker for AD may be promising in assisting 
the early diagnosis and drug candidate development of AD.  
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In the present study, animal and cellular models of both aging and AD were used 
for the metabolic profiling using GC/MS. Furthermore, the biomarkers related to 
aging and AD were indentified, and the similarities and differences were cross-
examined and discussed.  
1.5.2 Steroidal biomarker profiling in aging and AD models 
As underscored before, steroids have been reported to be important in the process 
of aging and neurodegeneration. Based on our literature review, however, no study 
has been reported on the profiling of endogenous steroids to study both aging and 
AD. This led us to the objective to profile and compare biological steroids in aging 
and AD models. 
1.5.3 Development and comparison of MS-based analytical techniques for 
bioanalysis of endogenous steroids 
The physiological concentrations of steroids in biological fluid is extremely low in 
pg-ng/mL levels. Therefore, it is critical to develop an accurate, sensitive and 
specific analytical method to analyze them. As elaborated before, various assays 
have been reported previously for the analysis of steroids, including RIA, EIA, 
GC/MS and LC/MS. Due to the physiological and clinical importance of steroids 
in aging and AD, steroidal profiling using an accurate and reliable analytical 
technique may be of interest. Therefore, it is warranted to elucidate the strengths 
and weakness of these methods, in order to develop an optimized approach for the 
profiling of endogenous steroids in biological samples. Herein, we compared and 
discussed various MS-based assays for steroid analysis, using both LC/MS and 
GC/MS with systems that are available in our department.  
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CHAPTER 2 GC/MS METABOLIC PROFILING OF AGING MODELS 
2.1 INTRODUCTION 
With the aging world population, research on aging and aging-related 
neurodegenerative diseases, such as AD and PD, has attracted increasing 
attentions. Metabolic profiling of aging and neurodegeneration may provide new 
insights into the underlying biological mechanisms of these processes. In addition, 
marker metabolites related to the neurodegenerative diseases may help to address 
the current shortcomings in the diagnosis and therapy of this class of neurological 
disorders.  
Three major “-omics” techniques (genomics, transcriptomics and proteomics) have 
been extensively reported for the biomarker studies of various physiological or 
pathophysiological conditions including aging and neurodegenerative diseases 
[427-434]. Genomics is a tool in tracking the potential genes associated with aging 
and age-related diseases like AD [427, 429], but provides little molecular 
characteristics related to aging process or disease stage within individuals. 
Transcriptomics profiling reflects the relevant transcriptome change related to 
normal aging or aging influenced by interventional factors, such as caloric 
restriction [428, 434]. However, the utility of transcriptomics is limited as it is 
unable to reveal information about more than one tissue at a time or about post-
transcriptional regulation. Proteomics is useful for elucidating the end-products of 
the genome’s transcription and for confirming the accumulation of damaged 
proteins that often accompanies aging-related processes. However, proteomics 
cannot reveal short-term regulation of protein expression [430, 432, 433]. 
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Furthermore, serum proteomic studies are often limited by a series of analytical 
difficulties, such as the primary serum proteome being made up of very few high-
abundance proteins like albumin [210]. In addition, identified potential markers 
had little utility outside the systems in which they were developed [210]. 
Metabonomics, the metabolite profiling on biofluids (e.g. plasma, serum, urine and 
CSF), can be useful for physiological evaluation, drug safety assessment, diagnosis 
of human disease and drug therapy monitoring [238]. Recently, this newly 
emerging technique offers a complementary approach to the other three -omics-
level technologies in the biomarker study of aging and AD [435]. In general, -
omics-level approaches have succeeded in generating new hypotheses, 
classification and comparisons between models, providing insights into unexpected 
mechanisms, and cementing and filling out older knowledge. Although there is no 
a priori reason to presuppose that metabonomics will be more successful than other 
-omics, is reasonable to expect that the most important benefits of metabonomics 
would be realized within these areas of knowledge.  
It is broadly accepted that aging may affect the metabolism qualitatively or 
quantitatively. As metabolism is primarily controlled at the level of biochemical 
inhibition and activation, transcriptomics and proteomics are not expected to 
provide us much information. In contrast, measurement of metabolites using 
metabonomics will be the most efficacious means of probing metabolism. 
Nicholson and colleagues has shown that metabonomics can be used in 
physiological monitoring, drug safety assessment and disease diagnosis [238]. It is 
possible to use metabonomics to trace the trajectory of shifts in metabolism 
associated with aging and aging-related disorders. So far, several biomarker studies 
on aging and/or development using metabonomics have been carried out in various 
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animal models, including dogs, rats and mice, with biological samples such as 
urine, hair and brain (Table 2-1). Most of these studies were reported after we 
started our study or during our study. 
Table 2-1 Biomarker studies on aging using metabonomics 
Species Biological matrices  Analytical method Year  Reference 
Cln3 null mutant mice Brain  1H NMR  2005 [436] 
Wistar-derived rats Urine 1H NMR; 
HPLC/TOFMS 
2005 [285] 
Labrador dogs Urine 1H NMR 2007 [298] 
SHR/Izm, SHRSP/Izm, and 
WKY/Izm rats 
Hairs UPLC/ESI/TOFMS 2007 [437] 
Labrador retrievers dogs Urine NA 2007 [438] 




C57BL/6J mice  
Brain 1H NMR 2008 [439] 
Sprague-Dawley rats  Urine  1H NMR 2008 [440] 
SHR and WKY rats Plasma GC/TOF/MS 2008 [441] 
SAM and SAMR1 mice Serum  1H NMR 2008 [442] 
Human  Plasma GC/MS and LC/MS 2008 [263] 
NA = not available; SHR/Izm = spontaneously hypertensive rat; SHRSP/Izm = stroke-prone SHR; 
WKY/Izm = Wistar Kyoto; VMAT2 = vesicular monoamine transporter 2; SHR = spontaneously 
hypertensive rat; WKY = Wistar Kyoto; SAM = senescence-accelerated; SAMR1 = senescence-
resistant 1 
In a metabonomic study using high resolution 1H NMR spectroscopy, metabolic 
profiling of the cortex, cerebellum and the remaining regions of the brain samples 
obtained from 1-6 months aged Cln3 null mutant mice were performed [436]. The 
results showed that the concentrations of glutamate, glutamine, myo-inositol, 
creatine and N-acetyl-aspartate (NAA) were increased, whereas levels of lactate 
and acetate were decreased with age.  
The effect of aging and development on the profiles of urinary endogenous 
metabolites in male Wistar rats was also investigated using both 1H NMR 
spectroscopy and HPLC/TOFMS based metabonomics [285]. The endogenous 
metabolites were profiled in urine samples collected every two weeks from 4 
weeks up to 20 weeks of age. Multivariate data analysis enabled clusters to be 
visualized within the data according to age, with 4 and 6 weeks showing the 
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greatest differences by both analytical techniques. Markers detected by 1H NMR 
spectroscopy including creatinine, taurine, hippurate and amino acids/fatty acids 
were found to increase with age, whilst citrate and glucose/myo-inositol were 
found to decline. HPLC/MS data found that a number of unidentified ions, such as 
m/z 181.0874, 229.1469 and 199.0988, were only detected at 4 weeks of age, while 
a range of ions such carnitine increased with age.  
Nicholson et al. [298] investigated the urinary metabolic profiles throughout the 
lifetimes of control-fed and diet-restricted dogs using 1H NMR-based 
metabonomics, and found that urinary metabolic variation was predominantly 
influenced by aging. A number of metabolites were found to vary with age, among 
which urine creatinine was most marked. Urine obtained from dogs at a very 
young age (13 weeks) presented relatively higher amounts of mixed N-
acetylglycoproteins and dimethylamine, but lower amounts of 2-oxobutyrate, 2-
propanol, dimethylglycine, creatinine, hippurate, and 3-(hydroxyphenyl) propionic 
acid (3-HPPA). The urine samples from growing dogs (1.5 years old) contained 
higher concentrations of taurine, hippurate, creatinine, and 3-HPPA and lower 
concentrations of acetate, dimethylamine, mixed glycoproteins, 1-
methylnicotinamide, lactate, succinate, and trimethylamine N-oxide, with respect 
to the samples from other age groups. Metabolites separating dogs aged 9 years 
from the younger dogs included elevated levels of α-ketobutyrate, 2-propanol, 
lactate, alanine, succinate, creatinine, dimethylglycine, and trimethylamine and 
lower concentrations of mixed glycoproteins. The authors believed that their study 
might form part of a strategy to monitor and reduce the impact of age-related 
diseases in the dog, as well as providing more general insights into extension of 
longevity in higher mammals. 
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An UPLC/ESI/TOFMS-based metabonomic study on hair collected from 
WKY/Izm mice at 10, 26 and 43 weeks age was reported [437]. The amount of the 
ion m/z 362.15 increased with age, while the ion m/z 265.11 decreased. The authors 
suggested that their method could be appropriate for screening marker compounds 
related to aging as well as for screening new biomarkers. However, the identities of 
these maker metabolites were not investigated.  
Lawler et al. investigated the effects of lifetime diet restriction study on Labrador 
retrievers dogs [438]. They observed 1.8 years longer median lifespan among diet-
restricted dogs, with delayed onset of late life diseases, and the metabonomics-
based urine metabolite trajectories reflected diet restriction-related differences.  
Schnackenberg et al. examined age-related urinary changes in Sprague Dawley rats 
of 25, 40 and 80 days old using both 1H NMR and UPLC/TOFMS-based 
metabonomics [426]. The two platforms revealed similar age-related differences, 
showing decreased concentrations of many Krebs cycle intermediates along with 
increased levels of oxidized antioxidants in urine of older rats, which is consistent 
with current theories on aging and its association with diminishing mitochondrial 
function and increasing levels of reactive oxygen species.  
A study on brain tissue [439] using 1H NMR indicated that myo-inositol, 
creatine/phosphocreatine, taurine, glutamate, choline and phosphocholine were 
age-specific in vesicular monoamine transporter 2 (VMAT2) and C57BL/6 mice.  
Wu et al. investigated the effects of aging on rat urinary metabolites and evaluated 
the anti-aging effects of the total flavone of Epimedium (TFE) using 1H NMR in 
Sprague-Dawley rats at age of 4, 10, 18 and 24 months old [440]. By multivariate 
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analysis, 26 compounds were found to be highly related to aging, including 
creatinine, lactate, alanine, methylamine and dimethylamine. In general, the 
potential markers included creatinine metabolites, aliphatic amines metabolites and 
intermediates or end products of energy metabolism.  
In another study, GC/TOFMS was used for the metabolic profiling of plasma 
samples obtained from spontaneously hypertensive rats (SHR) and Wistar Kyoto 
(WKY) rats [441]. Several age-related variations were observed from 10 to 18 
weeks for both the SHR and WKY rats, such as hexadecanoic acid, citric acid, 
tyrosine, tryptophan, threonine, tocopherol, sitosterol, and nonesterified 
cholesterol.  
Metabonomic methods utilizing 1H NMR spectroscopy was applied to investigate 
the metabolic profiles of senescence-accelerated mice (SAM) [442]. The serum 
metabolome of senescence-prone 8 (SAMP8), a murine model of age-related 
learning and memory deficits and AD, was compared with that of control 
senescence-resistant 1 (SAMR1), which shows normal aging process. Metabolite 
variations such as lack of inosine, decreased glucose, choline, phosphocholine, 
high-density lipoprotein (HDL), low-density lipoprotein (LDL), 3-hydoxybutyrate, 
citrate and pyruvate, as well as increased lactate, alanine, methionine, glutamine 
and very low-density lipoprotein (VLDL) were observed in serum of SAMP8 
compared with those of SAMR1, suggesting perturbed glucose and lipid 
metabolisms in SAMP8.  
In a very recent study [263], the effects of age, sex and race on the relative 
concentrations of small-molecule metabolites in the blood of 269 healthy adults 
were examined using GC/MS and LC/MS methods. The results showed that of the 
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more than 300 detected metabolites, significant changes in the relative 
concentrations of more than 100 metabolites were associated with age. Compounds 
related to lipid metabolism, including fatty acids, carnitine, β-hydroxybutyrate and 
cholesterol, were lower in the blood of younger individuals. By contrast, relative 
concentrations of DHEAS was lowest in the oldest age group [263].  
Based on the current metabonomic studies on aging, 1H NMR spectroscopy-based 
metabolic analysis on urine samples appeared to be the most popular strategy for 
aging biomarker profiling. On the other hand, GC/MS isles exploited as an 
analytical approach for metabolic profiling of aging. While the disparity in the 
adoption rats of NMR and GC/MS in the metabolic profiling of aging has not been 
formally discussed, it follows the same trends of other biomedical fields of 
metabonomic research. This is indicative that the greater adoption rate of NMR in 
aging metabonomic research is related to the earlier establishment of NMR 
spectroscopy in this filed rather than its analytical “superiority” compared to the 
respective chromatographic mass spectrometric techniques. In addition, most of 
these studies investigated only one species. Although endogenous metabolites may 
be conservative across species, brain aging is possibly species-specific. Since 
different animal models are adopted during the preclinical study on aging in 
pharmaceutical industries, it is pertinent to investigate, compare and understand the 
marker metabolites related to different species of animals. Recently, pigmented 
strains of rats such as the Lister Hooded (LH) rats have been used increasingly in 
neurological study of pain [443], PD [444], and AD [445]. However, no 
metabonomics aging study has been performed using LH rats thus far. In addition, 
current reported studies only examined the metabolic variations related to aging in 
a single biological matrix, such as brain tissue, serum or urine. In this thesis, we 
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aimed to identify the biomarkers related to aging in various in vivo and in vitro 
models. Instead of 1H NMR spectroscopy, we used GC/MS technologies in the 
metabolic profiling of various biological matrices including brain, plasma and 
urine obtained from various animal models including LH rats, C57BL/6J mice and 
in vitro cortical neuron cell cultures to elucidate the marker metabolites related to 
aging. In addition, LA, a natural occurring antioxidant, has been tested for the 
intervention of aging and AD in preclinical and clinical studies [206, 446-452]. 
Herein, we also examined the effects of LA treatment on the progression of aging 
in LH rats.  
2.2 MATERIALS AND METHODS 
2.2.1 Chemicals and reagents 
The lyophilized type III urease from Canavalia ensiformis 
(15,000-50,000 units/g solid powder), methoxyamine hydrochloride and pyridine 
(ACS grade) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, Mo. 
USA). The commercial derivatization reagent, MSTFA containing 1% TMCS was 
obtained from Pierce Biotechnology (Rockford, IL, USA). HPLC-grade methanol 
and acetonitrile were purchased from Tedia Company Inc. (Fairfield, OH, USA). 
HPLC grade toluene and acetone were from J.T. Baker (Mallinckrodt Baker, 
Phillipsburg, NJ, USA) and Mallinckrodt UltimAR (Mallinckrodt Baker, 
Phillipsburg, NJ, USA), respectively. GC-grade hexane was purchase from Fisher 
Scientific (Leicestershire, UK). The water used was of Milli-Q grade purified by a 
Milli-Q UV Purification System (Millipore, Bedford, MA, USA). All other 
chemicals and reagents used for the experiments were of analytical, HPLC or GC 
grades. 
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2.2.2 Animals and grouping schedules 
2.2.2.1 LH rats 
Healthy male LH rats were obtained from NGI CEDD R&D center of 
GlaxoSmithKline (GSK, Biopolis, Singapore). Each rat was housed in an 
individual cage in a room with controlled temperature (25 ± 1°C) and humidity (55 
± 5%) and a 12-hr light/dark cycle. Animals had free access to standard laboratory 
diet and water before the experiments. All animal experimental protocols and 
procedures were approved by the “Institutional Animal Care and Use Committee” 
(IACUC) of the National University of Singapore (NUS) or the National Advisory 
Committee for Laboratory Animal Care and Research of GSK Centre for Cognitive 
and Neurodegenerative Disorders. The samples collection and animal treatment 
were performed by GSK staff.  
Aged rats (2-year old, n=20) and young rats (2-month old, n=20) were used for the 
collection of urine, plasma and brain samples without any treatment. For LA 
treatment study, animals were randomized into three groups: young rats dosed with 
LA (LA-treated young, 2-month old, n=8, 50 mg/kg/day for 12 days), aged rats 
dosed with LA (LA-treated aged, 24-month, n=10, 50 mg/kg/day for 12 days), and 
aged rats dosed with vehicle solution (control-aged, 24-month old, n=8). The 2.5% 
sodium bicarbonate (clear orange) was freshly prepared in Milli-Q water. For the 
LA dosing solution, 5% sodium bicarbonate solution was first prepared, and LA 
was sonicated at 30ºC for 20 min at 20 mg/mL. Thereafter, LA solution was further 
diluted with Milli-Q water to a final concentration of 10 mg/mL in 2.5% sodium 
bicarbonate solution. The animals were dosed with vehicle solution (5 mL/kg/day) 
or LA solution (50 mg/kg/day) by oral gavage for 12 consecutive days. 
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2.2.2.2 C57BL/6J mice 
Healthy male C57BL/6J mice were purchased from the Laboratory Animals 
Centre, NUS. Mice were housed in cages individually in a room under controlled 
temperature (23-24ºC) and 12-hr day-night cycle. Animals were maintained at the 
Animal Holding Unit of NUS with free access to standard diet and tap water for 1 
or 5 months before the biological samples collection. All animal experimental 
protocols and procedures were approved by the IACUC of NUS.  
2.2.3 Cortical neuron cell culture 
The cortical neuron cells from C57BL/6J mouse used in this study were kindly 
provided by Dr. Sashi Kesavapany (Department of Biochemistry, Yong Loo Lin 
School of Medicine, NUS). Briefly, cortices of brain collected from C57BL/6J 
mice were dissected and the meninges were removed. The primary cortical neuron 
cells were prepared from the cortices and plated in 10 cm i.d. culture dishes 
(Falcon, Becton Dickinson and Company, San Jose, CA, USA) at approximately 2 
× 106 cells/dish. The cells were cultured in complete Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/mL 
penicillin G and 100 µg/mL streptomycin, maintained in a humidified atmosphere 
of 5% CO2 in air at 37ºC and provided with fresh medium every 2 days.  
2.2.4 Sample collection and preparation 
The urine samples were collected before the collection of blood and brain samples 
from animals (LH rats and C57BL/6J mice). All the frozen samples were thawed at 
room temperature for 2 h and vortexed before further preparation. 
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2.2.4.1 Urine 
Urine sample was collected from each animal 2 days before sacrificing the animal 
for blood and brain tissue collection. Each animal was placed in the metabolic cage 
individually and the urine sample was collected on dry ice for 24 h. During the 
period of urine sample collection, all animals were fasted while given free access 
to drinking water. Upon collection, each urine sample was vortex-mixed 
immediately, divided into 1-mL aliquots and stored at -80°C for subsequent 
metabonomic investigations. The total volume of each urine samples was also 
recorded.  
Urine sample was extracted using methanol as described previously with minor 
modification [248]. 100 µL of urine was added with 20 µL (30 units, 200 mg/mL 
in Milli-Q) of urease (Type III) and incubated at 37ºC for 1 h to decompose and 
remove excess urea. After adding 900 µL of ice-cold methanol, the sample was 
vortex-extracted for 10 min and centrifuged at 16,000 × g for 10 min at 4ºC. The 
supernatant (900 µL) was transferred to a glass tube with screw cap, and 
evaporated to dryness under nitrogen at room temperature (23ºC). Then, 200 µL of 
toluene was added to each sample, vortex-mixed for 1 min, and evaporated under a 
stream of nitrogen using TurboVap LV evaporator (Caliper life sciences, 
Hopkinton, MA, USA) to remove the trace amount of water residue. After that, 30 
µL of methoxyamine hydrochloride in anhydrous pyridine (20 mg/mL) was added, 
and the solution was vigorously vortexed for 10 min. Methoximation reaction was 
performed at 60°C for 1 h and room temperature for 16 h. The samples were then 
trimethylsilylated at 60°C for 1 h by adding 70 µL of MSTFA with 1% TMCS as 
catalyst. At last, the derivatized samples were added 50 µL of GC-grade hexane, 
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vortex-mixed for 1 min, and subsequently transferred to a 300-µL glass conical 
insert for GC/MS analysis within 24 h. 
2.2.4.2 Plasma 
After the urine collection, animals were acclimatized in the maintenance cages for 
two days. To collect the blood, animals were deeply anesthetized with 200 μL of 
ketamine/xylazine mixture (75 mg/kg, 5 mg/kg) by intraperitoneal (i.p.) injection. 
Blood was collected by cardiac puncture before animals were sacrificed by cervical 
dislocation for the brain collection. Blood samples were collected into an 
Eppendorf tube pre-coated with 20 μL of 5% EDTA (ethylenediaminetetra acetic 
acid) in Milli-Q water as anticoagulant. Before that, the syringe (1 mL or 2 mL) 
and needle (25 G) used were also coated with 5% EDTA to avoid the coagulation 
during the sampling. The collected blood were immediately placed on ice for 30 
min and centrifuged at 3,000 × g for 15 min at 4ºC. The plasma was collected and 
immediately stored at -80ºC until extraction for both metabonomic study and 
steroid analysis.  
The plasma sample was prepared according to the protocol previously reported 
[249] with minor modification. Briefly, 950 µL of methanol/water mixture (8:1 
v/v) was added to 50 µL of plasma, vigorously vortex-mixed for 1 min, and 
incubated at -20ºC for 30 min. After centrifugation at 16,000 × g for 30 min at 4ºC, 
900 µL aliquot of the supernatant was then transferred to a deactivated glass tube 
with screw cap and evaporated to dryness under a stream of nitrogen using 
TurboVap LV evaporator. Then, 200 µL of toluene was added to each sample, 
vortex-mixed for 1 min, and evaporated under nitrogen to remove the trace amount 
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of water residue. Thereafter, dried residue of each sample was subjected to the 
same derivatization steps as described in section 2.2.4.1.   
2.2.4.3 Whole brain 
Each animal was sacrificed by cervical dislocation and the whole brain (including 
cerebellum but excluding olfactory bulbs) was then rapidly collected and stripped 
of meninges. For the mice, after rinsing with ice-cold 1 × phosphate buffered saline 
(PBS) buffer, brain was cut longitudinally and stored at -80°C separately, and the 
right half was used for metabonomic study and steroid analysis.  
The whole brain of rat (1.5-2 g) or right half brain of mice (200-300 mg) was 
thawed at 4°C, weighed and recorded. After adding 2 mL/g tissue of Milli-Q water, 
brain tissues were homogenized thoroughly using a Heidolph DIAX 900 
homogenizer (Heidolph Instruments, Germany). During the homogenization, the 
probe was washed with methanol/water (50/50, v/v) twice and wiped to dryness 
with tissue paper after homogenizing each sample to avoid any cross-over 
contamination. All the procedures were performed on ice. After vortex-mixing, a 
100 µL aliquot of the brain homogenate was used for the metabonomic study, 
while the remaining sample was kept for steroid analysis.  
Each brain sample was prepared according to the protocol previously reported  
[269] with minor modification. The brain homogenate (100 µL) aliquot was added 
with 1 mL of pre-chilled one-phasic mixture solvent of methanol/chloroform (2:1, 
v/v), vortex-mixed for 3 min, ultrasonicated in water bath for 10 min and incubated 
at -20ºC for 30 min. The sample was then centrifuged at 16,000 × g and 4ºC for 30 
min. A 900 µL aliquot of the supernatant was then transferred to a deactivated 
 62 
glass tube. The protein pellets were re-extracted using 1 mL of one-phasic mixture 
of chloroform/methanol/water (2:5:2, v/v/v), and the supernatant was collected and 
pooled with the previous extraction. The combined extract was evaporated to 
dryness under a stream of nitrogen using TurboVap LV evaporator. Then, 200 µL 
of toluene was added to each sample, vortex-mixed for 1 min, and evaporated 
under nitrogen to remove the trace amount of water residue. Thereafter, dried 
residue of each sample was subjected to the same derivatization steps as described 
in section 2.2.4.1. 
2.2.4.4 Cell culture and medium 
The primarily cultured cells from mouse brain cortices were maintained in DMEM 
for 5, 7, 10, 18 and 21 days (batch 1) or 7, 14, 21, and 28 days (batches 2 and 3). 
After collecting the cell culture medium immediately at the ending of each time 
point, the cells were washed with ice-cold 1 × PBS buffer, and quenched by 
incubating with methanol/water (75/25, v/v) at -40°C for 30 min. The cells were 
then collected using cell scrapper samples, counted and then centrifuged at 500 × g 
and 4°C for 5 min. Both media and cell pellet were stored at -80ºC until analysis. 
The culture medium samples were prepared according to the protocol for plasma as 
described above with minor modification. Briefly, 900 µL of ice-cold methanol 
was added to 100 µL of culture medium and vortex-mixed for 10 min. After 
centrifugation at 16,000 × g and 4ºC for 15 min, 900 µL aliquot of the supernatant 
was transferred to a deactivated glass tube with screw cap and evaporated to 
dryness under a stream of nitrogen using TurboVap LV evaporator. Then, 200 µL 
of toluene was added to each sample, vortex-mixed for 1 min, and evaporated 
under nitrogen to remove the trace amount of water residue. Thereafter, dried 
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residue of each sample was subjected to the same derivatization steps as described 
in section 2.2.4.1. 
The cell pellets were quenched in methanol/water (75/25, v/v) at -30°C for 30 min 
to halt biological activity and minimize degradation immediately after the 
collection. Metabolites in the cells were extracted using a one-phasic 
methanol/chloroform method as described previously [250] with minor 
modification. Briefly, 1 mL of ice-cold methanol (pre-chilled at -20ºC) was added 
to the frozen cell pellets stored at -80ºC immediately. The tissue-solvent mixture 
was allowed to thaw at 4ºC for 30 min. After vortex-mixing, 400 µL of the cell 
suspension was added with 200 µL of ice-cold chloroform (pre-chilled at -20ºC) to 
break the cell membrane. The samples were vigorously mixed for 10 min, 
ultrasonicated in water bath for 10 min and incubated at -20ºC for 30 min. Then, 
the sample was centrifuged at 16, 000 × g for 30 min at 4ºC (cold room). The 
supernatant was collected into a deactivated screw-cap glass tube, while the pellets 
from the cells was re-extracted with 1 mL of ice-cold one-phasic mixture of 
chloroform/methanol/water (2:5:2, v/v/v, pre-chilled at -20ºC). The sample was 
centrifuged at 16, 000 × g for 30 min at 4ºC (cold room), and the supernatant was 
pooled with the original extracted fractions into the glass tube. The combined 
extracts were evaporated to dryness under a stream of nitrogen using TurboVap 
LV evaporator. Then, 200 µL of toluene was added to each sample, vortex-mixed 
for 1 min, and evaporated under nitrogen to remove the trace amount of water 
residue. Thereafter, dried residue of each sample was subjected to the same 
derivatization steps as described in section 2.2.4.1. 
2.2.5 GC/MS analysis 
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A Shimadzu QP-2010 GC/EI/MS system (Shimadzu Corp., Japan) was used for all 
GC/MS profiling experiments. A 30-m length DB-5 MS (5% phenyl 
polysilphenylene-siloxane phase) fused silica capillary column was used for 
separation (250 µm i.d., 0.25 µm film; J&W Scientific, Folsom, CA, Agilent 
Technologies, Palo Alto, CA, USA). GC/MS parameters were set up as listed in 
Table 2-2.  
Table 2-2  GC/MS configuration and condition parameters for the analysis of all biological 
samples 
Parameters (units) Settings 
GC  
Injection temperature (ºC) 250 
Injection mode  Split 
Injection volume (µL) 1 
Sampling time (min) 1 
Flow control mode Linear velocity  
Pressure  (kPa) 123.3  
Total flow (mL/min) 45.1 
Column flow (mL/min) 2 
Linear velocity (cm/s) 51.6 
Purge flow (mL/min) 3 
Split ratio  1:20 
High pressure injection (kPa) Off 
  
GC/MS interface and MS  
Ion source temperature (ºC) 200 
Interface temperature (ºC) 250 
Solvent cut time (min) 4 
Detector gain mode Relative to tuning value 
Detector gain  0 
Threshold 1000 
Acquisition mode  Scan 
Event time (sec) 0.5 
Scan speed  1428 
Scan m/z 50-700 
For each sample, a fresh microvial was taken to avoid sample carryover and cross-
contamination. The derivatized metabolites in the biological samples were injected 
in the split mode at a split ratio of 20:1. The injector temperature was set at 250°C. 
Helium, the carrier gas, was maintained at a constant flow rate of 1 mL/min during 
the analysis. EI ionization mode was used for mass detection, with an electron 
energy of 70 eV. The interface temperature and ion source were set at 250 and 
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200ºC, respectively. Mass spectra were acquired with a scan range of m/z 50 to 700 
and an acquisition rate of 20 spectra per second. Chromatogram acquisition, data 
handling, automated peak deconvolution and library search were performed using 
the GCMSsolution software (Version 2.5, Shimadzu Corp., Japan).  
Table 2-3  GC column temperature gradient programs for the analysis of animal and in vitro cell 
model biological samples 
Rate (ºC/min) Temperature (ºC) Hold time (min) 
Urine   
/ 60 2 
5 130 0 
2 160 5 
5 260 0 
20 300 5 
   
Brain  & Plasma    
/ 60 1 
5 280 1 
20 300 5 
   
Culture medium   
/ 60 0.5 
10 200 3.5 
20 300 5 
   
Cell pellet   
/ 60 1 
10 300 5 
 
Different temperature programs were used for urine, plasma, brain tissue, cell 
pellet and medium samples (Table 2-3). For example, for the analysis of urine 
samples, the column temperature was initially maintained at 60ºC for 1 min, and 
then increased to 280ºC in increments of 5ºC /min with a 1 min hold-time. After 
that, the oven temperature was increased to 300ºC at 20ºC /min with another 1 min 
hold-time, followed by an isocratic cool down to 60ºC and an additional 5 min 
delay before the next analysis. 
2.2.6 Data pre-processing 
 66 
The biological samples used for each metabonomic investigation were analyzed as 
a single batch and in a random order to minimize any systematic analytical error 
and subjective interference. In this way, retention time shift among the samples in 
one batch was kept to a minimum. Each sample analysis resulted in a GC/MS Total 
Ion Current (TIC) chromatogram generated by GCMSsolution (Table 2-4). These 
TIC chromatograms were zoomed in and compared by observing the overlapped 
peaks to confirm the chromatographic reproducibility of the method. After that, 
one of the typical chromatograms was used to generate a Mass Chromatogram 
(MC) compound table. As only the intensity of the target ion was used for the 
integration, the peak area of MC was expected to be smaller than that from TIC, 
which will integrate the intensity of all the fragmented ions. Therefore, MC was 
selected for the peak area integration due to its higher specificity.  
Table 2-4 Peak integration parameters used in the data pre-processing 
Parameters Settings 
Integration mode  Detail 
Slope 200/min 
Width  2 s  
Drift 200/min 
T. DBL 1000 min 
Number of smoothing times 5 
Smoothing width 3 s 
In order to create a robust and interpretable model for the comparison of the 
samples, the commensal and representative peaks shown in the GC/MS profile 
were extracted as variables for each sample. Only the peaks presented in more than 
80% of the TIC in each specific group were included. In addition, the specific 
peaks presented in a specific group were also included in the compound table. By 
these means, the acquired GC/MS data meet the following criteria [453]: (i) each 
sample was characterized by the same number of variables; (ii) each of these 
variables was represented across all observations with the same sequence; (iii) each 
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variable in one sample had the same biological meaning or represents the same 
metabolite throughout all samples; and (iv) all the peaks presented in the groups 
for the comparison purpose were included. The peaks with height S/N values lower 
than 10 were rejected. Peak areas were calculated using selected target ion for each 
metabolite. The total peak area for each detected peak was normalized against the 
sum of the peak areas within that sample chromatogram. Normalized area values of 
all the peaks were used as the variables for the multivariate data analysis.  
2.2.7 Multivariate and univariate data analyses 
All multivariate analyses and modeling on the normalized data were carried out 
using SIMCA-P 11.0 (Umetrics, Umeå, Sweden). Both unsupervised PCA and 
supervised PLS-DA were implemented to evaluate the models. The dataset was 
visualized by unsupervised PCA to check for the outliers, and followed by PLS-
DA to maximize the discrimination between groups. Both PCA and PLS-DA were 
carried out using unit variance scaling. For each model built, the loading scores 
and the Variable Importance in the Projection (VIP) parameters were examined to 
identify which metabolites contributed most to clustering of observations or a trend 
observed in the data. Loading scores describe the correlation between the original 
variables and the new component variables, whereas VIP parameters are 
essentially a measure of the degree to which a particular variable explains the Y 
variance (class membership or linear trend). Samples from the same groups were 
classified into one class in PLS-DA modeling. Model performance was evaluated 
using the R2 and Q2 parameters, both of which vary between 0 and 1, where 1 
indicates a perfect fit. Components with VIP value of greater than 1, which play 
important roles in the separation, were regarded as potential marker metabolites 
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and subjected to subsequent univariate statistical analysis performed using SPSS 
16.0 (SPSS, Inc., Chicago, IL, USA) and R module.  
Differences of marker metabolites between two groups were analyzed statistically 
using unpaired Welch’s t-test with Bonferroni correction and unequal variances 
assumed. The large number of variables measured simultaneously in “-omics” 
gives rise to a massive multiple testing situation with an accumulating risk of type 
I errors (i.e. falsely rejecting the null hypothesis) being increased. To help reduce 
the possibility of type I errors, the critical P-value was modified using a Bonferroni 
correction, which was calculated by dividing 0.05 with the number of parallel 
comparisons. If no variable fulfilled the corrected cutoff threshold, P < 0.05 or 
0.01 was used instead as the criteria for significance. For the cell line study with 
samples size less than 6, however, there is no guarantee of normality in the data, 
which is required by t-test. In these cases, Wilcoxon rank sum test instead of t-test 
was used, and the rank sums were referred when selecting the markers. The criteria 
for statistical significance was set using the cutoff with Bonferroni correction or P 
< 0.05. Finally, the potential biomarkers were selected accordingly and rigorously 
searched using National Institute of Standards and Technology (NIST) 05 (2005), 
NIST05s, NIST27, NIST147 and Wiley7 libraries and an in-house mass spectra 
library database with EI spectra. The variables with similarity index (SI) ≤ 70% 
were considered as unidentified, whilst those with greater SI as tentatively (70-
85%) or affirmatively (≥ 85%) identified. The identified maker metabolites were 
searched using HMDB (Human Metabolome Database) and KEGG (Kyoto 
Encyclopedia of Genes and Genomes), and the metabolites showed no biological 
significance (e.g. tetrapentacontane) were excluded. The tentatively identified 
variables (SI 70-85%) could provide structural information, although cannot give 
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us the confirmed compounds. However, it may not be reasonable to include the 
putative markers in the mechanism interpretation before confirming their structure 
using corresponding standards. In this thesis, only the affirmatively identified 
compounds (SI ≥ 85%) were involved in the discussion and interpretation of their 
biological significances in the metabolic pathways.  
2.3 RESULTS 
2.3.1 C57BL/6J mice 
We analyzed the brain, plasma and urine samples obtained from young (1-month 
old, n=10) and aged (5-month old, n=10) C57BL/6J mice. The representative 
GC/MS TIC chromatograms of these biological matrices are presented in Figure 
2-1, with 132, 84 and 125 peaks detected in brain, plasma and urine, respectively. 
Visual inspection of the TIC chromatograms of brain, plasma and urine revealed 
that, although many of the components were present similarly, there were a 
number of differences in overall composition of metabolites in these matrices 
between young and aged mice. The PCA scores plots of the normalized data 
showed aged mice were readily separated from the young mice based on the brain, 
plasma and urine metabolite profiles. Subsequently, supervised PLS-DA was used 
to maximize the separation of the two age groups of mice (Figure 2-2), which 
showed clear separations between the classes in the first component for all the 





Figure 2-1 Representative GC/MS TIC chromatograms of metabolites extracted from brain (A), 











Figure 2-2 PLS-DA score plots of GC/MS variables detected from whole brain (A), plasma (B) 
and urine (C) samples of C57BL/6J mice separating young (1-month old age, black, 
n=10) and aged (5-month old age, red, n=10) groups. Whole brain (R2X=0.606, 
R2Y=0.938, Q2Y=0.681); plasma (R2X=0.589, R2Y=0.964, Q2Y=0.829); urine 


















































Table 2-5 Potential marker metabolites related to aging identified from brain, plasma and urine 
samples of young (1-month old, n=10) and aged (5-month old, n=10) C57BJ/6J mice 
No. a Metabolite VIP P b, # Fold c SI d 
Brain      
114 Unidentified 1.99 3.00E-07 2.4 61 
78 Ribitol 1.87 8.10E-06 1.97 80 
16 Phosphoric acid 1.43 6.00E-04 1.8 90 
9 Oxalic acid 1.73 4.59E-05 1.73 87 
69 Isopropenyl succinic acid 1.87 2.80E-06 1.71 71 
12 Oxalic acid 1.62 2.93E-04 1.69 85 
66 2-keto-4-methylbutyrate 1.84 1.30E-06 1.65 73 
14 Butyric acid 1.4 1.00E-03 1.54 82 
76 Glycerol 1.78 4.00E-06 1.51 83 
79 Pantothenic acid 1.53 1.44E-04 1.27 82 
48 Threonic acid 1.45 9.05E-04 -1.45 94 
      
Plasma      
38 Unidentified 1.12 4.73E-02 17.05 63 
81 Unidentified 1.2 2.06E-02 5.74 65 
18 Unidentified 1.41 2.32E-02 1.39 64 
58 Stearic acid 1.03 4.37E-02 -1.18 95 
21 Unidentified 1.11 4.11E-02 -1.23 68 
14 Phosphoric acid 1.68 3.90E-03 -1.24 87 
74 Unidentified 1.19 4.67E-02 -1.25 54 
50 Ribonic acid 1.55 5.50E-03 -1.27 76 
82 Stigmasterol 1.92 2.30E-03 -1.37 85 
71 1-Monooleoylglycerol 1.16 3.05E-02 -1.39 71 
33 Unidentified 1.32 3.35E-02 -1.49 60 
73 Unidentified 1.39 2.47E-02 -1.51 65 
32 Unidentified 1.43 2.36E-02 -1.8 69 
68 Unidentified 1.4 3.86E-02 -1.92 62 
      
Urine      
40 Threonic acid 1.17 6.80E-04 -1.34 91 
65 Isocitric acid 1.12 5.28E-03 -1.38 92 
97 5-Hydroxyindoleacetic acid 1.16 5.40E-04 -1.44 77 
66 Ribo-hexitol 1.39 4.00E-05 -1.58 88 
54 Ribose 1.22 3.10E-04 -1.75 77 
105 Glucuronic acid 1.46 9.00E-05 -2.09 81 
a: peak numbers in the compound list; b: Welch’s t-test P-value; c: fold changes when 5-month 
group compared to 1-month group; d: SI (%) of library search; #: cutoff threshold with Bonferroni 
correction for brain, plasma and urine was 1.04E-03, 1.56E-03 and 9.43E-04, respectively;  
 
The statistics parameters for the regression modeling (R2X, R2Y, Q2Y) indicated 
that the models presented was able to discriminate between the young (1-month 
old) and aged (5-month old) mice (Figure 2-2). Finally, the dominant metabolites 
influencing the differentiation between young and aged mice were identified using 
EI libraries (Table 2-5).  
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The results showed that almost all the metabolites presented higher relative 
concentrations in brain, whilst declined in plasma and urine samples obtained from 
aged mice. In brain, the marker metabolites that increased in levels with aging 
included oxalic acid, phosphoric acid, butyric acid, isopropenyl succinic acid, 
glycerol and ribitol, while threonic acid declined in aged mice. The perturbation of 
the metabolism of butyric acid, a carboxylic acid, suggested that energy 
metabolism may be related to brain aging. On the contrary, metabolites detected in 
plasma (e.g. phosphoric acid, stearic acid, and stigmasterol) and urine (e.g. 
threonic acid, isocitric acid and ribo-hexitol) samples were all declined, except for 
some unidentified compounds, with two of those significantly elevated (Table 2-5). 
All these compounds are putatively related to energy metabolism, indicating that 
energy metabolism may play important role in the aging process regardless of 
brain or whole system. In particular, the decrease of stigmasterol levels in plasma 
may suggest the perturbation of cholesterol metabolism, which plays vital role in 
the brain function. 
2.3.2 LH rats 
In this study, we analyzed the brain, plasma and urine samples obtained from 
young (2-month old, n=20) and aged (24-month old, n=20) LH rats. The obtained 
GC/MS TIC chromatograms are presented in Figure 2-3, with 155, 94 and 162 
peaks detected in brain, plasma and urine, respectively. Visual inspection of the 
TIC chromatograms of brain, plasma and urine samples revealed differences in 
metabolite profiles between young and aged rats. The PCA score plots of the 
normalized data showed aged rats were readily separated from the young rats 
based on the brain, plasma and urine metabolite profiles. Two observations in aged 
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group were found to be far away from the remaining observations in plasma 
profiling study. They were therefore considered as an outlier and excluded from 
the subsequent analysis (data not shown). Subsequently, supervised PLS-DA was 
applied to the remaining observations to maximize the separation (Figure 2-4), 
which showed clear separations between the classes in the first component for all 
the samples. The statistics parameters for the regression modeling (R2X, R2Y, Q2Y) 
indicated that the models presented were able to discriminate between the young 
and aged rats. The dominant marker metabolites influencing the differentiation 
between young and aged rats are listed in Table 2-5.  
Like the results observed with C57BL/6J mice, a number of metabolites were 
found to vary with age across all three samples, suggesting the global perturbation 
of metabolic associated with aging. In brain, the aged rats showed increased 
concentrations of cholesterol, phosphorus acid and myo-inositol, while lower levels 
of glycolic acid, oxalic acid, fructose and mannose, as well as some possible 
cholesterol-derivatives. Notably, the increase of myo-inositol was consistent with 
the previous reports on aging [263, 285, 298, 426, 436-442]. In addition, the 
elevation in cholesterol while decline in its possible metabolites suggested the 
perturbation of cholesterol metabolism pathway. There were 39 and 63 compounds 
that varied with the aging process in plasma and urine, respectively. Most of the 
metabolites detected in plasma included organic acids, amino acids and sterols that 
increased their in the relative levels with aging. These metabolites were 
ethanolamine, carbamic acid, oleic acid, cholesterol, arachidonic acid, 
stigmasterol, stearic acid and myo-inositol. Only a few compounds such as 





Figure 2-3  Representative GC/MS TIC chromatograms of metabolites extracted from brain (A), 












Figure 2-4 PLS-DA score plots of GC/MS variables detected from whole brain (A), plasma (B) 
and urine (C) samples of LH rats separating young (2-month old age, black, n=20) 
and aged (24-month old age, red, n=20) groups. Whole brain (R2X=0.846, 
R2Y=0.987, Q2Y=0.924); plasma (R2X=0.445, R2Y=0.95, Q2Y=0.859); urine 
















































Table 2-6 Marker metabolites identified from brain, plasma and urine samples of young (2-
month old) and aged (24-month old) LH rats (n=20) 
No. a Metabolite VIP P b, # Fold c SI d 
Brain      
132 Unidentified 1.6 2.60E-04 2.06 59 
138 Unidentified 1.96 9.24E-07 1.69 66 
9 Isobutyric acid 2.14 1.92E-08 1.28 82 
151 Cholesterol 2.28 2.79E-10 1.23 96 
22 2-chloro-2’-oxy-Triethylamine 1.85 7.41E-06 1.22 78 
29 Phosphorus acid 1.82 1.24E-05 1.22 91 
100 Myo-inositol 2.08 1.33E-07 1.19 92 
15 Glycolic acid 1.81 8.40E-06 -1.19 97 
21 Oxalic acid 1.7 1.21E-04 -1.24 88 
82 [1,1’-Biphenyl]-4-carboxylic acid 1.7 6.35E-05 -1.26 95 
99 N-Acetyl glucosamine 1.74 6.28E-05 -1.36 71 
116 Fructose 1.78 3.48E-05 -1.46 87 
118 Mannose 1.84 2.31E-05 -1.51 88 
117 Mannose 1.87 1.48E-05 -1.52 93 
152 24-Nor-22,23-methyl ene cholest-5-en-3β-ol 2.08 1.58E-07 -2.14 75 
      
Plasma      
80 Ethanolamine 1.38 2.50E-06 7.73 85 
83 Carbamic acid 1.32 8.93E-06 6.72 76 
73 Carbamic acid 1.42 7.03E-08 5.34 88 
62 Palmitelaidic acid 1.29 1.51E-07 4.48 84 
70 Oleic acid 1.41 1.16E-09 3.79 96 
69 9,12-Octadecadienoic acid 1.46 4.34E-10 3.01 79 
89 Cholesterol 1.5 3.28E-10 2.85 96 
71 Oleic acid 1.35 1.06E-08 2.77 89 
92 Unidentified 1.13 2.29E-05 2.75 66 
76 Arachidonic acid 1.42 4.21E-07 2.65 91 
28 2-Methylbutane 1.38 1.70E-08 2.56 70 
91 Stigmasterol 1.26 5.05E-07 2.34 86 
86 Stearic acid 1.3 5.95E-05 2.31 88 
72 Stearic acid 1.5 1.26E-08 2.18 95 
15 Butanoic acid 1.13 1.78E-06 2.17 96 
85 2-Monostearin 1.23 2.20E-06 2.09 85 
64 Hexadecanoic acid 1.46 2.09E-10 2.07 95 
77 Myo-inositol 1.28 1.91E-06 1.9 86 
82 Hexadecanoic acid 1.06 4.96E-04 1.77 95 
55 Galactose 1.23 5.63E-07 1.61 89 
20 2-oxyethyl-amine 1.44 1.08E-10 1.59 91 
21 Carbamic acid 1.17 6.91E-07 1.58 86 
25 Threonine 1.26 3.64E-07 1.56 94 
66 Unidentified 1.37 3.09E-10 1.53 67 
74 Glycine 1.1 4.21E-06 1.36 70 
79 Unidentified 1.28 5.76E-08 1.33 61 
93 Unidentified 1.13 1.42E-06 1.32 65 
10 Valine 1.03 1.36E-05 1.3 92 
11 n-Butylamine 1.39 3.69E-10 1.29 85 
6 Isotridecanol 1.23 6.63E-07 1.29 81 
35 Unidentified 1.09 5.88E-05 1.29 57 
2 Unidentified 1.15 3.35E-06 1.28 63 
33 Unidentified 1.18 4.39E-07 1.28 58 
27 Unidentified 1.24 2.10E-07 1.25 65 
50 Unidentified 1.08 3.27E-05 -1.34 61 
41 Threonic acid 1.25 4.36E-04 -1.41 78 
68 Tryptophan 1.19 8.09E-07 -1.76 89 
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Urine      
99 N-Phenylacetyl glycine 1.22 1.32E-04 40.26 77 
85 Isobutanal 1.23 7.70E-05 7.56 94 
158 Unidentified 1.37 1.40E-06 6.51 56 
94 1H-Indole-1-acetic acid 1.11 3.05E-04 3.84 94 
96 Cadaverine 1.11 2.56E-04 3.15 82 
59 1-Desoxy-pentitol 1.27 4.36E-05 2.95 85 
127 Unidentified 1.16 2.20E-04 2.92 58 
53 Hydroxy-methylglutaric acid 1.12 2.83E-04 2.8 75 
55 Malic acid 1.5 2.78E-07 2.49 93 
37 2,3-Dihydroxybutanoic acid 1.49 3.48E-07 2.41 95 
62  2-(methoxyimino)-glutaric acid 1.16 1.21E-04 2.28 88 
69 Unidentified 1.37 3.54E-06 2.2 63 
87 Unidentified 1.18 4.48E-05 2.09 66 
48 β-Alanine 1.2 6.94E-05 1.92 88 
73 Fumaric acid 1.18 1.17E-04 1.91 71 
58 Pyroglutamic acid 1.2 6.95E-05 1.87 94 
93 [1,1’-Biphenyl]-4-carboxylic acid 1.39 2.79E-06 1.81 89 
81 Xylitol 1.34 5.67E-06 1.7 96 
86 Aconitic acid 1.28 1.53E-05 1.67 80 
89 4-Hydroxymandelic acid 1.17 2.02E-04 1.62 74 
107 Ribitol 1.18 8.44E-05 1.56 89 
56 2,3,4-trisoxy butanal 1.09 2.24E-04 1.51 95 
19 N-(1-oxopropyl)-glycine 1.16 1.46E-04 1.5 75 
22 4-amino-butanoic acid 1.17 8.43E-05 1.48 76 
50 3,4-bihydroxybutanoic acid 1.22 3.10E-05 1.21 94 
102 Galactose 1.22 1.66E-05 -1.35 88 
95 Erythrose 1.14 1.39E-04 -1.39 84 
111 Unidentified 1.49 9.03E-09 -1.41 67 
41 2-Ethyl-3-oxy butyrate 1.11 1.46E-04 -1.43 73 
70 Xylono-1,4-lactone 1.36 1.65E-06 -1.5 77 
79 5-Hydroxyindole 1.36 5.63E-07 -1.5 84 
10 n-Butylamine 1.21 5.05E-05 -1.57 73 
30 1,2,3-Butantriol 1.23 1.56E-05 -1.57 86 
121 N-acetyl glucosamine 1.38 3.49E-07 -1.58 80 
141 Unidentified 1.31 1.83E-06 -1.58 68 
133 Galactose 1.09 1.85E-04 -1.59 81 
23 2-oxyethyl-amine 1.16 1.29E-04 -1.62 90 
33 5-Ethylbarbituric acid 1.26 1.70E-05 -1.63 71 
122 Unidentified 1.18 9.73E-05 -1.63 65 
92 Ribitol 1.43 1.52E-07 -1.67 72 
118 Unidentified 1.49 7.33E-08 -1.67 57 
146 2-Ethylhexyl phthalic acid 1.51 3.61E-09 -1.69 89 
8 Formic acid 1.32 3.00E-06 -1.76 82 
18 Dodecamethylpentasiloxane 1.31 1.76E-06 -1.76 95 
34 Succinic acid 1.44 7.19E-07 -1.79 97 
4 2-Ethyl-1-butanol 1.33 1.66E-06 -1.84 79 
154 Fructose 1.38 4.58E-07 -1.84 84 
63 Threonic acid 1.61 3.98E-10 -1.88 93 
97 Unidentified 1.61 6.46E-10 -1.92 67 
153 Glucitol 1.39 3.40E-07 -1.94 84 
9 Glycolic acid 1.58 1.20E-09 -1.97 96 
45 Hydroquinone 1.43 5.78E-08 -1.99 76 
128 Unidentified 1.5 1.07E-07 -1.99 56 
26 Phosphoric acid 1.29 5.44E-06 -2.43 93 
42 Furanone 1.47 1.91E-07 -2.48 82 
139 Unidentified 1.55 3.77E-08 -2.63 66 
12 Hydroxylamine 1.35 1.10E-06 -2.98 90 
117 Unidentified 1.67 2.16E-12 -3.32 69 
14 Oxalic acid 1.47 4.13E-07 -3.52 93 
 79 
104 Nonadecanoic acid 1.62 7.89E-11 -3.72 88 
24 2-Keto-butyrate 1.65 9.44E-10 -4.06 78 
35 2,3-Bis-oxy-propanoic acid 1.74 3.34E-13 -4.69 97 
a: peak numbers in the compound list; b: Welch’s t-test P-value; c: fold changes when 24-months 
group compared to 2-months group; d: SI (%) of library search; #: cutoff threshold with Bonferroni 
correction for brain, plasma and urine was 2.78E-03, 1.25E-03 and 7.94E-4, respectively. 
 
In urine, many metabolites were found to be either elevated (e.g. isobutanal, malic 
acid, pyroglutamic acid, xylitol and 2,3,4 -trisoxy butanal) or declined (e.g. 2,3-
bis-oxy-propanoic acid, oxalic acid, phosphoric acid, glycolic acid, succinic acid  
and galactose) in urine obtained from aged rats. Notably, threonic acid was 
deceased in urine, which was consistent with the results obtained from C57BL/6J 
mice. Compared to young rats, 2,3-bis-oxy-propanoic acid declined by the greatest 
fold (4.69 fold), while N-phenylacetyl glycine (77% SI) showed the highest 
increase by 40.26 fold.  
 
2.3.3 LH rats treated with LA 
As described before, LA has shown its therapeutic effects against both aging and 
AD in animal models and patients [206, 446-452]. To the best of our knowledge, 
no studies have been performed to examine the metabolic profiles in biological 
systems after the treatment of LA. In this study, we analyzed brain and plasma 
samples from LA-treated young (2-month old, n=8, 50 mg/kg/day for 12 days), 
LA-treated aged (24-month old, n=10, 50 mg/kg/day for 12 days) and control-aged 
(24-month old, n=8, control vehicle for 12 days) LH rats. The obtained GC/MS 
TIC chromatograms are presented in Figure 2-5, with 163 and 88 peaks detected in 
brain and plasma, respectively. Visual inspection of the TIC chromatograms of 
brain and plasma revealed differences in overall composition among these three 
groups of rats (data not shown). The PCA scores plots of the normalized data 
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showed the samples from these three groups of rats were readily separated from 
each other. One observation in LA-treated aged group was found to be far away 
from the remaining observations in brain and plasma profiling study, respectively. 
They were therefore considered as an outlier and excluded from the subsequent 
analysis (data not shown). Subsequently, supervised PLS-DA was applied to the 
remaining observations to maximize the separation (Figure 2-6), which showed 
clear separations between the classes in the first component for all the samples. 
The statistics parameters for the regression modeling (R2X, R2Y, Q2Y) indicated 
that the models presented was able to discriminate the three groups of rats (Figure 
2-6). Basically, PC1 separated young rats from the aged ones (both treated and 
untreated), whilst PC2 separated aged-treated rats from the aged-untreated rats. 
The LA-treated aged rats were compared to LA-treated young and control-aged 
rats, respectively, and the dominant metabolites influencing the differentiation 
between young and aged rats were identified using available libraries and listed in 
Table 2-7 and Table 2-8, respectively.  
Compared to young-treated rats, aged-treated rats showed increased levels in 
stigmasterol, 11-eicosenoic acid and ethylamine, whilst decreased concentrations 
of butanoic acid and arachidonic acid in brain. Unfortunately, some variables were 
not identified and one of these marker metabolites was elevated in aged-treated rats 
by 8.15 folds. Both organic acids and cholesterol derivatives were either increased 
or decreased in brain, suggesting the global perturbations in the metabolism of 
these pathways. Interestingly, cholesterol level was not found to be elevated in LA-
treated aged rats when compared to LA-treated young rats, which was observed in 
aging study without LA dosing. This result may suggest the modification effects of 
LA treatment. In plasma, oleic acid and phosphoric acid showed elevated levels in 
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LA-treated aged rats, whilst myo-inositol and threonic acid were declined. Similar 
to our aging study using LH rats, threonic acid was declined in plasma. 
Surprisingly, myo-inositol, which was found to be increased in aged LH rats, was 
decreased in LA-treated aged rats comparing with LA-treated young rats.  
 
 
Figure 2-5  Representative GC/MS TIC chromatograms of metabolites extracted from whole 
brain (A) and plasma (B) of LH rats treated with LA (50 mg/kg/day) by gavage for 
12 days after derivatization with MSTFA. 
 
Compared to control-aged rats, LA-treated aged rats mainly showed decreased 
levels of malic acid, hexadecanoic acid and tetracosanoic acid, and increased level 






concentrations of putative 9-octadecenamide and serine. In plasma, decreased 
levels of amino acids (e.g. valine and threonine) and increased concentrations of 




Figure 2-6 PLS-DA score plots of GC/MS variables detected from whole brain (A) and plasma 
(B) samples of LH rats separating LA-treated young (2-month old age treated with 
LA, black, n=8), LA-treated aged (24-month old age, red, n=10) and control-aged 
(24-month old age, blue, n=8) groups. Whole brain (R2X=0.646, R2Y=0.982, 














































Table 2-7 Marker metabolites identified from brain and plasma of young-treated (2-month age 
treated with LA, n=8) and aged-treated (24-month age treated with LA, n=10) LH 
rats 
No. a Metabolite VIP P b, # Fold c SI d 
Brain      
40 Unidentified 1.8 4.38E-07 8.15 48 
154 5ξ-Ergost-7-ene, 3β 1.87 1.54E-07 3.95 76 
13 Unidentified 1.59 2.08E-05 3.53 65 
157 Unidentified 1.79 1.13E-07 3.45 66 
156 Stigmasterol 1.89 3.35E-09 3.07 86 
140 Undecanoic acid 1.6 2.95E-10 3.01 84 
65 Unidentified 1.63 1.01E-05 2.47 58 
159 7-Hydroxy cholesterol 1.8 4.39E-08 2.19 72 
12 Unidentified 1.45 2.81E-04 1.95 49 
155 26,27-Dinorergostan-3-ol 1.5 1.97E-04 1.86 79 
136 1-O-Heptadecylglycerol 1.23 2.83E-04 1.81 74 
138 2-Monooleglycerol 1.78 4.24E-07 1.5 83 
116 11-Eicosenoic acid 1.11 1.24E-05 1.39 89 
72 Unidentified 1.64 1.92E-05 1.35 68 
44 Unidentified 1.47 5.69E-04 1.31 69 
9 Unidentified 1.48 4.20E-04 1.29 63 
16 Ethylamine 1.58 1.26E-04 1.28 92 
94 Unidentified 1.1 6.89E-04 1.23 63 
113 Arachidonic acid 1.41 1.63E-04 -1.18 92 
91 Unidentified 1.51 9.86E-05 -1.23 66 
55 Butanoic acid 1.65 1.95E-04 -1.24 86 
125 Arachidonic acid 1.29 2.65E-04 -1.29 88 
124 Arachidonic acid 1.6 1.48E-05 -1.42 86 
57 Creatinine enol 1.66 1.53E-04 -1.94 79 
152 3β,5α-cholesta-8,24-dien-3-yl oxy 1.9 4.83E-08 -2.1 76 
153 (3β,5α)-cholest-7-en-3-yloxy 1.86 1.23E-06 -2.56 79 
      
Plasma      
67 Oleic acid 1.9 2.51E-06 2.28 93 
16  N-(1-oxopropyl)-glycine 1.49 8.19E-04 1.48 75 
22 Phosphoric acid 1.78 8.35E-05 -1.22 97 
63 Myo-inositol 1.81 1.51E-04 -1.34 90 
40 Threonic acid 1.88 9.95E-06 -1.47 92 
65 Unidentified 1.83 4.33E-05 -1.65 60 
78 Unidentified 1.74 1.30E-04 -1.7 56 
70 Unidentified 1.84 1.32E-04 -1.77 61 
82 Unidentified 1.81 3.39E-04 -1.94 64 
a: peak numbers in the compound list; b: Welch’s t-test; c: fold changes when aged-treated group 
compared to young-treated group; d: SI (%) of library search; #: cutoff threshold with Bonferroni 
correction for brain and plasma were 7.35E-04 and5.56E-03, respectively. 
 
Table 2-8 Marker metabolites identified from brain and plasma of aged-treated (24-month age 
treated with LA, n=10) and control-aged (24-month age treated with control vehicle, 
n=8) LH rats 
No. a Metabolite VIP P b, # Fold c SI d 
Brain      
162 Unidentified 1.49 4.05E-04 2.12 39 
116 11-Eicosenoic acid 1.52 1.45E-04 1.23 89 
60 Unidentified 1.5 6.17E-04 1.16 62 
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95 Hexadecanoic acid 1.61 9.71E-05 -1.07 95 
21 Acetamide 1.63 1.64E-04 -1.15 80 
26 Serine 1.55 2.73E-04 -1.19 82 
144 Tetracosanoic acid 1.61 1.19E-04 -1.22 87 
52 Malic acid 1.69 3.87E-06 -1.25 97 
32 N-(phenylmethylene)amine 1.61 4.26E-05 -1.34 76 
9 Unidentified 1.55 2.47E-04 -1.35 63 
149 9-Octadecenamide 1.48 3.52E-04 -1.57 86 
      
Plasma      
52 Fructose 1.17 3.59E-03 1.52 94 
36 Unidentified 1.57 1.93E-03 1.28 51 
61 Mannopyranoside 1.9 1.90E-04 -1.26 85 
37 Unidentified 1.62 3.71E-03 -1.31 64 
16 1-Oxopropyl-glycine 1.87 2.31E-04 -1.49 75 
19 2-(Methoxyimino)-propanoic acid 1.86 2.81E-04 -1.5 72 
18 Valine 1.87 1.19E-03 -1.67 95 
31 Threonine 1.76 5.02E-03 -2.26 97 
a: peak numbers in the compound list; b: Welch’s t-test; c: fold changes when aged-treated group 
compared to control-aged group; d: SI (%) of library search; #: cutoff threshold with Bonferroni 
correction for brain and plasma were 4.55E-03 and 5.00E-03, respectively. 
 
2.3.4 Cell culture media and lyses 
To investigate the aging trend metabolically, we profiled the metabolic fluxes in 
cell culture medium and cell pellet from cortical neuron cells obtained primarily 
from C57BL/6J mice. The representative GC/MS TIC chromatograms are 
presented in Figure 2-7, with 56 and 57 peaks detected in the medium and pellet 
samples, respectively. The PCA scores plots of the normalized data showed the 
samples from these three groups of rats were readily separated from each other 
(data not shown). Subsequently, supervised PLS-DA was used to maximize the 
separation (Figure 2-8 and Figure 2-9), which showed clear aging-related 
clustering and trend among different groups for both culture medium and cell 
pellet samples. The statistics parameters for the regression modeling (R2X, R2Y, 
Q2Y) indicated that the models presented was able to discriminate the test groups of 
different ages (Figure 2-8 and Figure 2-9). The 3-D plots showed clear trajectory 
of age-related changes. The samples used in this study were from 3 different 
batches, with batch 1 covering 5-, 7-, 10-, 18- and 21-day, while batch 2-3 
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covering 7-, 14, 21- and 28-day. Based on the PCA plots, the samples in batch 1 
were divided into two arbitrary age groups: young group (5-, 7-, 10-days) and aged 
group (18- and 21-days). In batch 2-3, however, 7-day samples was used as young 
group to compare with 28-days samples as aged group. The dominant metabolites 
influencing the differentiation between young and aged groups were identified and 
listed in Table 2-9 and Table 2-10, respectively.  
Although there were some differences of maker metabolites between batch 1 and 
batch 2-3, most of the metabolic changes were similar. Compared to the young 
groups, the aged groups showed differences with regard to a number of metabolites 
in the cell culture medium, mainly consisted of organic acids, amino acids and 
sugars, which were either increased or decreased. Notably, much higher levels of 
galactose and homocysteine were observed with the aged group, which suggested 
either elevated excretion or decreased consumption of these compounds. Some 
other metabolites were also detected, such as the increased levels of 5-oxo-1-
proline and 2-oxy-propanoic acid, and decreased levels of 2-(methoxyimino)-
propanoic acid, norleucine and glycine (Table 2-9). For cell pellet, samples 
obtained from aged group showed higher levels of cholesterol, ethanolamine and 
stearic acid, whilst [(2-fluorophenyl)methyl]-1H-purin-6-amine, methyl phthalate, 
pentadecyl ester of 2-bromopropionic acid and tridecanol declined (Table 2-10). In 
particular, cholesterol was found to be elevated in aged groups, which suggested 






Figure 2-7  Representative GC/MS TIC chromatograms of metabolites extracted from cortical 









       
       
Figure 2-8 PLS-DA scores plot of GC/MS variables detected from cortical neuron culture 
medium separating aging trend. A: 5-day = black; 7-day = red; 10-day = blue; 18-day 
= green; 21-day = orange; 5-, 7- and 10-day samples were as young group while 18- 
and 21-day samples as aged group (n=3, R2X=0.734, R2Y=0.995, Q2Y=0.957); B: 7-
day = black; 14-day = red; 21-day = blue; 28-day = green. 7-day was used as young 



















































       
      
Figure 2-9  PLS-DA score plots of GC/MS variables detected from cortical neuron cell pellet 
separating aging trend. A: 5-day = black; 7-day = red; 10-day = blue; 18-day = green; 
21-day = orange; 5-, 7- and 10-day samples were as young group while 18- and 21-
day samples as aged group (n=6, R2X=0.675, R2Y=0.993, Q2Y=0.976); B: 7-day = 
black; 14-day = red; 21-day = blue; 28-day = green. 7-day was used as young group 
to compare with 28-day as aged group (n=6, R2X=0.777, R2Y=0.988, Q2Y=0.976). 
 
Table 2-9 Marker metabolites identified from cortical neuron cell culture medium in the aging 
study (n=3 for each group/batch) 
No. a Metabolite VIP Sum b Fold c SI d 
Batch 1     
17 Homocysteine 1.41 0 Infinite 74 
31 Cadaverine 1.37 0 5.64 78 
36 Galactose 1.16 2 4.4 88 
50 Unidentified 1.07 3 2.5 61 
16 1-Methyl-2-phenylethyl-amine 1.21 0 2.28 79 
22 Proline, 5-oxo-1- 1.39 0 2.27 95 
48 Unidentified 1.36 0 2.19 60 
52 Unidentified 1.17 0 2.1 67 
2 2-Oxo-propionic acid 1.06 0 2.02 96 
49 Unidentified 1.31 0 1.93 61 
30 [1,1’-Biphenyl]-4-carboxylic acid 1.26 0 1.83 91 
21 Pipecolic acid 1.31 0 1.76 81 
















































23 Phenyl-alanine 1.17 0 1.52 96 
35 Mannitol 1.18 53 -1.56 78 
11 2-Oxy ethylamine 1.21 54 -1.69 90 
33 Fructose 1.26 54 -1.76 93 
32 Fructose 1.26 54 -1.79 95 
29 Arabinofuranose 1.15 54 -2.73 72 
51 Unidentified 1.32 54 -3.17 67 
      
Batch 2-3     
37 Galactose 1.31 0 836.26 88 
17 Homocysteine 1.33 0 26.25 74 
26 Fructose 1.29 0 11.27 91 
30 [1,1’-Biphenyl]-4-carboxylic acid 1.19 0 7.49 91 
9 2-(methoxyimino)-3-methyl-Pentanoic acid 1.22 0 2.58 85 
43 Unidentified 1.17 0 2.25 61 
22 Proline, 5-oxo-1- 1.32 0 1.84 95 
21 Pipecolic acid 1.3 0 1.7 81 
2 2-oxy-Propanoic acid 1.27 0 1.52 96 
56 Fructose 1.23 0 1.3 75 
55 Fructose 1.26 0 1.25 72 
5 Ethanedioic acid 1.17 36 -1.42 80 
3 n-Butylamine 1.23 36 -1.59 76 
1 2-(methoxyimino)-Propanoic acid 1.23 36 -1.68 92 
36 Mannitol 1.17 36 -1.68 78 
25 Mevalomic acid 1.3 36 -1.7 71 
6 bis(acetoxyethyl)sulfide 1.29 36 -1.72 75 
47 Unidentified 1.21 36 -1.74 59 
8 Norleucine 1.29 36 -2.02 85 
15 Glycine 1.31 36 -2.31 94 
16 1-methyl-2-phenylethyl-amine 1.17 36 -2.55 79 
a: peak numbers in the compound list; b: Wilcoxon rank sum test; c: fold changes when young group 
compared to aged group (batch 1, 5-, 7- and 10-day vs 18- and 21-day; batch 2-3, 7-day vs 28-day); 
d: SI (%) of library search.  
 
Table 2-10 Marker metabolites identified from cortical neuron cell pellet in the aging study (n=3 
for each group/batch) 
No. a Metabolite VIP Sum b Fold c SI d 
Batch 1     
40 Cholesterol 1.51 0 13.63 93 
22 Galactose 1.46 0 6.79 82 
28 Oleic acid 1.31 1 2.55 91 
24 Palmitolic acid 1.41 0 2.54 74 
25 Hexadecanoic acid 1.45 0 1.92 91 
29 Stearic acid 1.44 0 1.78 94 
7 Oxalic acid 1.39 0 1.41 73 
8 Pentasiloxane, dodecamethyl- 1.29 0 1.29 91 
16 Malic acid 1.34 36 -1.29 75 
15 Oxalic acid 1.24 35 -1.31 83 
      
Batch 2-3      
56 Cholesterol 1.25 0 2.46 93 
15 Ethanolamine 1.26 0 2.29 87 
35 Stearic acid 1.27 0 2.25 91 
19 Phosphoric acid 1.24 0 2.18 73 
4 Norleucine 1.3 0 2.02 72 
57 Unidentified 1.14 0 2.02 72 
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57 Unidentified 1.14 0 1.53 68 
37 Tetrapentacontane 1.16 36 -1.33 87 
36 1-Docosene 1.2 36 -1.39 87 
33 Tridecanol 1.23 36 -1.4 83 
48 n-Docosane 1.14 36 -1.42 87 
31 Tridecanol 1.12 36 -1.44 87 
23 Methyl phthalate 1.2 36 -1.65 88 
53 Tetrapentacontane 1.23 36 -1.76 87 
18 Unidentified 1.19 36 -2.05 68 
47 2-Bromopropionic acid, pentadecyl ester 1.23 36 -2.06 87 
28 Tridecanol 1.22 36 -2.13 82 
46 [(2-fluorophenyl)methyl]-Purin-6-amine 1.28 36 -2.54 87 
30 Tetracosamethyl-cyclododecasiloxane 1.28 36 -8.28 80 
25 Cyclohexasiloxane, dodecamethyl- 1.02 36 -10.36 73 
27 Unidentified 1.22 36 -10.66 69 
a: peak numbers in the compound list; b: Wilcoxon rank sum test; c: fold changes when young group 
compared to aged group (batch 1, 5-, 7- and 10-day vs 18- and 21-day; batch 2-3, 7-day vs 28-day); 
d: SI (%) of library search. 
 
2.4 DISCUSSION 
Metabonomics has been widely used and proven to be a powerful approach for 
diagnosis of human diseases [269, 275, 299] and biomarker discovery [274, 454]. 
In this chapter, we investigated the metabolic changes with aging in brain, plasma 
and urine samples obtained from in vivo animal models and in vitro cell culture 
model using GC/MS metabonomics. GC/MS has been used widely and considered 
as one of the most effective tools in metabonomic study due to its powerful 
separation and sensitivity [242, 244-250, 265, 455, 456]. As brain is the organ 
related closest to memory, behavior and aging-related neurodegenerative diseases, 
results related to aging with regards to brain tissue were of critical importance for 
the understanding of underlying metabolic mechanisms involved in the aging 
brain. However, brain tissue is only available postmortem in patient, which 
prevents it to be an accessible source for routine biomarker screening. Blood and 
urine are the most frequently used biological matrice in metabolic profiling 
experiments, and the latter is especially advantageous as urine samples are 
noninvasively accessible.  
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2.4.1 Metabolite extraction 
The efficient extraction of metabolites from the samples is important and will 
improve data validity and integrity. Due to the large variety of metabolites 
contained in tissues with highly differing physical and chemical properties, there is 
no one ideal way to simultaneously extract all classes of metabolites with high 
efficiency. Polar organic solvents such as methanol, ethanol, acetonitrile and 
acetone, are typically mixed with water to extract hydrophilic metabolites [457, 
458] and chloroform can be used to extract hydrophobic metabolites [457, 458]. A 
bi-phasic methanol/chloroform/water (2/2/1.8) extraction can be used for 
separating the polar and non-polar fractions [459]. To collect both polar and non-
polar compounds, the entire supernatant should be collected for the analysis.  
A et al. [249] developed an extraction and derivatization protocol for analyzing 
human plasma by GC/MS. Their results demonstrated that methanol extraction was 
particularly efficient and highly reproducible. The optimized protocol for the 
extraction from 100 μL of plasma is adding 900 μL of methanol/water mixture (8:1 
v/v) followed by centrifugation. In other studies, methanol alone or methanol-
dominated mixtures of solvents were also used for various biological samples, such 
as plasma or serum [249, 460], cell cultures [461-464], bacteria [465, 466], and 
even tissues [269, 467, 468]. These studies suggest that methanol is the ideal 
solvent for the extraction of most metabolites from various samples. 
For urine analysis, A et al. [469] recently investigated various extraction methods, 
including incubation, ultrasonication and organic extraction solvent, and compared 
to achieve maximal extraction method. They found that methanol and water 
(methanol/water/urine, 3:1:1) were shown to be the most important solvents and 
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were positive for the majority of the detected peaks. Specifically, A et al. [469] 
strongly recommended that urine samples for metabonomic research should not be 
centrifuged, as compounds that are insoluble or absorbed into the sediment may be 
lost.  
In our study, the samples were stored at -80ºC until homogenization. 
Methanol/water mixture (8:1) was used for the extraction of urine and plasma 
[249], while chloroform/methanol (2:1) one-phasic mixture [269] for brain tissue.  
2.4.2 Derivatization 
Various derivatizing reagents have been used in the derivatization of metabolites 
for GC/MS analysis. Silylation is the most widely used derivatization procedure 
because of their ease of use and formation of derivatives. In silylation, a labile 
hydrogens on a wide range of polar compounds is replaced by an alkylsilyl group 
such as TMS or t-butyldimethylsilyl (t-BDMS). Compared to their parent 
compounds, silyl derivatives are more volatile, less polar, and more thermally 
stable. As a result, GC separation is improved and detection is enhanced. The 
alkylsilyl reagents, such as BSA, BSTFA and MSTFA, are the most versatile and 
universally applicable derivatizing agents used for GC. Nearly all functional 
groups present in metabolites that are problematic in GC analysis, such as 
hydroxyl, amine, amide, phosphate, and thiol groups, can be converted to alkylsilyl 
derivatives.  
MSTFA is an effective TMS donor similar to BSA and BSTFA. One advantage of 
MSTFA over other silylating reagents is the volatility of its byproduct, N-
methyltrifluoroacetamide. MSTFA is the most volatile TMS-amide available and 
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N-methyltrifluoroacetamide has an even lower retention time than MSTFA. TMS 
derivatives of small molecules can often be analyzed using MSTFA, because 
byproducts and the reagent usually elute with the solvent front. TMCS is added at 
concentrations from 1-10 % to enhance the reactivity of MSTFA. With the addition 
of a catalyst such as TMCS, amides, many secondary amines and hindered 
hydroxyls, which cannot be derivatized by MSTFA alone, can be readily 
derivatized.  
For some compounds like sugars, direct silylation of sugars leads to a number of 
different peaks for each individual sugar, related to cyclic and open-chain 
structures [250]. By introducing a methoximation step prior to silylation, 
cyclization is inhibited, resulting in fewer peaks per sugar. In addition, α-ketoacids 
are protected against decarboxylation, and enolizable keto groups are fixed by 
oximation, facilitating the identification of the original molecular structures of 
metabolites. Almost all published GC/MS-based metabonomic studies used 
derivatization with both oximation and silylation.  
In this study, the metabolites extracted from samples were derivatized in two steps: 
first, carbonyl functions were protected by methoximation using 30 μL of a 20 
mg/mL solution of methoxyamine hydrochloride in pyridine at 60ºC for 2 h. 
Afterwards, acidic protons (e.g. hydroxyl, amine, sulfhydryl, and carboxyl groups) 
were exchanged against trimethylsilyl group using 70 μL of MSTFA at 60ºC for 1 
h to increase the volatility of polar metabolites.  
2.4.3 Data pre-processing  
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Prior to the PCA analysis, the raw data obtained using the GC/MS are subjected to 
a series of pre-processing steps, such as de-noising, peak alignment, deconvolution 
and identification. Several free software packages such as XCMS [470], MetAlign 
[471], MZmine [472] had been developed and reported in the previous 
metabonomic studies. In addition, the commercial software MATLAB [274] has 
also been widely used in the data pre-processing. In our study, we tried to use the 
free softwares. However, XCMS could not be readily used for the GC/MS data 
analysis when we started to process the data (personal communication). Indeed, 
based on our literature review, no publication was published until very recently, a 
few metabonomic studies were reported by Xu et. al [262, 473, 474] using 
Shimadzu GC/MS instrument with the data pre-processed by XCMS [473]. 
MetAlign and MZmine define default values for various brands of GC/MS 
instruments (i.e. Agilent, Thermo, Leco etc), but not for Shimadzu. In addition, we 
could not find a way to convert the data file format obtained from the Shimadzu 
operation software GCMSsolution into the compatible format with MATLAB. 
Therefore, manual determination by Shimadzu software GCMSsolution as 
described in section 2.2.6 was used for the peak integration. By using the MC 
integration, we can easily avoid the most abundant ions 73 and 147, which were 
also presented as the major ions in the baseline. As the data for the comparison 
purpose were obtained in the same batch, the RT shift was negligible. Finally, 
NIST and other libraries were used for the identification of the metabolites in the 
data. Therefore, we believe that our manual integration was suitable to pre-process 
the raw data prior to the PCA analysis, although it was more labor intensive and 
time consuming. PCA is an unsupervised technique that assumes no a priori 
knowledge of class structure and transforms the variables in a data set into a 
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smaller number of new latent variables called principal components (PCs), which 
are uncorrelated with each other and account for decreasing proportions of the total 
variance of the original variables. Each new PC is a linear combination of the 
original variables such that a compact description of the variation within a data set 
is generated. Observations are assigned scores according to the variation measured 
by the PCs with those having similar scores clustering together. In this thesis, the 
dataset was visualized by unsupervised PCA to check for the outliers, and followed 
by PLS-DA to maximize the discrimination between groups. As both PCA and 
PLS-DA were carried out using unit variance scaling, the variables of high or low 
concentration accounted for equal influence on the separation. PLS-DA is a 
supervised extension of PCA used to distinguish two or more classes by searching 
for variables (X matrix) that are correlated to class membership (Y matrix). In this 
approach, the axes are calculated to maximize the separation between groups and 
can be used to examine separation that would otherwise be across three or more 
PCs. PLS is used to maximize the correlation between the design matrix X (the 
normalized peak areas) to matrix Y (e.g. age), so that the response variable Y can 
be predicted from X. For each model built, the loading scores and the Variable 
Importance in the Projection (VIP) parameters were examined, in conjunction with 
the original GC/MS chromatograms, to identify which metabolites contributed 
most to clustering of observations or a trend observed in the data. Loading scores 
describe the correlation between the original variables and the new component 
variables, whereas VIP parameters are essentially a measure of the degree to which 
a particular variable explains the Y variance (class membership or linear trend). 
Samples from the same groups were classified into one class in PLS-DA modeling. 
Model performance was evaluated using the R2 and Q2 parameters, both of which 
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vary between 0 and 1, where 1 indicates a perfect fit. R2X is the cumulative 
modeled variation in X, providing an indication of how much of the variation 
within a data set can be explained by the various components of the model; R2Y is 
the cumulative modeled variation in Y; and Q2Y is the cumulative predicted 
variation in Y, indicating how accurately the data, either classed or non-classed, 
can be predicted according to cross-validation.  Q2Y is more relevant to supervised 
pattern recognition processes. Q2 scores over 0.08 indicate a model that is better 
than chance, whereas a score above 0.7 demonstrates good predictability and a 
highly robust trend or separation [436]. Components with VIP value of greater than 
1, which play important roles in the separation, were regarded as potential marker 
metabolites and subjected to subsequent univariate statistical analysis. 
For the univariate data analysis, we used Welch’s t-test with Bonferroni correction 
for data set with sample number more than 6, while Wilcoxon rank sum test for 
data set with sample number ≤ 6. Both of these tests have their strengths and 
weaknesses. For examples, t-test requires a normal distribution of the population, 
while Wilcoxon rank sum test ignores how much the levels has changed. So far, 
these are among the most common univariate data analysis methods used in 
metabonomic studies. In the future study, some other computational methods may 
also be tested.  
2.4.4 Metabolic changes associated with aging  
As discussed before, metabonomics have been used for the investigation of aging 
in several studies, most of which used NMR as the analytical technique. In this 
chapter, GC/MS was applied to examine metabolic profiles of biological samples 
obtained from various aging models. Our results supported that GC/MS based 
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metabonomic platform is a powerful technique for the separation and prediction of 
aging-related metabolic changes, as evidenced by the clear clustering trends 
observed with aging. Profound metabolic changes were detected across the 
investigated animal and cell culture aging models. Some common markers of aging 
were identified in the C57BL/6J mice and LH rat models, with some of them being 
consistently reported. For example, myo-inositol was found to be elevated in both 
brain and plasma of aged LH rats compared to young animals. In one previous 
study using 1H NMR or HPLC/MS in mice brain and rat urine [285], glutamate, 
glutamine, myo-inositol, creatine, and NAA concentrations increased with age, 
whereas lactate and acetate concentrations decreased. Myo-inositol, a glial cell 
marker, has previously been implicated in the osmoregulation of glial cells [475-
477]. The activation of microglia and astrocytes (gliosis) is a well known 
pathological response readily observed in neurodegenerative diseases [478]. The 
increase of myo-inositol concentration in brain and plasma of aged rats may 
indicate the perturbation of inositol metabolism during aging. In addition, lipid 
acids (e.g. stearic acid) and sterols (e.g. cholesterol and stigmasterol) were either 
increased or decreased in aged C57BL/6J mice or LH rats, which were also 
reported in previous studies [263, 441].  
The aging maker metabolites related to the C57BL/6J mice and LH rats models are 
presented and compared in Table 2-11. All the identified maker metabolites 
showed SI values greater than 85%. Some of the marker metabolites were shared 
by both C57BL/6J mice and LH rats, whilst some others showed opposite direction 
of regulations between C57BL/6J mice and LH rats. For example, threonic acid 
was declined in urine samples of both mouse and rat models; however, plasma 
levels of stearic acid and stigmasterol were decreased in aging C57BL/6J mice 
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while increased in aging LH rats. While these variances remain unclear thus far, a 
possible explanation is that they might be due to species differences with regards to 
the progress of aging. This represents the current challenges in preclinical aging 
studies. The biochemical processes involved in aging may vary significantly across 
different animal species. Such challenges may become more marked when the 
preclinical aging data are used to extrapolate similar biological end-points in 
humans. Another possible answer lies in the poor correlation of the different ages 
of animals. For examples, the “aged” C57BL/6J mice used in this study were 5-
month old, while LH rats were 2-year old. Therefore, a process of growth and 
development rather than aging per se may be a more suitable perspective to adopt 
when analyzing of the mice data.  
Table 2-11  Comparison of marker metabolites of development/aging identified from C57BL/6J 
mice and LH rats 
Samples  Changes C57BL/6J mice LH rats 
Brain ↑ Phosphoric acid  












Plasma ↑ Unidentified (17.05 folds) 


















 ↓ Stearic acid Tryptophan 
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In both C57BL/6J mice and LH rats, the identified marker metabolites were mainly 
intermediates or end-products involved in tricarboxylic acid (TCA) cycle (e.g. 
oxalic acid, succinic acid and malic acid), sugar (e.g. galactose, fructose and 
erythrose), amino acid (e.g. alanine, valine and threonine), lipid (e.g. palmitelaidic 
acid, oleic acid and stearic acid) or sterol (e.g. cholesterol and stigmasterol) 
metabolism. These results suggested that the aging process observed in these 
animals was associated with global dysregulation of metabolism and biosynthesis 
of endogenous metabolites. This is consistent with findings of previous studies 
performed in animals [298, 426] and humans [263].  
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To examine the effects of LA on the aging process, the marker metabolites were 
compared and listed in Table 2-12. Our results suggested that LA-treated aged rats 
demonstrated different metabolic changes when compared to LA-treated young or 
control-aged rats. LA-treated aged rats showed higher stigmasterol and ethylamine 
concentrations in brain, which were elevated in plasma of aged LH rats (Table 
2-11). Myo-inositol was found to be decreased in LA-treated aged rats compared to 
control-aged animals. This result suggested that LA treatment modified the 
perturbation of myo-inositol metabolism in aged animals, or the metabolic 
processes within glial cell were down-regulated during aging. Interestingly, 11-
eicosenoic acid, a fatty acid, was relatively higher in brain of LA-treated aged rats 
when compared to either LA-treated young or control-aged rats. This indicated that 
LA treatment might have increased the levels of this fatty acid more in aged rather 
than younger animals, or young rat naturally has lower concentration of this 
metabolite. Similarly, some of sugars (e.g. fructose), fatty acids (e.g. arachidonic 
acid and oleic acid), amino acids (e.g. serine, valine and theronine) and sterols (e.g. 
stigmasterol) were also relatively changed by LA treatment or aging.  
Table 2-12  Comparison of marker metabolites of aging identified from LH rats treated with LA 
or control vehicle 
Samples  Changes LA-treated aged vs control-
aged 
LA-treated aged vs LA-treated 
young 












Plasma ↑ Fructose Oleic acid 







LA is a natural dithiol compound which is known as a co-factor in the α-ketoacid 
dehydrogenase mitochondrial complex and for its complex antioxidant properties 
[479-481]. These diverse actions suggest that LA acts by multiple mechanisms, 
both physiologically and pharmacologically, many of which are only now being 
explored (Table 2-13). LA can be obtained from diet and synthesized via de novo 
mitochondrial synthesis [480, 481]. Exogenous LA is quickly absorbed, 
transported to the intracellular compartment, and reduced to dihydrolipoic acid 
(DHLA) under the action of certain enzymes [479, 482]. The reduction process 
results in two free thiol groups, which are responsible for the superior antioxidant 
effect of the reduced form (DHLA) as compared to the oxidized form (LA) [482].  
Table 2-13  Functions of LA 
No. Functions References 
1 Increases ACh production by activation of choline acetyltransferase; 
supplies more acetyl-CoA for the production for ACh 
[449, 483] 
2 A potent metal chelator [484] 
3 Scavenges reactive oxygen species (ROS), downregulates inflammatory 
processes as an anti-inflammatory antioxidant and modulator of redox-
sensitive signaling 
[485] 
4 Scavenges ROS, induces the enzymes of GSH synthesis and other 
antioxidant protective enzymes,  increases levels of total and reduced GSH 
[486, 487] 
5 A carbonyl scavenger [488] 
6 A stimulator of glucose uptake and utilization (“insulinomimetic”) [489-491] 
7 An activator of compromised cerebral blood flow [492] 
8 Protection of cultured neurons against toxicity of Aβ, iron and other 
neurotoxins by LA 
[493-496] 
9 Protective effects against age-related cognitive deficits in aging rats and 
mice 
[446-451] 
Currently, the oxidized form of LA is used as complement therapy in the treatment 
of diseases such as diabetic neuropathy [481, 497, 498]. Notably, LA has been 
shown to have a variety of pro-energetic and antioxidant properties that can 
interfere with pathogenic principles of AD like oxidative stress and neuronal 
energy depletion. It is therefore conceivable that LA might delay the onset or slow 
down the progression of the disease [209]. In a previous study [206], 600 mg LA 
was given daily to 9 patients with AD receiving a standard treatment with choline-
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esterase inhibitors over an observation period of 12 months. The treatment led to a 
stabilization of cognitive functions in the study group, demonstrated by constant 
scores in two neuropsychological tests. In another report [207], treatment of 43 AD 
patients with LA over 48 months slowed down the progression than untreated 
patients or patients on choline-esterase inhibitors. However, no study has been 
reported on the effects of LA treatment on the metabolic changes of biological 
system. Our metabonomic profiling of brain and plasma samples for LA treated 
LH rats suggested that LA could modify metabolism of lipid, amino acid, 
cholesterol and sugar metabolism.  
In addition to the animal studies on aging, we investigated the age-related 
metabolic changes of the culture medium and cell pellet obtained from cortical 
neuron cells using GC/MS. Our results showed comparable metabolic changes 
with those observed in our animal studies, including varied levels of lipid, amino 
acids, sugars and alcohols in medium and/or pellet of aged cells (Table 2-14). In 
particular, galactose and tentatively indentified homocysteine (SI 74%) were 
remarkably elevated in the culture medium of aged cells. The increased galactose 
in the culture medium may indicate the reduced absorption and consumption of the 
galactose by cells. Elevated homocysteine has been shown to be an independent 
risk factor for cardiovascular disease [499] and AD [500, 501], although the 
pathophysiology is still unknown. As the SI for homocysteine was only 74%, 
further investigation may be needed to confirm its identification affirmatively. 
Interestingly, n-docosane and tetrapentacontane were also detected and identified 
to be potential markers of aged cell pellet.  
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Table 2-14 Marker metabolites of aging identified from culture medium or pellet of cortical 
neuron cells 
Samples  Changes Medium Cell pellet 











 ↓ 2-oxyethyl-amine Oxalic acid 
 



















2-Bromopropionic acid, pentadecyl 
ester  
2-Bromopropionic acid, pentadecyl 
ester  
This chapter aimed to investigate the metabolic changes associated with natural 
aging. Using GC/MS-based metabonomics, we profiled the brain, plasma and urine 
samples of LH rats and C57BL/6J mice, as well as the culture medium and cell 
pellet of aging cortical neuron primary culture prepared from C57BL/6J mice. The 
biological samples were distinguished according to their aging trend using the 
GC/MS metabolic profiles, which enabled us to differentiate young and aged 
samples metabolically. By multivariate and univariate analysis, we identified a 
profound perturbation in the metabolic profiles of all the biological samples 
obtained from different aging models. To the best of our knowledge, this is the 
most comprehensive study covering several types of biological sample from two 
species of animals. The identification of biomarkers could be relatively 
straightforward, but the successful exploitation and explanation of these 
biomarkers in various pathways could be somewhat challenging. We tried to 
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compare the identified markers either between different species or among various 
treatment strategies. It can be speculated from our data that aging is a progressive 
progress involving global metabolic changes, including varied metabolism of 
organic acids, amino acid, lipid, sugar and cholesterol. In summary, a GC/MS 
based metabolic profiling approach was successfully applied in the metabolic 
profiling of various aging biological samples, leading to the identification of 
marker metabolites related to natural aging and growth. This method will be a 
useful technique for future aging study in order to better elucidate the mechanism 
of aging and other aging-related disease such as AD. Due to the complexity of the 
study, which covers several biological samples from several models, selective 
analysis of the data set only approximately captured changes caused by aging. A 
more comprehensive approach to the data analysis is necessary to fully elucidate 
the biological processes of aging in different samples from different sources. In 
addition, the potential markers are still needed to be validated using authentic 




CHAPTER 3 GC/MS METABOLIC PROFILING OF AD MODELS 
3.1 INTRODUCTION 
Currently, the definitive diagnosis of AD is only possible postmortem by detecting 
the two hallmarks of the disease, i.e. amyloid plaques and NFT, in brain tissue of 
the deceased patient [502]. The development of more effective diagnostic tests for 
AD with high specificity and sensitivity has become increasingly important given 
the growing aging population and increasing longevity worldwide. Unfortunately, 
accurate diagnosis of AD especially at the early stage remains difficult due to the 
complex spectrum of symptoms, their similarities to other neurodegenerative 
disorders, and the lack of definitive disease markers. Biomarkers derived from 
global profiling techniques performed on readily accessible biofluids (such as CSF, 
plasma, serum and urine) could be helpful in the understanding of the molecular 
characteristics underlying the disease processes of AD. These biomarkers would 
help to monitor disease progression, aid in predicting and monitoring treatment 
response and compliance, and identify novel drug targets. These biomarkers can 
expedite the development of new early or pre-symptomatic diagnostics of AD to 
improve therapeutic outcomes or even prevent the progression of the pathology. 
Up to date, genomics [503, 504], transcriptomics [505, 506] and especially 
proteomics [507-511] have been extensively used in biomarker discovery of AD. 
These studies indicated that rare mutations in the APP, PS 1, and PS 2 genes are 
important in the AD development. Converging evidence of these studies suggested 
the existence of several pathogenetic pathways of AD, such as APP processing, Aβ 
degradation, tau phosphorylation, proteolysis, protein misfolding, 
neuroinflammation, oxidative stress and lipid metabolism. Therefore, the 
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integration of knowledge derived from genomic, transcriptomic and proteomic 
studies will greatly advance our understanding of the causes of AD, improve our 
capability of establishing an early diagnosis, and ultimately help to improve and 
tailor the treatments [512]. Metabonomics, aiming at the small molecule 
metabolites, provides us an alternative -omics technology, and it has recently 
begun to play more prominent role in biomarker identification of various human 
diseases, including neurodegenerative disorders. However, due to its novelty, 
metabonomic studies on biomarker of AD models has just started to be 
sporadically reported (Table 3-1), mainly in animal models using magnetic 
resonance spectroscopy (MRS) or NMR.  
Transgenic mouse models, which mimic the main features of AD, are employed to 
better understand the pathophysiological process and to test potential therapies. 
One of the reported mouse models over-expressed mainly mutated forms of human 
APP [513-515] while accelerated Aβ deposition was achieved in another mouse 
models co-expressing human PS 1 and APP proteins [516, 517]. A double-
transgenic mouse line PS2APP that over-expresses mutant forms of human PS2 
and APP has also been reported [518]. Several animal models of AD have been 
used in biomarker studies using metabolic profiling techniques. In some pilot 
studies, the metabolic profiling by MRS on animal models and AD patients 
indicated the decrease of NAA, often interpreted as indicating loss of neurons or 
neuronal function, although the role of NAA in the brain is not yet fully understood 
[519, 520]. In AD patients treated with donepezil, a transient recovery of NAA 
level has been recently reported [521]. In addition, an increase of inositol has also 
been observed in patients with probable AD [522].  
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APPTg2576 is a transgenic mice that express mutant human APP and develop Aβ 
plaques throughout the cortex starting at 10-12 months of age. Dedeoglu et al. 
[523] examined the neurochemical profile of APPTg2576 mice using in vitro and in 
vivo MRS. They observed decreased NAA, glutamate and GSH, whilst increased 
taurine in APPTg2576 mice at 19 months of age compared to wild-type. Marjanska et 
al. [524] investigated the in vivo neurochemical abnormalities in APP-PS1 mice 
(which co-express mutated human PS 1 and APP) using 1H MRS. They also found 
a reduction in NAA and glutamate and an increase in myo-inositol with age in the 
mutant mice. Notably, the authors found that the concentration of myo-inositol was 
dramatically increased with age in APP-PS1 mice, which was not observed in 
wild-type mice. The age-dependent neurochemical changes observed in APP-PS1 
mice agree with results obtained from in vivo human MRS studies. Therefore, the 
authors suggested that among the different transgenic mouse models of AD that 
have been studied with 1H MRS, APP-PS1 mice seem to best match the 
neurochemical profile exhibited in human AD. The authors also took into account 
the metabolic changes that occur during normal aging [525], which should not be 
neglected.  
Table 3-1 Current publications on the biomarker study on AD using metabonomics 
Species Samples  Analytical methods Years  References 
APPTg2576 mice Brain 1H MRS 2004 [523] 
PS2APP mice Brain 1H MRS 2005 [526] 
APP-PS1 mice  Brain 1H MRS 2005 [524] 
SAMP8 mice Serum 1H NMR 2008 [442] 
Human  Serum  1H NMR 2008 [527] 
MRS: Magnetic resonance spectroscopy; SAMP8: Senescenceprone 8;  
 
A newly published paper reported serum metabolic profiling of lipoproteins, 
various low-molecular-weight metabolites, and individual lipid molecules in 
human using a three-molecular-window approach for 1H NMR spectroscopy [527]. 
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After examining 180 serum samples of which 30% were related to MCI, a 
neuropsychological diagnosis with severely increased risk for AD, they found that 
the low relative amount of ω-3 fatty acids appears indicative of MCI. The analyses 
also feature the role of elevated glycoproteins in the risk for AD development, 
supporting the view that coexistence of inflammation and the metabolic syndrome 
forms a high risk condition for cognitive decline. 
Although metabolic studies of AD models have previously been carried out, global 
metabonomic analysis is currently lacking. To the best of our knowledge, there 
were only two studies reported on the metabolic profiling of AD using 
metabonomics. In one study, Kienlin et al. examined the metabolic profiling of 
transgenic mouse line PS2APP (PS2N141I × APPswe) using pattern recognition 
method [526]. This mouse model over-expresses mutant forms of human PS2 and 
APP, developing an age-related cognitive decline at 8 months associated with 
severe amyloidosis, mimicking the pathophysiologic processes in AD. By using 1H 
MRS, the authors reported a decreased NAA and glutamate in PS2APP mice 
compared to wild type controls. When spectra were analyzed by support vector 
machine (SVM), wild type animals could be differentiated with a sensitivity of 
92% and a specificity of 82% [526].  
In the other study, 1H NMR spectroscopy based metabonomics was applied to 
investigate the metabolic profiles of senescence-accelerated mouse (SAM) [442]. 
The serum metabolome of senescenceprone 8 (SAMP8), a murine model of age-
related learning and memory deficits and AD, was compared with that of control, 
senescence-resistant 1 (SAMR1), which shows normal aging process. Metabolite 
variations such as lack of inosine, decreased glucose, choline, phosphocholine, 
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HDL, LDL, 3-hydoxybutyrate, citrate and pyruvate, as well as increased lactate, 
alanine, methionine, glutamine and VLDL were observed in serum of SAMP8 
compared with those of SAMR1, suggesting perturbed glucose and lipid 
metabolisms in SAMP8.  
While there are scarce data regarding pattern recognition in AD, metabonomics has 
been applied in the biomarker discovery for several other neurodegenerative 
disorders in animal models, such as PD [439], schizophrenia [528] and Batten 
disease [436]. Notably, these neurodegenerative diseases shared some metabolite 
changes such as glutamate and NAA. Therefore, such biomarkers should be 
considered as “common” biomarkers for these neurodegenerative diseases, rather 
than specific one for AD.  
Interestingly, Drosophila melanogaster expressing toxic Aβ has also been used as 
an AD model by Crowther and collaborators [529]. Using this model, therapeutic 
agents that interfere with the generation of toxic aggregates of Aβ have been 
shown to rescue the flies [530].  
The initiation and development of AD are poorly understood and there are no 
distinct biomarkers allowing early detection in order to facilitate preventive 
treatment. Recent evidence suggests that systemic metabolite and lipid levels 
associate strongly with the development of AD than previously believed [83, 86]. 
Thus, it can be anticipated that metabonomic analysis would provide new 
molecular insights on the potential early changes in systemic metabolism that 
relate to MCI and thereby to high risk for AD.  
 110 
As discussed above, we proposed that metabonomic study on both aging and AD 
models might be uniquely well suited to help us to address the metabolic changes 
associated with  aging and AD, as well as the similarities and differences between 
these two conditions. Here, GC/MS based metabonomics technique was used for 
the metabolic profiling of plasma, brain and urine samples to identify perturbations 
in biochemical pathways from two animal models, i.e. TASTPM and human p25 
over-expressing mice. In addition, the culture medium and the cell pellet collected 
from primarily cultured cortical neuron from C57BL/6J mice treated with 
glutamate were also analyzed.  By this, we aimed at profiling the metabolic 
features and discovering the changes associated with AD.  
3.2 MATERIALS AND METHODS 
3.2.1 Chemicals and reagents 
Refer to section 2.2.1. Glutamic acid was purchased from Sigma-Aldrich Chemical 
Co. (St. Louis, Mo. USA).   
3.2.2 Animals and grouping schedules 
3.2.2.1 TASTPM and wild type mice 
Aged (50-week old) double-mutant APPswe × PS1.M146V (TASTPM) transgenic 
mice (n=16) and the wild-type C57BL/6J mice (n=5) were obtained from Charles 
River Laboratories (Wilmington, MA, USA), and maintained in SPF laboratory of 
GSK (Harlow, UK). All animal experimental protocols and procedures were 
approved by the IACUC of NUS.  
3.2.2.2 Human p25 over-expressing transgenic mice  
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Breeding 
Human p25 over-expressing transgenic mice were developed and obtained from 
the laboratory of Dr. Sashi Kesavapany (Department of Biochemistry, NUS). 
Briefly, a transgenic vector was generated containing a human cyclin-dependent 
kinase 5 regulatory subunit 1 (CDK5R1) sequence encoding the carboxy terminal 
proteolytic fragment p25 all under transcriptional control of the tetracycline 
operator (tetO). The construct was microinjected into C57BL/6J fertilized mouse 
eggs and re-implanted into FVB foster mothers. Male offspring were bred to 
C57BL/6J females and transgenic positive mice were selected. The purpose of the 
green fluorescent protein (GFP) tag is to differentiate immunologically the 
transgene-encoded p25 from the endogenous p35 protein. The calcium-calmodulin-
dependent kinase II (camk2a) transgenic mice express the tetracycline-controlled 
transactivator protein (t-TA) under regulatory control of the forebrain-specific 
camk2a promoter. Mating these camk2a transgenic mice with p25 transgenic mice 
gets bitransgenic offspring that allow doxycyline-controlled inducibly expression 
of the human p25 gene specifically in forebrain neurons. In the presence of the 
tetracycline derivative doxycycline, expression of the p25 transgene was inhibited. 
All mice in this study were conceived and raised in the presence of doxycycline 
(200 µg/mL) in drinking water, changed twice a week for 6 weeks postnatal before 
induction of p25 to prevent any potential developmental consequences from the 
expression of p25. 
Genotyping 
The offspring were genotyped by two independent polymerase chain reactions 
(PCRs) with primers for both camk2a-tTA and p25-GFP transgenes using a small 
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piece of tail at the age of 21 days. The samples showed bands for both primers 
were considered as bitransgenic.  
Induction of p25 gene expression 
p25 gene expression was induced by withdrawal of doxycycline water at the age of 
6 weeks of bi-transgenic mice. Urine and brain samples were collected at 4 week 
and 8 week of induction.  
All the induced p25, non-induced p25 and their wild type C57BL/6J mice were 
maintained in the specific pathogen free (SPF) laboratoryof Satellite Animals 
Holding Unit, NUS. Same maintenance conditions as described above in section 
2.2.2.1 were applied. All animal experimental protocols and procedures were 
approved by IACUC of NUS.  
3.2.3 Sample collection and preparation 
3.2.3.1 Brain, plasma and urine 
Refer to section 2.2.4.  
3.2.3.2 Cell culture and medium 
The culture media and cell pellet of mouse cortical neuron cell lines used in this 
study were also kindly provided by Dr. Sashi Kesavapany as described in section 
2.2.3. The primarily cultured cells were maintained in DMEM for 5 days before 
the treatment. Thereafter, the cells were treated with glutamic acid (1mM) or 
vehicle in 2 mL of DMEM for 6 h. After collecting the cell culture medium 
immediately at the ending of time points, the cells were washed with ice-cold 1× 
PBS buffer, and quenched by incubating with methanol/water (75/25, v/v) at -40°C 
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for 30 min. The cells were then collected as described above and stored at -80ºC 
until analysis. The experiment was repeated in duplicate.  
3.2.4 GC/MS analysis 
Refer to section 2.2.5.  
3.2.5 Chromatogram acquisition and data pre-processing  
Refer to section 2.2.6.  
3.2.6 Multivariate and univariate data analyses  
Refer to section 2.2.7.  
3.3 RESULTS 
3.3.1 TASTPM mice  
We investigated brain and plasma samples from AD transgenic model TASTPM 
mice (50-week old, n=16) and wild type C57BL/6J mice (50-week old, n=8). The 
obtained GC/MS TIC chromatograms are presented in Figure 3-1, with 143 and 75 
peaks detected in brain and plasma, respectively. Visual inspection of the TIC 
chromatograms revealed that there were a number of different peaks observed in 
TASTPM mice when compared to C57BL/6J mice (data not shown). The PCA 
scores plots of the normalized data showed the samples from TASTPM mice were 
readily separated from C57BL/6J mice (data not shown). Subsequently, supervised 
PLS-DA was used to maximize the separation (Figure 3-2), which showed clear 
separations between the classes in the first component for all the samples. The 
statistics parameters for the regression modeling (R2X, R2Y, Q2Y) indicated that the 
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models presented was able to discriminate between TASTPM mice and C57BL/6J 
mice (Figure 3-1). Finally, the dominant metabolites influencing the differentiation 
between TASTPM and C57BL/6J mice were identified and listed in Table 3-2.  
 
 
Figure 3-1  Representative GC/MS TIC chromatograms of metabolites extracted from brain (A) 
and plasma (B) of TASTPM mice after derivatization with MSTFA.  
 
The results showed that a number of metabolites were found to change in 
TASTPM mice in both brain and plasma. In brain, the levels of norvaline, 
pentanamide, valine, acetamide, serine and threonine were increased, while some 






valine, serine and threonine suggested the perturbation of amino acid metabolism 
in AD animals. In plasma, 2-oxyethyl-amine was elevated in the concentration, 
whilst glucose, galactose, 9,12-octadecadienoic acid, arachidonic acid, 
hexadecanoic acid and gluconic acid declined.  
 
 
Figure 3-2  PLS-DA score plots of GC/MS variables detected from whole brain (A) and plasma 
(B) samples separating TASTPM (50-month old age, black, n=21) and wild type 
C57BL/6J mice (50-month old age, red, n=5) groups. Whole brain (R2X=0.545, 


































Table 3-2  Marker metabolites identified from brain and plasma samples of TASTPM (50-week 
old, n=16) and wild type C57BL/6J mice (5-month old, n=5). 
No. a Metabolite VIP P b, # Fold c SI d 
Brain      
65 Unidentified 1.78 2.47E-05 2.16 67 
22 Norvaline 1.83 6.37E-05 1.88 85 
17 Pentanamide 1.87 2.98E-05 1.83 81 
68 Fructose 1.94 8.58E-07 1.74 73 
9 Valine 1.84 1.33E-04 1.49 87 
90 Unidentified 1.76 3.56E-05 1.31 57 
20 Acetamide 1.51 4.16E-04 1.3 81 
27 Serine 1.89 2.70E-04 1.28 81 
30 Threonine 1.81 3.81E-05 1.18 91 
40 32-Hydroxy-3-methyl valerate 1.66 9.90E-05 -1.1 79 
140 Zymosterol 1.83 1.14E-03 -1.16 75 
142 4β-Methyl cholesterol 2.05 2.76E-02 -1.2 71 
      
Plasma      
17 Unidentified 1.23 1.17E-02 1.32 60 
35 2-Deoxy-glucose 1.8 3.17E-03 1.3 83 
5 2-Oxy ethylamine 1.27 4.70E-02 1.29 92 
20 Unidentified 1.01 5.45E-03 1.23 57 
12 1-Methyl-2-phenyl ethylamine 1.28 8.57E-05 1.15 81 
3 Isotridecanol 1.22 2.88E-03 1.12 83 
36 Glucose 1.03 2.72E-03 -1.1 87 
37 Galactose 1.01 1.16E-02 -1.15 89 
43 Hexadecanoic acid 1.31 1.11E-02 -1.15 95 
47 9,12-Octadecadienoic acid 1.16 8.50E-04 -1.18 93 
71 Monooleoylglycerol 1.27 4.87E-02 -1.26 80 
52 Arachidonic acid 1.49 1.96E-02 -1.3 91 
46 Unidentified 1.12 2.39E-03 -1.33 62 
74 Unidentified 1.77 2.43E-02 -1.47 65 
28 Unidentified 1.19 1.78E-03 -1.62 69 
29 Gluconic acid 1.63 1.08E-02 -2.06 88 
a: peak numbers in the compound list; b: Welch’s t-test; c: fold changes when TASTPM group 
compared to wild-type group; d: SI (%) of library search; #: cutoff threshold with Bonferroni 
correction for brain and plasma were 1.09E-03 and 1.56E-03, respectively. 
 
3.3.2 Human p25 over-expressing mice 
We investigated brain and urine samples obtained from induced human p25 over-
expressing transgenic mice (induced for 4- or 8-week, n=3 each) and non-induced 
mice (n=3 each). The obtained GC/MS TIC chromatograms are presented in Figure 
3-3, with 102 and 121 peaks detected from brain and urine, respectively. Visual 
inspection of the TIC chromatograms revealed that there were a number of peaks 
changed in p25 induced mice when compared to non-induced mice (data not 
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shown). The PCA scores plots of the normalized data showed the samples from 
p25 induced mice were readily separated from non-induced mice (data not shown). 
Subsequently, supervised PLS-DA was used to maximize the separation, which 
showed clear separations between the classes in the first component for all the 
samples (Figure 3-4). The statistics parameters for the regression modeling (R2X, 
R2Y, Q2Y) indicated that the models presented was able to discriminate between 
induced and non-induced mice (Figure 3-4). Finally, the dominant metabolites 
influencing the differentiation between induced and non-induced mice were 
identified and listed in Table 3-3 and Table 3-4. The results showed that a number 
of metabolites were found to change in p25 over-expressing mice in both brain and 
urine.  
In brain of p25 mice induced for 4-week, the levels of fructose, inositol (myo- and 
scyllo-), allose, propanoic acid, cholesterol and erythrose were increased, while 
malic acid, arachidonic acid, isobutyric acid, hexadecanoic acid, glucitol, fumaric 
acid, octadecanoic acid, 2-monostearin, ascorbic acid, monooleoylglycerol, 
phosphoric acid, proline and urea were decreased. Notably, two tentative marker 
metabolites, glycine (SI 72%) and pantothenic acid (SI 77%), presented in the non-
induced mice, were absent in the induced animals. In urine samples of the p25 
mice induced for 4-week, β-arabinopyranose, galactose, glucuronic acid, glucose, 
β-galactofuranose and acetic acid were elevated in the concentration, whilst 
pentanoic acid, 2-methyl-2-hydroxybutyric acid, propanoic acid, 2-
piperidinecarboxylic acid, tryptophan and α-galactopyranose declined.  
In the brain of p25 mice induced for 8-week, inositol (myo- and scyllo-) and 
propanoic acid were increased, whilst hexadecanoic acid decreased. In urine, the 
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levels of citric acid, acetic acid, glucopyranose, glucose, myo-inositol, xylose, 
galactose, propanoic acid, ribonic acid, glucose were elevated, whilst 2-methyl-2-
hydroxybutyric acid and pentanoic acid were declined.  
 
 
Figure 3-3  Representative GC/MS TIC chromatograms of metabolites extracted from brain (A) 









     
     
Figure 3-4 PLS-DA score plots of GC/MS variables detected from whole brain (A) and urine 
(B) samples separating induced p25 mice (black, n=3, induced for 4 or 8 weeks), 
non-induced p25 mice (red, n=3) and wild type C57BL/6J mice (blue, n=3) groups. 
Whole brain-4week (R2X=0.845, R2Y=0.974, Q2Y=0.782); urine-4week (R2X=0.98, 
R2Y=0.993, Q2Y=0.907); Whole brain-8week (R2X=0.779, R2Y=0.984, Q2Y=0.754); 
urine-8week (R2X=0.842, R2Y=0.979, Q2Y=0.836).  
 
Table 3-3  Marker metabolites identified from brain and urine samples of induced (for 4 weeks) 
and non-induced p25 bitransgenic mice (n=3)  
No. a Metabolite VIP Sum b Fold c SI d 
Brain       
43 Unidentified 1.06 9 10.86 69 
64 Fructose 1.23 9 6.53 76 
50 Scyllo-inositol 1.14 9 3.45 71 
2 Butanol 1.02 9 2.21 79 
45 Allose 1.16 9 2.19 90 
55 Myo-inositol 1.3 9 1.8 91 
32 Fructose 1.21 9 1.78 88 
52 Scyllo-inositol 1.25 9 1.67 87 
3 Propanoic acid 1.29 9 1.63 96 
99 Cholesterol 1.06 9 1.56 97 
42 Erythrose 1.24 9 1.4 83 
25 Malic acid 1.13 0 -1.28 96 
73 1-O-Heotadecylglycerol 1.16 0 -1.3 77 
76 1-O-Heotadecylglycerol 1.13 0 -1.36 74 
1 Isobutyric acid 1.12 0 -1.64 80 






































































86 9,12 Octadecadienoic acid 1.18 0 -1.68 78 
85 Unidentified 1.2 0 -1.83 64 
12 Unidentified 1.28 0 -1.86 66 
91 2-Monostearin 1.05 0 -2.02 74 
84 Hexadecanoic acid 1.1 0 -2.1 96 
24 Unidentified 1.08 0 -2.17 68 
47 Glucitol 1.26 0 -2.29 84 
81 Arachidonic acid 1.1 0 -2.45 88 
22 Fumaric acid 1.03 0 -2.46 93 
23 2-Hydroxy-3-methyl valerate 1.17 0 -2.48 79 
95 Octadecanoic acid 1.24 0 -2.74 89 
93 2-Monostearin 1.19 0 -2.85 88 
48 Ascorbic acid 1.29 0 -3.16 97 
71 Unidentified 1.14 0 -3.3 69 
29 Unidentified 1.18 0 -3.31 61 
94 Monooleoylglycerol 1.15 0 -3.72 90 
79 Unidentified 1.19 0 -4.5 59 
77 n-Tridecanol 1.25 0 -4.51 73 
35 Xylonic acid 1.29 0 -5.29 74 
38 Phosphoric acid 1.24 0 -5.52 94 
28 Unidentified 1.29 0 -5.63 69 
89 Unidentified 1.19 0 -8.67 62 
20 Unidentified 1.31 0 -11.34 66 
75 Unidentified 1.24 0 -14.72 67 
31 N-(1-oxobutyl)-glycine 1.31 0 -24.29 71 
19 Butanoic acid 1.33 0 -29.02 73 
26 Proline 1.32 0 -59.7 94 
13 Urea 1.27 0 -383.41 94 
34 Glycine 1.28 0 -Infinite 72 
51 Pantothenic acid 1.31 0 -Infinite 77 
      
Urine      
4 Acetic acid 1.94 9 3.56 92 
68 β-Galactofuranose 1.23 9 3.2 86 
66 Galactose 1.26 9 3.12 86 
76 Glucose 1.14 9 2.66 96 
75 Glucuronic acid 1.11 9 2.55 92 
65 Galactose 1.12 9 2.47 95 
48 β-Arabinopyranose 1.66 9 1.26 84 
92 Xylose 1.57 0 -1.8 82 
60 α-Galactopyranose 1.56 0 -1.83 96 
24 2-Hydroxyglutaric acid 1.64 0 -2.11 75 
86 Tryptophan 1.76 0 -2.51 87 
17 Butanedioic acid 1.88 0 -3.01 72 
121 Hexopyranose 1.35 0 -3.44 74 
97 2-Piperidinecarboxylic acid 1.48 0 -3.62 82 
15 Propanoic acid 1.67 0 -5.52 89 
9 2-Methyl-2-hydroxybutyric acid 1.8 0 -6.8 89 
14 Pentanoic acid 1.95 0 -12.62 89 
a: peak numbers in the compound list; b: Wilcoxon rank sum test; c: fold changes when induced 




Table 3-4  Marker metabolites identified from brain and urine samples of induced (for 8 weeks) 
and non-induced p25 bitransgenic mice (n=3) 
No. a Metabolite VIP Sum b Fold c SI d 
Brain       
52 Scyllo-inositol 1.6 9 1.56 87 
47 Glucitol 1.78 9 1.33 84 
3 Propanoic acid 1.7 9 1.28 96 
55 Myo-inositol 1.06 9 1.15 91 
72 1-O-Heotadecylglycerol 1.67 0 -1.23 77 
53 Hexadecanoic acid 1.05 0 -1.26 95 
57 n-Pentadecanoic acid 1.38 0 -1.45 74 
64 Fructose 1.75 0 -1.74 76 
43 Fructose 1.48 0 -1.82 71 
71 Unidentified 1.36 0 -1.9 69 
39 Glucose 1.34 0 -2.05 75 
83 Glucuronic acid 1.37 0 -2.41 74 
      
Urine      
54 Citric acid 1.74 9 5.02 88 
4 Acetic acid 1.92 9 2.76 92 
118 Glucopyranose 1.59 9 2.48 86 
117 Glucose 1.68 9 2.31 88 
83 Myo-inositol 1.57 9 1.89 90 
103 Maltose 1.6 9 1.75 78 
88 Xylose 1.44 9 1.59 84 
66 Galactose 1.55 9 1.52 86 
2 Propanoic acid 1.68 9 1.42 91 
47 Ribonic acid 1.57 9 1.41 87 
76 Glucose 1.62 9 1.37 96 
10 N-(1-oxopropyl)-glycine 1.35 0 -1.16 75 
9 2-Methyl-2-hydroxybutyric acid 1.54 0 -6.93 89 
14 Pentanoic acid 1.52 0 -19.14 89 
a: peak numbers in the compound list; b: Wilcoxon rank sum test; c: fold changes when induced 
group compared to non-induced groups; d: SI (%) of library search 
 
3.3.3 Glutamate treated cortical neuron cells 
In this section, we investigated the metabolic profiles from medium and pellet of 
cortical neurons treated with or without glutamate (n=6 in triplicate) for 6 h. The 
obtained GC/MS TIC chromatograms were similar to those presented in Figure 
2-7. Visual inspection of the TIC chromatograms revealed that there were a 
number of peaks changed in glutamate-treated group when compared to control 
group (data not shown). The PCA scores plots of the normalized data showed the 
samples from glutamate-treated group were readily separated from control group 
(data not shown). Subsequently, supervised PLS-DA was used to maximize the 
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separation (Figure 3-4), which showed clear separations between the classes in the 
first component for all the samples. The statistics parameters for the regression 
modeling (R2X, R2Y, Q2Y) indicated that the models presented was able to 
discriminate between glutamate-treated group and control group (Figure 3-4).  
 
 
Figure 3-5  PLS-DA score plots of GC/MS variables from medium (A) and pellet (B) samples 
separating control (black, n=6) and glutamate treated (red, n=6) groups. Medium 
(R2X=0.654, R2Y=0.991, Q2Y=0.977); pellet (R2X=0.788, R2Y=0.988, Q2Y=0.972). 
Each experiment was repeated in triplicate. 
 
Finally, the dominant metabolites influencing the differentiation between 











































The results showed that a number of metabolites were found to change with 
glutamate-treated group in both medium and pellet.  
Table 3-5  Marker metabolites identified from cell culture medium and pellet lyses of cortical 
neuron cells incubated with glutamate or control vehicle (n=18) 
No. a Metabolite VIP P b Fold c SI d 
Medium      
53 Unidentified 1.1 2.86E-02 2.47 66 
15 Threonine 1.31 3.84E-02 2.44 72 
56 Unidentified 1.39 3.89E-03 2.39 45 
4 Hydroxylamine 1.17 1.80E-02 2 92 
10 2-Oxyethyl-amine 1.08 3.18E-02 1.7 91 
47 Unidentified 1.31 8.70E-03 1.5 60 
7 Unidentified 1.12 3.51E-02 1.48 60 
13 Glycine 1.85 3.52E-05 1.44 86 
20 2-Keto-gluconic acid 1.16 1.42E-02 1.43 78 
3 Acetamide 1.02 3.52E-02 1.41 82 
5 Oxalic acid 1.01 3.87E-02 1.37 72 
23 1,4-Butanediamine 1.16 5.04E-02 1.36 95 
17 Proline, 5-oxo-1- 1.18 1.06E-02 1.34 94 
28 Citric acid 1.08 4.52E-02 -1.42 94 
1 2-(Methoxyimino)-propanoic acid 1.32 2.71E-02 -1.43 73 
31 Turanose 1.62 3.64E-03 -1.66 82 
27 Fructose 1.17 1.01E-01 -1.74 84 
26 β-Galactofuranoside 1.15 9.11E-02 -1.84 85 
32 Glucose 1.29 1.08E-02 -1.93 97 
      
Pellet       
44 Stearic acid 1.13 2.39E-08 18.86 75 
63 Myo-inositol 1.24 6.92E-08 10.58 89 
61 Palmitelaidic acid 1.16 1.26E-09 10.32 88 
19 Unidentified 1.17 8.91E-11 6.2 62 
79 Cholesterol 1.28 2.83E-09 4.95 95 
45 Stearic acid 1.28 2.36E-13 4.45 75 
76 Oleic acid 1.28 3.55E-09 3.95 94 
43 Methoxyacetic acid 1.13 2.28E-07 -1.43 75 
56 Methoxyacetic acid 1.09 9.91E-07 -1.66 84 
37 Methoxyacetic acid 1.29 6.90E-11 -1.67 70 
50 Phthalic acid 1.09 1.86E-06 -1.69 80 
41 7-Hexadecenal 1.01 5.55E-05 -1.73 71 
55 n-Octadecane 1.12 2.26E-07 -1.73 83 
42 1-Monoolein 1.16 2.55E-09 -1.77 73 
62 Tetrapentacontane 1.26 1.09E-07 -1.82 89 
74 Octadecan-1-ol 1.28 3.09E-09 -1.89 90 
60 Docos-13-enoic acid 1 2.17E-05 -1.95 87 
34 Unidentified 1.18 3.24E-09 -2.02 68 
49 Methoxy acetic acid 1.1 9.31E-07 -2.08 77 
52 3-Mercapto-propanoic acid 1.21 4.29E-07 -2.17 82 
a: peak numbers in the compound list; b: Wilcoxon rank sum test; c: fold changes when glutamate 
treated group compared to control group; d: SI (%) of library search.  
 
In medium, the levels of hydroxylamine, 2-oxyethyl-amine, glycine, acetamide, 
1,4-butanediamine and 5-oxo-1-proline were increased, while citric acid, fructose, 
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β-galactofuranoside, glucose were decreased in the glutamate-treated group. In 
pellet, glutamate treatment led to the increase of myo-inositol, palmitelaidic acid, 
cholesterol and oleic acid concentrations, but the decrease of  methoxyacetic acid, 
tetrapentacontane, octadecan-1-ol and docos-13-enoic acid levels. 
3.4 DISCUSSION 
3.4.1 Animal and cell models for AD 
Transgenic mice models for AD are essential for the understanding of disease 
pathophysiology, development of robust behavioral models and prediction of 
outcomes from pharmacological interventions. Several novel transgenic mice 
models, such as APPTg2576 [523], APP-PS2 [526], APP-PS1 [524], APP23 [531-
533], APP[V7171] [534] and TASTPM [535-539], have been developed focusing 
on the APP-processing and PS1 pathway as well as tau pathology. Each model has 
unique pathologies that provide insights into disease mechanisms and interactive 
features of neuropathologic cascades, which may potentially help in understanding 
the disease pathogenesis [540]. In our study, TASTPM transgenic and human p25 
induced mice model were used for metabolic profiling. In addition, cortical 
neurons treated with glutamate was utilized as an in vitro model for the 
investigation of metabolic changes related to neurodegeneration.  
TASTPM, heterozygote double-mutant mice over-expressing both the 695-amino 
acid isoform of human APP (APP695) harboring the Swedish double familial AD 
mutation (K670N, M671L) and human PS-1 harboring the familial mutation 
M146V, were generated and maintained at GlaxoSmithKline as described in detail 
previously [536, 541]. Although the PS1 transgene alone does not cause amyloid 
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plaque deposition [542], the addition of mutant PS (a risk factor for familial AD) to 
create double transgenic models may result in the acceleration of amyloid plaque 
deposition in APP mice [517]. In TASTPM mice model, expression of the two 
transgenes results in progressive amyloid deposition and pathology in the brain. Aβ 
(Aβ 1-40, Aβ 1-42 and total Aβ) loads increase with age between 3- and 6- months of 
age [536]. Meanwhile, TASTPM mice exhibit an age-dependent cognitive 
impairment in the object recognition test compared to wild-type animals, with the 
impairment becomes apparent from 6 months of age [536]. In addition, the MAPK-
activated protein kinase 2 (MK2) activity was also reported to be up-regulated in 
the cortex of 15-month-old TASTPM mice [543]. This double-mutant transgenic 
line has been widely used in neuroscience studies [535, 538, 539, 543].  
Our results showed that a number of metabolites were found to change in 
TASTPM mice in both brain and plasma. In brain, the levels of norvaline, 
pentanamide, valine, acetamide, serine and threonine were increased, while some 
tentative markers, possibly sterols, were decreased. The changes of norvaline, 
valine, serine and threonine suggested the perturbation of amino acid metabolism 
in AD animals. In plasma, 2-oxyethyl-amine was elevated in the concentration, 
whilst glucose, galactose, 9,12-octadecadienoic acid, arachidonic acid, 
hexadecanoic acid and gluconic acid declined.  
Cyclin-dependent kinase (cdk5), a molecular mediator linking the AD hallmarks 
including plaques, tangles and neuronal death, is a proline-directed protein kinase 
that phosphorylates serine and threonine residues [544]. Cdk5 is a pleiotropic 
kinase that plays numerous functions in the mammalian CNS. It is increasingly 
apparent that the deregulation of this kinase is neurotoxic and might contribute to 
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the pathogenesis of AD [545] and other neurodegenerative disease [544, 546]. 
Increased cdk5 activity has been observed in several neurodegenerative diseases 
including AD [545]. Monomeric cdk5 has no enzymatic activity and requires 
binding to a neuron-specific activator p35 or p39 for its activation. p35 can be 
cleaved into a C-terminal p25 fragment, which contains all the necessary elements 
to bind to and activate cdk5 [547]. In addition, p25-cdk5 is more stable than p35-
cdk5 complex, as the half-life of p25 is about 5-fold longer than that of p35 [545]. 
The aberrant hyperactivation of cdk5 through the association of p25 is responsible 
for the abnormal phosphorylation of tau protein and APP, which leads to 
intracellular NFT formation and extracellular Aβ plaques [544, 548]. In addition, 
p25-cdk5 complex can trigger neuronal death via several different pathways [544]. 
Several studies have observed an accumulation of the protein fragment p25 in AD 
brain [544, 549]. Transgenic mice expressing high levels of p25 exhibit 
hyperphosphorylation of tau as seen in AD [544]. In order to investigate the 
metabolic changes induced by p25/cdk5 mediated effects, the p25 transgenic mice 
that exhibit pathological lesions reminiscent of AD were used in this study. 
Metabolic profiling using cell culture model allows the analysis of the cell 
metabolome that may provide information on understanding the mechanism of the 
metabolic changes associated with AD. In order to explore the underlying 
metabolism and investigate the relationship between in vivo and in vitro models, 
glutamate-treated cortical neuron cells were also included in our study.  
Glutamate is the principle excitatory neurotransmitter in cortical and hippocampal 
neurons. In addition to its transmitter function, glutamate is a neurotoxin that has 
been implicated in the pathogenesis of a variety of neurodegenerative disorders 
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including AD as a key factor [74]. It has been shown that, glutamate induces 
different types of neuronal death including necrosis and apoptosis in vitro [75], 
which are known to occur during the course of neurodegeneration observed in AD 
[76]. Glutamine synthetase is oxidized in the brains of individuals with AD, 
leading to excess glutamate. Excitotoxicity resulting from excessive activation of 
NMDA receptors may enhance the localized vulnerability of neurons in a manner 
consistent with AD neuropathology and may be involved in neuronal degeneration 
and loss in AD [78]. In summary, glutamate toxicity and glutamatergic dysfunction 
play important roles in the pathogenesis of AD. 
In this study, we utilized a cortical neuron cells that was primarily cultured from 
the forebrain of C57BL/6J mice. As changes in medium metabolites reflect the cell 
physiological state and thus the cell metabolome, we investigated if the monitoring 
of metabolites consumed by and released into the medium by cells cultivated with 
glutamate or control vehicle provide sufficient information on the metabolic 
pathways involved. In this respect, GC/MS, in combination with multivariate data 
analysis, was proven to be a suitable technique allowing the simultaneous 
quantification of a large number of metabolites without any a priori hypothesis 
regarding the involved biochemical pathways and leading to the identification of a 
specific metabolic fingerprint. 
Our results showed that GC/MS based metabonomic approach allowed us to 
discriminate two different metabolic profiles in relation to the presence of 
glutamate treatment. The PLS-DA represents the interconnectivity of the fluxes of 
metabolites with respect to glutamate treatment, which can be interpreted as a 
fingerprint of the underlying system. This provides information about the specific 
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physiological state of the cells at a given point in time that can be interpreted as 
changes in the regulation of metabolic fluxes among the different intracellular 
pathways. 
3.4.2 Metabonomics of AD 
In our study, we found different potential makers in the brain of TASTPM and p25 
over-expressing mice. In TASTPM mice, three amino acids were found to be 
elevated when compared to those of wild type animals. However, in p25 over-
expressing mice, inositol (myo- and scyllo-), propanoic acid were found to be 
increased, while hexadecanoic acid were found to be decreased. These differences 
suggested that the markers may vary depending on the different animal models. 
Interestingly, sugars and lipid acids were found to be declined in plasma of 
TASTPM mice, whilst sugars in the urine of p25 mice were increased, which may 
indicate the metabolic perturbation of these compounds. Similar biomarkers like 
amino acids and myo- and scyllo-inositol have also been found to be associated 
with aging [263, 285, 436]. Some other amino acids like homocysteine were also 
indicated to be an independent risk factor for AD [500]. The elevation of amino 
acids in the brain of TASTPM mice may be due to the resistance to insulin action 
in the AD animals [263], although the plasma glucose levels were found to be 
decreased. It is also possible because of the decreased rate of the transamination 
and subsequent oxidation of their carbon skeletons which generally end up in the 
citric acid cycle [263]. In the plasma of TASTPM mice, the decreased sugars and 
fatty acids suggested the perturbation of their metabolisms. Surprisingly, the 
human brain arachidonic acid consumption has been reported to be increased in 
AD patients than in age-matched controls [550]. The elevated consumption is 
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consistent with evidence of inflammation and excitotoxicity in the postmortem 
brain from AD patients, as it also occurs in animal models of neuroinflammation 
and excitotoxicity [551].  
Identification of metabolite markers associated with AD would aid both the 
diagnosis of the disease and the development of effective therapies against it. The 
markers would allow validation of the animal models that have been used to select 
candidate therapies. If the animal models share a wide range of markers with 
human patients, this may increase the likelihood that treatments effective in the 
animal model would also ultimately be effective in humans. In addition, following 
changes in markers, particularly in the pre-symptomatic or early symptomatic 
phases of the disease should simplify and shorten early clinical trials examining the 
efficacy of candidate therapies. Any such treatment that successfully rescued 
markers in animal models in the early symptomatic phase and delayed disease 
progression could be viewed optimistically if it had a similar effect on markers in 
early symptomatic patients. As different metabolite markers were found in 
TASTPM and p25 over-expressing mice in our study (Table 3-6), it would be 
much more valuable if the identified markers in this study could be validated in 
AD patients.  
In the medium of the cell culture, the up- or down-regulation of the metabolites 
may indicate that uptake and/or excretion of the metabolites have been modulated 
with the addition of glutamate (Table 3-7). In pellet, the increase of the myo-
inositol and cholesterol concentrations was consistent with results observed in 
animal models. In addition, the increase of palmitelaidic acid and oleic acid and 
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decrease of octadecan-1-ol and docos-13-enoic acid may indicate the molecular 
disturbances of fatty acid metabolism involved in AD.  
Table 3-6  Comparison of marker metabolites of AD identified from TASTPM and p25 mice 
Samples  Changes TASTPM mice p25 over-expressing mice 
















Plasma ↑ 2-Oxy ethylamine N/A 
















 ↓ N/A 2-Methyl-2-hydroxybutyric acid 
Pentanoic acid 
N/A: not applicable 
Non-hypothesis driven systems biology approaches can be used effectively in the 
biomarker discovery. To date, however, it has not been possible to accurately 
determine the levels of all metabolites simultaneously, because of the substantial 
chemical and physical heterogeneity of the metabolome. As a result, only some 
subsets of metabolites can be studied using a single technique. The current study 
underscores the power of GC/MS-based metabonomics to present a broad picture 
of the biochemical profile of a population and changes in that profile with aging 
and AD conditions. The major strength of the GC/MS approach is the large 
number of metabolites that can be identified and quantified in a single sample. This 
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permits the identification of specific interactions of metabolic pathways that occur 
with aging or as the result of other pathological perturbations being investigated. 
However, further studies are still needed to validate the potential markers using 
authentic compounds to confirm their identities. Furthermore, a larger sample size 
is needed in the future study since the samples size of each test group in this thesis 
was relatively small. In addition, bioinformatics plays a vital role in “-omics” 
studies, including metabonomics. In this thesis, we used PCA and PLS-DA 
algorithms provided by commercial software SIMCA-P. In the future, some 
statistical leaning methods such as clustering, bi-clustering or machine learning 
methods [SVM, neural network (NN)] may also be exploited to process the data. In 
addition, it should be remembered that metabonomics should ideally form part of 
systems biology-based strategy for the study of organisms integrated with other 
omics technologies such as genomics and proteomics [552-554]. 
Table 3-7  Marker metabolites of AD identified from glutamate treated cortical neuron cells 
Samples  Changes Glutamate treated cell 














 ↓ Octadecan-1-ol 
Docos-13-enoic acid 
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CHAPTER 4 DETERMINATION OF ENDOGENOUS STEROIDS IN 
AGING AND AD ANIMAL MODELS 
4.1 INTRODUCTION 
There is an increasing need for early and accurate diagnosis of sporadic AD. 
Unfortunately, AD is difficult to diagnose, especially during the early phase of the 
disease course, and a definite diagnosis is possible only post-mortem. Therefore, 
biological markers that allow an early and accurate diagnosis of AD are highly 
desirable. Such biomarkers could also aid in the assessment of the efficacy of 
treatment strategies in AD management. The most extensively evaluated markers 
of sporadic AD are Aβ proteins, total tau and P-tau.  
Steroids play important roles in the modulation of GABAA [333-335, 555, 556], 
NMDA [337] and Sigma type 1 receptors [338, 557, 558]. The endogenous levels 
of steroids in brain and PNS have been shown to relate to a variety of cognitive, 
physiological and pathological processes [340-342], such as learning and memory, 
neurodevelopment, protection and regeneration of nervous system [340, 343-346]. 
Furthermore, circulating levels of steroids were found to be associated with aging, 
as well as onset and progress of neurological disorders such as schizophrenia, 
epilepsy, AD and PD [335, 340, 341, 347-351].  
A number of studies have been reported on the aging or AD-associated 
modulations of steroid levels. A clinical study found that the 3α,5α-THP levels in 
dementia patients was much lower when compared to controls, although further 
work is needed to establish the sensitivity and specificity in AD patients [372]. 
Progesterone and its derivatives were found to be promising neuroprotective agents 
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in several models of neurodegeneration, including experimental diabetic 
neuropathy [367]. The PROG plasma levels was markedly lowered in male rats 
with  months of diabetes induced by streptozotocin, while chronic treatment with 
PROG restored them, with protective effects on peripheral nerves. Recent studies 
suggest that alloprognanolone is a promising agent for promoting neurogenesis in 
aged brain and restoring neuronal populations in brains recovering from 
neurodegenerative disease or injury in transgenic mouse model of AD [368, 369]. 
It was found that allopregnanolone induced, in a dose dependent manner, a 
significant increase in the proliferation of neuroprogenitor cells derived from the 
rat hippocampus and human neural stem cells derived from the cerebral cortex. A 
study on the postmortem brain tissue showed the increased levels of PREG and its 
neuroactive metabolite allopregnanolone in autopsied brain tissue from cirrhotic 
patients who died in hepatic coma [370]. In another study, however, 
allopregnanolone was found to be reduced in prefrontal cortex in AD [371]. The 
phasing of total and unbound cortisol showed no major modifications with age, sex 
or senile dementia [366]. In addition, AD is associated with significantly higher 
DHEA and lower DHEAS levels in CSF, and the increased DHEA levels were not 
found to be neuroprotective [347]. Such changes may be due to the 7α-, 7β-, and 
16α-hydroxylations of DHEA, which are either present at lower levels or 
transformed through natural polymorphism into less-efficient enzymes [347]. 
Plasma DHEAS and the DHEAS/cortisol ratio were also reported to be 
significantly lower in AD than in controls [373]. The serum levels of cortisol, 
DHEA and androstenedione were significantly increased in AD patients than 
healthy elderly controls [559]. All these studies suggested that steroids might be 
potential biomarker of aging or for the early and accurate diagnosis of AD. 
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Therefore, the analysis of endogenous steroids in biofluids may provide a potential 
means in the diagnosis of neurological disorders like AD and shed new insights of 
possible treatment strategies. Herein, the steroid levels were measured in brain and 
plasma samples obtained from aging and AD animal models. By this, we aimed at 
discovering the steroidal markers that may be associated with aging and AD. 
4.2 MATERIALS AND METHODS 
4.2.1 Materials and Chemicals 
HPLC-grade methanol was purchased from Tedia Company Inc. (Fairfield, OH, 
USA). Water used was of Milli-Q grade purified by a Milli-Q UV Purification 
System (Millipore, Bedford, MA, USA). Strata-X solid-phase extraction (SPE) 
cartridges (100 or 200 mg adsorbent, 6 mL reservoir volume) were purchased from 
Phenomenex (Torrance, CA, USA). All other chemicals and reagents used for the 
experiments were of analytical or HPLC grades that are commercially available.  
Table 4-1 Parameters of the EIA kits used for the determination of endogenous steroids in the 
biological samples 
Catalogue No. Target steroid Sensitivity  Precision Cross-reactivity 
DSL-10-2000 Cortisol 1 ng/mL ≥ 88% < 10.9% * 
DSL-10-4000 Testosterone 0.04 ng/mL ≥ 93.2% < 6.6% 
DSL-10-3800 Androstenedione  0.03 ng/mL ≥ 89.7% < 10% 
DSL-10-9000 DHEA 0.1 ng/mL ≥ 88.2% < 3.7% 
DSL-10-3700 Estriol  0.04 ng/mL ≥ 93.3% < 0.26 % 
DSL-10-6800 17-Hydroxy-progesterone 0.035 ng/mL ≥ 93.2% < 4.1% 
582601 Progesterone  10 pg/mL ≥ 83.6 % < 7.2% 
582251 17β-Estradiol  19 pg/mL ≥ 88% < 14 % 
900-097 Corticosterone  26.99 pg/mL ≥ 92% < 28.6%# 
*: 58.3% cross reactivity with prednisolone (synthetic analogue whilst not endogenous compound); 
#: Cross-reactivity with deoxycorticosterone. 
The EIA kits for the determination of testosterone, androstenedione, DHEA, 
cortisol, estriol, and 17-hydroxy-progesterone were obtained from Diagnostic 
Systems Laboratories (Webster, TX, USA); kits for PROG and estradiol were from 
Cayman Chemical (Ann Arbor, Michigan, USA); and kit for corticosterone from 
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Assay Design (Ann Arbor, Michigan, USA). The parameters in the inserts of these 
kits are listed in Table 4-1.  
4.2.2 Animals and grouping schedules 
Refer to sections 2.2.2 and 3.2.2, respectively.  
4.2.3 Sample collection and preparation 
For the details on sample collection, please refer to sections 2.2.4.2 and 2.2.4.3. 
Plasma samples were analyzed directly using EIA kits without further processing. 
Brain samples were homogenized as described above, the volume of each 
homogenate was recorded and kept at -80°C until analysis. To extract the steroids, 
the thawed brain homogenate was added with approximately 5 mL of methanol-
acetic acid (99:1, v/v) [401]. The homogenate was then ultrasonicated (Ultrasonik 
57H; Ney Company, Bloomfield, USA) for 15 min, vortex-mixed for 1 min, and 
centrifuged at 6,000 × g and 4ºC for 15 min. The supernatant was collected, while 
the precipitate was re-extracted twice with 5 mL of methanol-acetic acid (99/1, 
v/v) and centrifuged at 10,000 × g and 4ºC for 15 min. The supernatants were 
combined, evaporated to remove the methanol under nitrogen at 50ºC using 
TurboVap LV. The remaining acetic acid mixture was subjected to freeze-drying 
(Labconco Corporation, Kansas City, Missouri, USA) at 0.14 mBar and -50ºC for 
6 h. The dried residue was reconstituted with methanol-water (50/50, v/v) to the 
concentrations of 1 g brain tissue/mL and stored at -80ºC prior to testing (this 
solution was subsequently referred to the brain extract). Aliquots of brain extract 
(0.5 mL, corresponding to 500 mg of brain tissue) was pipetted into a tube, and 
diluted with 4 mL of Milli-Q water. The final organic content of methanol in the 
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mixture was 5%. The samples were then applied to a pre-conditioned Strata-X SPE 
cartridge (200 mg adsorbent, 6 mL volume). The sulfated steroids were eluted with 
4 mL of methanol-water (40/60, v/v), followed by unconjugated steroids being 
eluted with 4 mL of methanol. The organic solvent of the resultant unconjugated 
fractions was collected into a screw-cap deactivated glass tube (VWR Scientific) 
and evaporated under a gentle stream of nitrogen at 50ºC. The resultant residue 
was dissolved in 1 mL of assay buffer in the EIA kit package for analysis.  
4.2.4 EIA 
The EIA analyses were performed according to the manufacturer’s instructions. 
The sensitivity and precision of each kit were examined in our laboratoryand 
confirmed to be suitable for the analysis. To avoid the inter-assay variation, all the 
samples that were arranged for the comparison were analyzed in one plate. In 
addition, the samples were stored in small aliquots to avoid the possible 
degradation due to the repeated freeze-thaw cycles.  
The absorbance was measured at 450 nm with reference 600 nm using Tecan 
Infinite® 200 Microplate Reader (Tecan, Switzerland). The standard curves were 
fitted with four-parameter logistic data reduction, Sigmoidal model, using 
GraphPad Prism® (La Jolla, CA, USA). The steroid concentrations were expressed 
as nanograms per milliliter (ng/mL) or picograms per milliliter (pg/mL) of plasma, 
or nanograms per gram (ng/g) or picograms per gram (pg/g) of brain tissue. 
4.2.5 Data processing and statistical analysis 
Statistical analysis was performed using SPSS 16.0 (SPSS, Inc., Chicago, IL, 
USA). Data were expressed as mean ± SD (standard deviation), except otherwise 
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indicated. Comparisons for multiple groups were performed using a one-way 
analysis of variance (ANOVA) followed by Welch’s t-test. Differences between 
two groups were analyzed using unpaired t-test with unequal variances assumed. 
The criterion for statistical significance was set as P < 0.05.  
4.3 RESULTS 
4.3.1 Aging study 
The levels of 17-OH-progesterone, androstenedione, corticosterone, cortisol, 
estradiol, estriol, DHEA, PROG, and testosterone were measured in the brain and 
plasma of young and aged male LH rats and C67BL/6J mice to examine whether 
the endogenous steroid levels were affected with aging, as shown in Figure 4-1 to 
Figure 4-6.  
In brain of aged (5-month old) C57BL/6J mice, higher levels of 17-OH-
progesterone (P < 0.001), androstenedione (P < 0.01), and estradiol (P < 0.01), 
while lower DHEA (P < 0.001) were detected when compared to those of young 
(1-month old) animals (Figure 4-1). No significant difference was observed 
between young and aged mice for corticosterone, cortisol, PROG, and testosterone. 
Estriol was not detectable in brain samples of both aged and young mice.  
In plasma of aged C57BL/6J mice, androstenedione (P < 0.01), cortisol (P < 0.05), 
and testosterone (P < 0.05) were found to be significantly elevated when compared 
to those of young animals (Figure 4-2). No significant difference was observed 
between young and aged mice for corticosterone, estradiol, estriol, DHEA, and 


























































































































































Figure 4-1 Steroid levels in whole brain homogenate of male C57BL/6J mice at the age of 1- 































































































































































Figure 4-2 Steroid levels in plasma of male C57BL/6J mice at the age of 1- and 5-month old 
(n=10). 17-OH-progesterone and estriol were not detectable. *, P < 0.05; **, P < 0.01; 
***, P < 0.001. 
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The level of androstenedione was consistently increased in both brain and plasma 
of aged mice when compared with young animals, as shown in Figure 4-1 and 
Figure 4-2. On the contrary, DHEA was decreased in brain, whilst increased in 
plasma of aged mice.   
In brain of aged (2-year old) LH rats, higher levels of 17-OH-progesterone (P < 
0.001), progesterone (P < 0.001) and corticosterone (P < 0.001), while lower 
estradiol (P < 0.05) and testosterone (P < 0.01) were detected when compared to 
those of young (2-month old) animals (Figure 4-3). No significant difference was 
observed between young and aged rats for androstenedione, cortisol, DHEA, and 
estradiol. Estriol was not detectable. In plasma of aged LH rats, 17-OH-
progesterone (P < 0.001) and corticosterone (P < 0.01), cortisol (P < 0.001), 
DHEA (P < 0.01), estradiol (P < 0.05) and PROG (P < 0.001) were significantly 
elevated, while testosterone (P < 0.001) was decreased when compared to those of 
young rats (Figure 4-4). No significant difference was observed between young 
and aged rats for androstenedione and estriol. The levels of 17-OH-progesterone 
and corticosterone were consistently increased while testosterone was consistently 
decreased, in both brain and plasma of aged rats when compared with young 
animals (Figure 4-3 and Figure 4-4). On the contrary, estradiol was decreased in 























































































































































Figure 4-3 Steroid levels in whole brain homogenate of male LH rats at the age of 2-month 
(n=20) and 2-year old (n=20). Estriol was not detectable. *, P < 0.05; **, P < 0.01; 























































































































































Figure 4-4 Steroid levels in plasma of male LH rats at the age of 2-month (n=20) and 2-year old 
(n=20). *, P < 0.05; **, P < 0.01; ***, P < 0.001.  
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Table 4-2  Comparison of steroids markers of aging identified from C57BL/6J mice and LH rats 
Samples  Changes C57BL/6J mice LH rats 






















 ↓ / Testosterone  
 
To examine the effects of LA treatment on the endogenous steroid levels, 2-month 
and 2-year old LH rats were treated with LA for 14 days (LA-young and LA-aged, 
respectively), while the control group of 2-year old LH rats were treated with 
vehicle solution (control-aged). The changes of steroids observed in the 
comparison of LA-young vs LA-aged were relatively consistent with those 
between young and aged rats without LA treatment. 
As compared to LA-young rats, LA-aged rats showed higher brain levels of 17-
OH-progesterone (P < 0.05), androstenedione (P < 0.05), corticosterone (P < 0.05) 
and PROG (P < 0.01), as shown in Figure 4-5. No significant difference was 
observed between young and aged rats dosed with LA for cortisol, DHEA, 
estradiol and testosterone. Estriol was not detectable. When compared to control-




























































































































































Figure 4-5 Steroid levels in whole brain homogenate of male LH rats dosed with LA (2-month 
and 2-year old, n=8 and n=10, respectively) or vehicle (2-year old, n=8) at the age of 
2-month and. Estriol was not detectable. *, P < 0.05 vs LA-young group; **, P < 0.01 






























































































































































Figure 4-6 Steroid levels in plasma of male LH rats dosed with LA (2-month and 2-year old, 
n=8 and n=10, respectively) or vehicle (2-year old, n=8) at the age of 2-month old. *, 
P < 0.05 vs LA-young group; **, P < 0.01 vs LA-young group; ***, P < 0.001 vs 
LA-young group. #, P < 0.05 vs control-aged group. 
 
In plasma, LA-aged rats showed higher levels of 17-OH-progesterone (P < 0.01), 
cortisol (P < 0.05), DHEA (P < 0.001), estradiol (P < 0.01) and PROG (P < 0.05), 
while lower estriol (P < 0.001) than those in LA-young group (Figure 4-6). It 
should be noted that although there was no significant difference between LA 
treated young and aged rats for corticosterone, its concentration was much elevated 
in LA-aged animals. In addition, LA-treatment decreased estradiol (P < 0.05) 
significantly when compared to control-aged animals.   
4.3.2 AD study 
The concentrations of steroids in C57BL/6J and TASTPM mice are presented in 
Figure 4-7 and Figure 4-8.  
In AD model TASTPM mice, the brain androstenedione level was dramatically 
decreased (P < 0.05) in brain homogenate. Notably, 17-OH-progesterone was not 
detectable in TASTPM mice brain, while it was readily detected in control animals 
(Figure 4-7). In plasma, both cortisol (P < 0.05) and testosterone (P < 0.01) were 
significantly decreased in TASTPM mice than in C57BL/6J mice (Figure 4-8). No 
significant difference was observed between these two groups for the other tested 
steroids, although corticosterone was marginally decreased in brain, while 

























































































































































Figure 4-7 Steroid levels in whole brain homogenate of male TASTPM (n=5) and C57BL/6J 
(n=16) at the age of 50-week. Estriol was not detectable. *, P < 0.05; **, P < 0.01; 


























































































































































Figure 4-8 Steroid levels in plasma of male TASTPM (n=5) and C57BL/6J (n=16) at the age of 
50-week. 17-OH-progesterone and estriol was not detectable. *, P < 0.05; **, P < 
0.01; ***, P < 0.001. 
 
4.4 DISCUSSION 
The present study examined the endogenous levels of nine steroids in brain and 
plasma obtained from aging and AD animal models.  
Among the developed methods for the analysis of endogenous steroids, EIA has 
been widely used due to their high sensitivities [373, 384, 385] , which is crucial 
for the analysis of steroids in biological samples. The introduction of steroid 
immunoassay methods has enabled clinical chemists to measure low concentration 
of a large number of different endogenous steroids, which has led to a dramatic 
increase in our understanding of steroid physiology. In addition, many 
commercially available EIA kits circumvent tedious sample preparation steps. A 
comparison study [560] showed that although absolute concentrations may differ 
for some steroids, immunoassay and MS can yield similar estimates of between-
subject differences in serum concentrations of the majority steroids commonly 
measured in population studies, including estradiol, estrone, androstenedione, 
testosterone, and DHEAS etc. Moreover, regardless of its inherent disadvantages, 
EIA remains the most widely accepted method for the endogenous steroid analysis 
rather than MS in many clinical settings. In our study, therefore, we utilized the 
commercially available EIA kits to measure the concentrations of the targeted 
steroids.  
4.4.1 Aging study 
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Our results suggested that the levels of endogenous steroids might change with 
aging or under AD condition. As shown in Table 4-2, all the impacted steroids 
were increased from 1-month to 5-month age, except that DHEA was deceased in 
brain of 5-month C57BL/6J mice, which was conversely marginally increased in 
plasma. Similarly, the concentrations of steroids were mainly increased, except 
estradiol and testosterone were decreased in brain and brain/plasma of LH rats, 
respectively. As the “aged” C57BL/6J mice were only 5-month old, the changes of 
steroids levels may reflect the outcome of development rather than aging. 
However, LH rats of 2-year old reflected clearly steroidal changes associated with 
aging progress. In aged LH rats, corticosterone and 17-OH-progesterone were 
consistently increased, while testosterone was decreased in both brain and plasma 
of LH rats. Whilst PROG (precursor of corticosterone and 17-OH-progesterone), 
DHEA (precursor of testosterone), cortisol (metabolite of 17-OH-progesterone), 
and estradiol were increased in plasma of aged rats. These results indicate that 
steroid equilibrium was remarkably altered by aging process showing the changes 
in the levels of plasma steroids. 
The results on the changes of steroid levels associated with aging as reported in the 
literatures are discrepant. For example, the basal levels of plasma corticosterone 
were reported to be age-dependently elevated in normal [561-563] and diestrous 
[564] rats. Goya et al. found that the circulating plasma levels of corticosterone did 
not show significant differences between young (3 month) and old (26 month) 
male Sprague-Dawley rats [565]. On the contrary, plasma corticosterone and 17-
OH-progesterone in Sprague-Dawley rats decreased with aging [566]. In a study 
with postmenopausal women [567],  PREG and 17-hydroxypregnenolone; PROG 
and 17-hydroxyprogesterone; and cortisol did not change with age. DHEA and 
 147 
DHEAS declined significantly with age, whereas no change was noted in 
androstenedione and testosterone, estradiol and estrone. However, in another study 
with young (age 20 to 21 years) with elderly (age 77 to 86 years) healthy male 
subjects [568], the results showed that the mean basal levels of PREG, 17-
hydroxypregnenolone, DHEA, PROG, 17-hydroxyprogesterone, androstenedione 
and aldosterone gradually decreased with advance in age. In addition, testosterone 
and its precursors decreased, while PROG and 17 α-hydroxyprogesterone 
increased in the testicular tissue of old men [569].  
It is assumed that these age-dependent changes are caused by an impaired oxygen 
supply of the aging testes [569]. This hypothesis is supported by the observation 
that the same changes in steroid pattern seen in old age can be observed under 
reduced oxygen supply in in vitro incubation experiments with testicular tissue. 
Data concerning changes in brain and plasma steroid levels with age are still 
fragmentary and do not allow scientists to draw definite conclusions concerning 
the role of steroids in the aging process of the nervous system [340]. Steroids have 
been reported to be able to reverse the age-dependent changes to some extent in the 
nervous system. Several experiments using aged animals have provided evidence 
that the aging nervous system indeed retains sensitivity to the protective effects of 
steroids. Intrahippocampal injection of PREGS was reported to transiently correct 
the spatial memory deficits of cognitively impaired 2 years old aged rats [570]. 
Moreover, treatment with progestins (PROG, 5α-dihydroprogesterone or 3α,5α-TH 
PROG) reversed age-related structural abnormalities of the peripheral myelin 
sheaths [571]. In our study, the increased steroid levels in aged animals may reflect 
a distorted secretion, and/or alterations in metabolism of these hormones. On the 
 148 
other hand, the increment of steroids could be viewed as a counter-regulatory 
mechanism invoked in old rats to compensate, at least partially, for the declined 
responsiveness of the receptors of ACTH and corticosterone caused by their 
elevated plasma concentrations [572]. 
By scavenging ROS that can affect steroidogenic enzyme activities, LA treatment 
was reported to significantly reverse the decreased level of testosterone induced by 
adriamycin treatment [573]. In our study, estradiol and cortisol were found to be 
increased in brain and plasma of aged C57BL/6J mice, respectively. However, LA 
treatment did not reverse these potential steroid markers of aging. Compared to 
control group, LA increased cortisol and estradiol in brain and plasma, 
respectively. This may due to the effects of decreasing oxidative damage [486, 
487] or downregulating inflammatory processes as an anti-inflammatory 
antioxidant [485]. As mentioned above, increased steroid levels may exhibit 
neuroprotective function on aging, which may partially explain the beneficial 
effects of LA on aging progression. Further studies are still needed to investigate 
the mechanisms involved.  
4.4.2 AD study 
AD has been found to be associated with significantly higher DHEA levels in CSF, 
which may due to the decreased production of its metabolites such as DHEAS 
[347]. Increased total 7α-hydroxy-DHEA levels were also reported in serum of 
patients with AD [574]. The increased DHEA levels in AD are not 
neuroprotective. In our study, we also found that DHEA was insignificantly higher 
in both brain and plasma of TASTPM mice when compared to the control 
C57BL/6J mice. In addition, 17-OH-progesterone (precursor of androstenedione) 
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and testosterone (metabolite of DHEA and 17-OH-progesterone) were significantly 
lower in brain and plasma of TASTPM mice, respectively. Furthermore, 
androstenedione (metabolite of DHEA and 17-OH-progesterone) was decreased 
significantly in brain and marginally in plasma of TASTPM mice, respectively. 
The change of 17-OH-progesterone levels may also contribute to the disease-
related disturbances of DHEA production and metabolism, as they share a common 
precursor, which is 17-OH-pregnenolone. These observations could be outcomes 
due to sulfotransferase and cytochromes P450 enzymes responsible for the 
metabolism of 17-OH-progesterone and DHEA were either up- or down-regulated 
or transformed through natural polymorphism into more- or less-efficient enzymes 
in AD brain. More importantly, the changed steroid levels in AD mice may reflect 
a distorted secretion, and/or alterations in metabolism of these hormones, which 
may influence the symptomatology and progression of the disease [559].  
In summary, the increasing understanding of the modulation of steroid levels in 
brain and plasma in normal aging and AD helps us understand the involvement of 
steroids in the pathogenesis and progress of AD [575]. In addition, it provides a 
potential class of biomarkers for the diagnosis of AD at the early stage. Further 
studies, including both preclinical and clinical trials, are still needed for the 





CHAPTER 5 MS-BASED TECHNIQUES FOR THE BIOANLAYSIS OF 
ENDOGENOUS STEROIDS IN BIOLOGICAL SAMPLES 
In this chapter, a series of MS-based methods for the analysis of endogenous 
steroids in biological samples are described, including 1) LC/ESI/MS analysis of 
intact steroids; 2) LC/APPI/MS analysis of intact steroids; 3) LC/ESI/MS analysis 
of steroids derivatized with hydroxylamine (HA); 4) LC/ESI/MS/MS analysis of 
steroids derivatized with 2-sulfobenzoic acid cyclic anhydride (SBA); and 5) 
GC/EI/MS analysis of steroid derivatized with HFBA. These methods were 
explored in our laboratory and compared in terms of sample preparation, 
sensitivity and applicability for the analysis of endogenous steroids in biological 
samples. 
5.1 INTRODUCTION  
Due to the extensive biological and clinical significance of steroids, the analysis of 
endogenous steroids in biofluids may provide a potential means in the metabolic 
profiling of neurological disorders and shed new insights of their molecular 
characteristics. However, the physiological levels of endogenous steroids in 
complex biological matrices, such as plasma, CSF and brain tissue, are very low 
(pg-subng/mL biofluids or gram tissue). Therefore, it is necessary to develop and 
validate highly sensitive, accurate and selective analytical methods for their 
analysis. To date, various analytical methods have been developed for the 
determination of endogenous steroids in biological samples. In particular, MS 
combined with GC or LC has been extensively used for the determination of 
steroids in biological samples. 
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GC/MS is the current “gold” standard for steroid analysis due to its unsurpassed 
chromatographic resolution, high sensitivity and informative first dimension MS 
spectra. Various derivatization methods have been reported for the determination 
of steroids using GC/EI/MS, including BSTFA + TMCS [396-398], MSTFA [398, 
399] and MTBSTFA [398, 400] that lead to the formation of TMS and TBS 
derivatives. Another derivatizing reagent HFBA has also been successfully used 
for the determination of steroids in the biological samples such as plasma and 
brains [350, 371] using GC/EI/MS [401]. Using this method, the authors achieved 
the on-column detection limits of 1 pg for PREG, DHEA and their sulfate esters 
PREGS and DHEAS, 2 pg for PROG and 5 pg for 3α,5α-THP. In some studies, 
even much better detection limits were reported, ranging from 2-120 pg/g brain 
[402] or 1-2000 pg/g brain or mL plasma [403] for different steroids. However, 
many steroids (e.g. estradiol) were still undetectable due to the trace amount in the 
biological samples. Thus, efforts have been made to develop more sensitive 
methods for the analysis of trace levels of endogenous steroids, such as 
GC/ECNCI/MS [392, 394]. The major advantages of GC/NCI/MS is that 
ionization is specific to compounds containing the electron capturing tag, and it 
provides excellent sensitivity in terms of S/N ratio. Using this method, Kim et al. 
[392] achieved instrumental detection limits for steroids in the pg range, and 
quantified androsterone (~50 pg/mL), testosterone (~200 pg/mL), 
allopregnanolone (~50 pg/mL) and PREG (~40 pg/mL) in human CSF. Vallee et 
al. [394] determined the levels of allopregnanolone, epiallopregnanolone, PREG, 
testosterone and DHEA in frontal cortex of rat brain to be near or below their limit 
of quantification (2.5 ng/g). In a recent study [370], the ether derivatives of 
steroids were also analyzed using GC/NCI/MS following derivatization. 
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Despite the advantages GC/MS provides, this technique is unable to analyze polar 
and thermally labile steroids directly, such as the sulphated steroids. Moreover, 
GC/MS methods require extensive sample purification procedures [393], including 
the removal of any conjugating groups (e.g. sulphate esters) and time-consuming 
derivatization of the remaining polar functional groups of nonvolatile steroids to 
enhance thermal stability and volatility of the analyte [394, 395].  
Recently, the advantages of LC/MS are being exploited for steroid analysis and the 
technique has gained popularity [393, 408, 409]. These LC/MS methods allow the 
analysis of intact conjugates or even avoid the derivatization procedures. LC 
coupled with ESI [410, 411], nanoESI [408], APCI [409] or APPI [409, 411-413] 
have been studied for the determination of steroids. However, these conventional 
LC/MS methods do not offer favorable sensitivity due to the poor ionization 
efficiencies of unconjugated steroids. To overcome this challenge, various 
chemoselective derivatization schemes suitable for each ionization method were 
examined to enhance sensitivity [393, 414-416, 419, 420, 576]. Liu et al. 
derivatized the oxo groups of steroids with hydroxylamine to generate steroid 
oximes [393]. Steroid oximes are more readily protonated in the electrospray 
process than underivatized analogues and give an enhancement in sensitivity of at 
least 20-fold [419]. Detection limits for testosterone, DHEA, PREG and PROG 
oximes in LC/ESI/MRM experiments ranged from 0.1 to 0.5 pg [393]. Analysis of 
neutral steroid fraction in rat brain resulted in detection levels ranging from 0.1 to 
38 ng/g for various steroids, which are comparable to reported GC/NCI/MS assay 
[394]. Mitamura et al. used a reversed-phase LC negative ESI method which 
involved derivatization of the oxo group of PREGS with 4-(N,N-
dimethylaminosulphonyl)-7-hydrazino-2,1,3-benzoxadiazole [417], giving an on-
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column detection limit of  around 100 pg [417]. Higashi et al. derivatized the oxo 
group of steroids with 2-nitro-4-trifluoromethylphenylhydrazine to the 
corresponding hydrazone and performed LC-electron capture atmospheric pressure 
ionization LC/ECAPCI/MS in the analysis of neutral steroids in rat brain [422]. 
They found that they were able to enhance sensitivity to an on-column detection 
limit of 1-6 pg. Griffiths et al. derivatized steroids possessing an oxo group with 
GirP to give a GirP-hydrazone [424, 425]. Steroid-GirP hydrazones can be 
detected at the sub-pg level at 50 pg level. 
Compared to positive ionization mode, negative ionization mode may improve the 
detection sensitivity due to its relatively low background noise. The introduction of 
acidic moieties, such as carboxyl or sulfonic group, which can be easily 
deprotonated, could effectively increase the sensitivity of ESI/MS experiment. A 
sulfur trioxide-pyridine complex has been used to derivatize cholesterol for the 
precursor ion scan analysis on nanoESI/MS/MS, which enabled the determination 
of cholesterol at the low picomole level [577]. In another study [408], testosterone 
was derivatized with a sulfur trioxide N,N-dimethylformamide complex in 
dimethylformamide/pyridine and subjected to nanoESI/MS analysis. The limit of 
detection of the steroid sulfates extracted from the biological matrix was 200 
amol/µL (approximately 80 pg/mL) with only 1 µL of sample being injected. 
However, it may be disadvantageous to use this method since it is impossible to 
distinguish the endogenous sulfates from the derivatized ones.  
Recently, SBA was adopted for the preparation of a sulfonic acid library via 
reaction with the alpha-amino alcohols [578]. Ukena et al. [579] reported the 
structural analysis of the [M-H]- ions of ostreooin-D derivatized with SBA at the 
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terminal amino or hydroxyl group of the molecule. More interestingly, a patent 
published by Schering Aktiengesellschaft (Germany) [580] used SBA to react with 
the hydroxyl group in steroids to produce prodrugs, which resulted in high yield. 
Hence, SBA is a potential derivatizing reagent to consider for LC/ESI/MS analysis 
of steroids in negative mode. However, relevant study for the analysis of 
endogenous steroids via SBA derivatization has not been reported yet.  
Due to the physiological and clinical importance of steroids in aging and AD, 
steroidal profiling of aging and AD models using an accurate and reliable 
analytical technique may be of high interest. Notably, “steroidomics” has been 
termed to refer to the characterization and quantification of metabolic profiles of 
steroids [581-583]. Herein, in order to develop an optimized method for steroidal 
profiling in this study, we compared various MS-based assays for unconjugated 
steroid analysis using both LC/MS and GC/MS techniques. Both published and 
newly developed MS-based assays of steroids were investigated and compared 
using the instrumentations available in our laboratory. The developed methods 
were applied to profile the endogenous steroids in biological samples. The 
optimization, strengths and limitations of the methods are discussed. 
5.2 MATERIALS AND METHODS  
5.2.1 Materials and chemicals 
Standard unconjugated steroids listed in Table 5-1 and Figure 5-1, pregnenolone-
16α-carbonitrile (internal standard, IS), HA, SBA, HFBA, molecular sieve were all 
purchased from Sigma-Aldrich Chemical (St. Louis, MO, USA).  
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Table 5-1 List of steroid standards used in our study  
No. Chemical name Trivial name (abbreviation) 
Sigma 
Cat.  No. MW 
1 3β-Hydroxy-5-pregnen-20-one Pregnenolone (PREG) P9129 316.48 
2 3α-Hydroxy-5β-pregnan-20-one Pregnanolone (3α,5β-TH 
PROG) 
P8129 318.49 
3 Pregn-4-en-3,20-one Progesterone (PROG) P8783 314.46 
4 21-Hydroxy-4-pregnene-3,20-dione 21-Hydroxyprogesterone  D6875 330.46 
5 3β,17α-Dihydroxy-5-pregnen-20-one 17α-Hydroxypregnenolone H5002 332.48 
6 17α-Hydroxy-4-pregnene-3,20-dione 17α-Hydroxyprogesterone H5752 330.46 
7 11β,17α-Dihydroxy-4-pregnene-3,20-
dione 
21-Deoxycortisol P9521 346.46 
8 4-Pregnene-11β,17α,21-triol-3,20-dione Hydrocortisone (Cortisol) H4001 362.46 
9 3β-hydroxyandorost-5-en-17-one Dehydroepiandrosterone 
(DHEA) 
D4000  288.42 
10 4-Androstene-3,17-dione Androstenedione 46033  286.41 
11 Estrone Estrone E9750 270.37 
12 / 17α-Estradiol   E8750 272.38 
13 5α-Pregnane-3,20-dione (allo) Allopregnane-3,20-dione P7754 316.48 
14 3α-Hydroxy-5α-pregnan-20-one 3α-OH-DHP P8887 318.49 
15 17β-Hydroxy-5α-androstan-3-one Androstanolone 10300 290.44 
16 11β,21-Dihydroxyprogesterone Corticosterone C2505 346.46 
17 1,3,5-Estratriene-3,17β-diol 17β-Estradiol E1024  272.38 








Androsterone 219010 290.44 
21 6α-Hydroxyestradiol, 3,16α,17β-
Trihydroxy-1,3,5(10)-estratriene 
Estriol E1253 288.38 
22 1-Dehydrohydrocortisone Prednisolone 46656 360.44 
The HPLC-grade methanol and acetonitrile were purchased from Tedia Company 
Inc. (Fairfield, OH, USA). Hexane and ethyl acetate were purchased from Fisher 
Scientific (Leicestershire, UK). HPLC grade toluene and acetone were obtained 
from J.T. Baker (Mallinckrodt Baker, Phillipsburg, NJ, USA) and Mallinckrodt 
UltimAR (Mallinckrodt Baker, Phillipsburg, NJ, USA), respectively. Ammonium 
acetate of 99% purity was purchased from VWR International Ltd. (Leicestershire, 
UK). Pyridine (ACS grade) and albumin from bovine serum were obtained from 
Sigma-Aldrich Chemical (St. Louis, MO, USA). The water used was of Milli-Q 
grade purified by a Milli-Q UV Purification System (Millipore, Bedford, MA, 
USA). Strata-X polymeric SPE cartridges were purchased from Phenomenex 
 156 
(Torrance, CA, USA). All other chemicals and reagents used for the experiments 






































































































Figure 5-1 Chemical structure of the unconjugated steroids tested in our study (Cat. numbers are 
cited in Table 5-1) 
 
5.2.2 Preparation of anhydrous solvents 
HPLC grade solvents, including acetone, acetonitrile and toluene, were used to 
prepare the anhydrous solvents using activated molecular sieves (Sigma-Aldrich, 
St. Louis, MO, USA). The molecular sieves were activated by heating at 180ºC 
overnight in a Heraeus® vacutherm® 6000 BL Vacuum Drying Oven (Weiss-
Gallenkamp, Loughborough, United Kingdom). After cooled down in a glass 
desiccator, the molecular sieves were immediately transferred to the solvent 
container, and kept in the desiccator overnight before use.  
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5.2.3 Preparation of stock and working solutions 
Stock solutions of standard steroids and pregnenolone-16α-carbonitrile (IS) were 
prepared in methanol at the concentration of 1 mg/mL. A mixture containing the 
standard steroids were prepared in methanol at the concentration of 25 µg/mL of 
each steroid using the stock solutions. The working solutions were subsequently 
prepared by serial dilution with methanol to required concentrations (1 and 10 
ng/mL) for calibration, limit of detection (LOD), limit of quantification (LOQ) and 
system suitability determination. An IS working solution was prepared by dilution 
with methanol from IS stock solution to the concentration of 10 µg/mL.  
5.2.4 Preparation of calibrators and quality controls  
To examine the accuracy, intra- and inter-day precision and recovery of the 
method, calibration standard samples are needed to be prepared. Since plasma that 
was free of endogenous steroids was not available, a 6% albumin solution in 
physiological saline was used to prepare all calibration standards [394]. Each 
calibration standard was prepared by spiking 10 µL of the specified working 
solution into 990 µL of albumin. One milliliter of each calibration standard was 
spiked with 100 ng of pregnenolone-16α-carbonitrile (for SBA derivatization) or 
prednisolone (for HA derivatization) as IS (10 µL of working solution at 10 
µg/mL), diluted with 2 mL of Milli-Q water, and passed through Strata-X SPE 
polymeric cartridge (100 mg adsorbent in 6 mL volume) as described below. The 
eluted steroid fraction was evaporated under nitrogen at 50ºC for 30 min using 
TurboVap LV evaporator (Caliper life sciences, Hopkinton, MA, USA), and the 
residue was subjected to further analysis.  
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For the brain tissue, the pooled tissue samples from four rats were homogenized 
and extracted as described in section 5.2.5.3. The pellet, which was assumed to be 
free of steroids, was re-suspended in physiological saline (0.9% NaCl) and used as 
the matrix for standard sample preparation as described in section 2.2.4.  
5.2.5 Biological samples collection and preparation 
Plasma and brain of LH rats were collected as described in section 2.2.4.  
5.2.5.1 Extraction of steroids  
The extraction efficiency of steroids from a pooled rat plasma sample was 
evaluated and compared using protein precipitation by methanol or SPE by 
UPLC/UV detection. An ACQUITY UPLC system (Waters, Milford, MA, USA) 
was equipped with a tunable UV detector. The chromatographic separations were 
performed on an ACQUITY UPLC BEH C18 1.7 μm 50 × 2.1 mm i.d. column 
(Waters). The mobile phases consisted of Milli-Q water (solvent A) and methanol 
(solvent B). The elution conditions were: gradient (curve 5) of 15 to 60% solvent B 
(0-8 min), isocratic at 60% solvent B (8-9 min) and isocratic at 5% solvent B (9-10 
min). Each wash cycle consisted of 1000 µL of weak washing solvent (water) and 
1000 µL of strong washing solvent (methanol/water: 90/10, v/v). The column 
heater and sample manager were set at 40 and 4ºC, respectively and flow rate was 
set at 0.5 mL/min. The injection mode was partial loop with needle overfill and the 
injection volume was 5 µL. The UV detector was set at 210 and 247 nm in dual 
monitoring mode. 
17β-estradiol and 21-deoxycortisol were selected as model steroids to examine the 
recovery, as they represent the main structural differences of the steroids studied. 
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The albumin solution was spiked with steroid stock solution (1 mg/mL in 
methanol) at the concentration of 1 µg/mL, and prepared as described in section 
5.2.3. Each experiment was performed in triplicate.  
For the methanol protein precipitation, control samples prepared in albumin (1 mL) 
were added 1 mL of IS solution in methanol (10 µg/mL) to precipitate the proteins. 
The tubes were vortexed vigorously for 10 min and centrifuged at 16,000 × g and 
4ºC for 15 min. Then 500 μL of the supernatant was collected into autosampler 
vials and 5 μL aliquots were injected into the UPLC/UV system.  
For SPE, Strata-X polymeric cartridges were used for the steroid extraction and 
sample clean-up. Prior to sample loading, the SPE cartridges were successively 
conditioned and activated with 4 mL of methanol followed by equilibration with 4 
mL of Milli-Q water. Milli-Q water containing 0, 5, 10 or 20 % of methanol was 
used as the washing solutions, while methanol, acetonitrile, ethyl acetate and 
isopropanol were used as eluting solvents. The same control samples were diluted 
with Milli-Q water (1/1, v/v), passed through the SPE cartridges and eluted with 
methanol, and diluted with Milli-Q water (1/1, v/v). The diluted elute was 
collected, and each sample (5 µL) was injected into the UPLC/UV system for the 
recovery study. To optimize the extraction efficiency, different washing and 
elution solvents were examined in SPE (Table 5-2).  
Table 5-2 Optimization scheme of washing and elution solvents used in SPE for the extraction 
of sulfated and neutral steroids from brain and plasma samples 
Procedures  Solvents 
Condition Methanol 
Equilibration Water 
Washing 0, 5, 10 or 20 % of methanol in water 
Elution of sulfated steroids 40 % of methanol in water (discarded as sulfated steroids) 
Elution of neutral steroids Methanol, acetonitrile, ethyl acetate or isopropanol 
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Meanwhile, the standard solutions prepared in methanol/water (50:50, v/v) at the 
same concentrations were subjected directly to UPLC/UV analysis. The recovery 
was calculated by comparing the peak areas obtained by extracted sample to those 
of standard solutions representing 100% recovery of steroids. The extraction 
method that gave the optimal results in terms of extraction efficiency and system 
suitability (backpressure stability) was used subsequently in the studies of 
biological samples.  
5.2.5.2 Plasma sample preparation 
One mL each of an aliquot of plasma or calibrator prepared in 6% albumin was 
diluted with 2 mL of Milli-Q water, spiked with 100 ng of pregnenolone-16α-
carbonitrile as IS (10 µL, 10 µg/mL) and passed through the Strata-X SPE 
polymeric cartridge (100 mg adsorbent, 6mL volume). The cartridges were pre-
conditioned and activated by consecutive addition of 4 mL of methanol and Mill-Q 
water. After sample was loaded and drained by gravity, the cartridges were washed 
with Milli-Q water (4 mL) and methanol-water mixture (5/95, v/v, 4 mL) and 
vacuum-dried for 1 min. Subsequently, the steroid sulfate fraction was eluted with 
4 mL of methanol/water (40/60, v/v). Finally, the cartridges were further eluted 
with 4 mL of methanol, and this elute constituted the neutral steroid fraction. The 
steroid sulfate fraction was disposed to waste, while the neutral steroid fraction 
was evaporated separately under a stream of nitrogen at 50ºC using TurboVap LV 
evaporator and subjected to further analysis.  
5.2.5.3 Brain sample preparation 
 161 
The brain samples were homogenized as described in section 2.2.4.3, recorded the 
volume and kept at -80°C until analysis. To extract the steroids, the thawed brain 
homogenate was spiked with 100 ng of pregnenolone-16α-carbonitrile as IS (10 
µL, 10 µg/mL) and added with approximately 5 mL of methanol-acetic acid (99:1, 
v/v) [401]. The homogenate was then ultrasonicated (Ultrasonik 57H; Ney 
Company, Bloomfield, USA) for 15 min, vortex-mixed for 1 min, and centrifuged 
at 6,000 × g and 4ºC for 15 min. The supernatant was collected, while the 
precipitate was re-extracted twice with 5 mL of methanol-acetic acid (99/1, v/v) 
and centrifuged at 10,000 × g and 4ºC for 15 min. The supernatants were 
combined, evaporated to remove the methanol under nitrogen at 50ºC using 
TurboVap LV. The remaining acetic acid was applied to freeze-drying using a 
FreeZone 2.5 freeze-dry system (Labconco Corporation, Kansas City, Missouri, 
USA) at 0.14 mBar and -50ºC for 6 h. The dried residue was reconstituted with 
methanol-water (50/50, v/v) to the concentration of 1 g brain tissue/mL and stored 
at -80ºC prior to use (this solution is called the brain extract). Each aliquot of brain 
extract (0.5 mL, corresponding to 500 mg of brain tissue) was pipetted into a tube, 
and diluted with 4 mL of Milli-Q water to reach a final concentration of 5% 
methanol. The samples were then applied to a pre-conditioned Strata-X SPE 
cartridge (200 mg adsorbent in 6 mL) and washed in the same way as described in 
section 5.2.5.2. The sulfated steroids were eluted with 4 mL of methanol-water 
(40/60, v/v), followed by unconjugated steroids eluted with 4 mL of methanol. The 
organic solvent of the resultant unconjugated fractions was collected into a screw-
cap deactivated glass tubes (VWR Scientific) with PTFE-lined caps. The elutions 
were evaporated under a gentle stream of nitrogen at 50ºC, and the residue was 
subjected to further analysis. The resultant brain homogenate after the steroid 
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extraction was re-suspended in 0.9% NaCl at around 100 mg/mL of brain pellet, 
and stored at -80ºC as blank matrix for calibration curve study.  
5.2.6 UPLC/ESI/MS and UPLC/APPI/MS analysis of intact steroids 
To compare the ionization efficiencies of TurboIonSpray electrospray ionization 
(ESI) and PhotoSpray electrospray ionization (APPI) on steroids, both these two 
ionization sources were used for the analysis of standard steroids. The compound- 
and source-dependent parameters of the MS spectrometer were optimized for each 
individual steroid under these two ionization sources. The optimized conditions 
were then used to obtain the intensities for each steroid, and the data were 
compared between these two ionization modes.  
5.2.6.1 UPLC/ESI/MS instrumentation and optimization  
An ACQUITY UPLC system (Waters, Milford, MA, USA) was interfaced to a 
hybrid triple quadrupole linear ion trap mass spectrometer (Q-TRAP® 2000) 
equipped with a TurboIonSpray electrospray ionization (ESI) source (Applied 
Biosystems, Foster City, CA, USA). The chromatographic separations were 
performed on an ACQUITY UPLC BEH C18 1.7 mm 50 × 2.1 mm i.d. column 
(Waters). The UPLC and MS systems were controlled by separate processes of 
MassLynx 4.1 (Waters) and Analyst® 1.4.1 software (Applied Biosystems), 
respectively. The UPLC experimental parameters (i.e. sample name, inlet method, 
vial position and injection volume) were specified within the sample list of 
MassLynx (Waters) while the MS specific parameters (i.e. sample name, data path 
and MS method) were documented within the sample set of the Analyst® software 
(Applied Biosystems). The inter-module communication was achieved as 
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previously described [584]. Sample injections executed by the UPLC sample 
manager were leveraged as contact closure events to deliver start signals to the 
mass spectrometer for data acquisition. 
The optimization of the compound-dependent MS parameters for the ESI 
ionization of steroids was performed by the direct infusion of 1 µg/mL each of the 
steroids (prepared in 50% v/v methanol in water) into the ESI/MS. The solutions 
were infused into the ESI source at a flow rate of 10 μL/min using the built-in 
microsyringe pump (Harvard Apparatus Inc., Holliston, MA, USA). For each 
infusion, full scan data (m/z 200-600) were acquired using both positive and 
negative ionization modes. The intensity of [M+H]+ or [M-H]– ion derived from 
multiple channel acquisition (MCA) scans obtained in 5 min were recorded and 
compared. The compound-dependent parameters optimized were declustering 
potential (DP), entrance potential (EP), collision cell entrance potential (CEP), 
collision energy (CE), and collision cell exit potential (CXP). The collision-
activated dissociation (CAD) gas was set to ‘Medium’ throughout the experiments.  
For the optimization of the source-dependent MS parameters, a split infusion setup 
with the column excluded was adopted. Full scan data (m/z 200-600) were acquired 
using both positive and negative ionization modes at constant optimized DP (60 V) 
and EP (10 V). The optimization of the mass spectrometric parameters was 
performed by continuous flow analysis using the UPLC pump at various flow rates 
(100, 200, 300, 400 and 500 μL/ min), while individual steroid standard solution 
(1µg/mL prepared in 50% v/v methanol in water) was infused at 10 µL/min. To 
determine a suitable mobile phase composition for the ionization of the steroid, 
each of them was prepared at 1 µg/mL in various solutions shown in Table 5-3.  
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Table 5-3 Solvents used as mobile phases for the LC/MS assays in this study  
(a) Methanol in water 
(b) Methanol in water (0.1% formic acid) 
(c) Methanol in water (10mM ammonium acetate) 
(d) Acetonitrile in water 
(e) Acetonitrile in water (0.1% formic acid) 
(f) Acetonitrile in water (10mM ammonium acetate) 
These solutions were introduced simultaneously into the Q-TRAP MS via the 
three-way Tee-connector. The source-dependent parameters optimized were 
nebulizer gases 1 and 2 (GS1 and GS2), temperature (TEM), curtain gas (CUR) 
and ionspray voltage (IS). The interface heater was set to ‘ON’ mode to maximize 
the ion signal and prevent contamination of the ion optics. Nitrogen was used as 
sheath gas, ion sweep gas and auxiliary gas. Unit mass resolution was set in mass-
resolving quadrupole Q1. The intensity of the main ion of the analyte was 
monitored and the parameters giving the highest signal were used in the final 
method.  
For the UPLC/MS analysis, mobile phases consisted of Milli-Q water (with 0.1% 
formic acid or 10mM ammonium acetate, solvent A) and methanol (with 0.1% 
formic acid or 10mM ammonium acetate, solvent B) were delivered by UPLC at 
the optimized flow rate of 0.2 mL/min. The elution conditions were: linear gradient 
of 35 to 65% solvent B (0-10 min), isocratic at 65% solvent B (10-11 min) and 
isocratic at 35% solvent B (11-12 min). The injection mode was partial loop with 
needle overfill and the injection volume was 5 µL. The column heater and sample 
manager were set at 60 and 4ºC, respectively. Each wash cycle consisted of 1000 
µL of weak washing solvent (Milli-Q water) and 1000 µL of strong washing 
solvent (methanol).  
5.2.6.2 UPLC/APPI/MS instrumentation and optimization  
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Similar LC and MS configuration was used as described in section 5.2.6.1, except 
that Q-TRAP® 2000 was equipped APPI source, with HPLC grade toluene as a 
dopant of APPI ionization as shown in Figure 5-2. The photoionization lamp used 
was a 10-eV krypton discharge lamp. Nitrogen was produced by a high purity 
nitrogen generator (Peak Scientific Instruments Ltd., Renfrewshire, Scotland), and 
employed as curtain, nebulizer, collision, and lamp gases. Unit mass resolution was 
set in mass-resolving quadrupole Q1. HPLC grade toluene dopant at a flow rate of 
20 μL/ min was delivered using the built-in microsyringe pump (Harvard 
Apparatus Inc., Holliston, MA, USA). 






Figure 5-2 Direct infusion setup of the UPLC/MS system for APPI experiments 
The optimization of LC and MS parameters were performed the same as described 
in section 5.2.6.1, and the optimized parameters were used in the final study. The 
same UPLC elution conditions, except the flow rate (0.1 mL/min), were used here 
in the APPI experiments.  
5.2.7 UPLC/ESI/MS analysis of steroid-HA derivatives 
As stated above, HA has been used as an efficient derivatization reagent for the 
analysis of steroids in previous studies, especially using nanoLC/ESI/MS [393, 
419, 585]. In our study, we investigated derivatization of steroids containing 
carbonyl groups using HA.  
5.2.7.1 Derivatization of steroids with HA 
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Similar HA derivatization protocols have been reported previously [393, 419, 585]. 
Liu et al. performed the reaction by heating the mixture of steroids and HA at 60 or 
70 °C in 70% methanol for 3 h [393, 419], while another study utilized the 
protocol of heating the mixture of steroids and HA in water at 90 °C for 30 min 
[585]. In addition, Liu et al. reported that the incubation of steroids with HA at 
60°C for 3 h gave no or incomplete derivatization of the 11-oxo group and oxo 
groups hindered by two adjacent hydroxyl groups of the steroids [419]. To ensure 
the completion of the derivatization, the reaction should be carried out in 100 µL 
of pyridine at 60 °C for 1 h using 10 mg of reagent. 
In this study, the dried residues purified by SPE were re-dissolved in 300 µL of an 
aqueous hydroxylamine hydrochloride solution (1.5 M) for derivatization. The 
tubes were vortex-mixed and incubated in an oven (Binder, Crown Scientific, 
NSW, Australia) at 90 °C for 60 min. The reaction mixture was added 2 mL of 
methyl tert-butyl ether (MTBE) [585], vortex-mixed for 30 min, and centrifuged at 
13,000 rpm for 30 min. The supernatant containing the derivatives were collected 
and evaporated, and the residue was reconstituted with 50 µL of methanol-water 
(50:50, v/v), and the samples were analyzed on LC/ESI/MS instrument. In 
addition, we followed the protocol from Liu et al. [419] to incubate the samples in 
100 µL of pyridine at 60 °C for 1 h using 10 mg of reagent, in case the 
derivatization for some steroids was not completed.  
5.2.7.2 UPLC/MS instrumentation and optimization 
The same UPLC/ESI/MS system as described in section 5.2.6.1 was used in this 
experiment. The LC and MS parameters were optimized using the same strategies 
and applied in the final analytical method. Mobile phases consisted of Milli-Q 
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water (solvent A) and methanol (solvent B) were delivered by UPLC at the 
optimized flow rate of 0.2 mL/min. The elution conditions were: linear gradient of 
25 to 85% solvent B (0-10 min), isocratic at 65% solvent B (10-11 min) and 
isocratic at 35% solvent B (11-12 min). The injection mode was partial loop with 
needle overfill and the injection volume was 5 µL. The MS was operated in 
positive mode.  
5.2.8 UPLC/ESI/MS analysis of steroid-SBA derivatives 
5.2.8.1 Derivatization of steroids with SBA 
Derivatization conditions were optimized using a mixture of standard steroids 
dissolved in methanol before the biological sample experiments. The effect of 
experimental variables on the efficiency of derivatization was studied. The variable 
investigated included concentration of SBA, type of solvents, reaction time and 
temperature. Chloroform was used first as the solvent in the derivatization, and 
was found to give poor derivative yield. As an alternative, anhydrous acetonitrile 
was used to prepare the SBA solution at the concentration of 10 mM. One mg (in 
methanol solution, 1 mg/mL) of single standard steroid (including DHEA, 17β-
Estrodiol, PREG) or mixture of all the tested steroids, was pipetted into reaction 
vial and blown dried under nitrogen using TurboVap LC evaporator. Thereafter, 
100 µL of SBA solution in anhydrous acetonitrile were added, and the mixture was 
subjected to an incubation in an oven (Binder, Crown Scientific, NSW, Australia) 
at various temperatures (room temperature, 37, 50, 60, 70 and 80ºC) for 0.5, 1, 2, 
4, 6, 8, 10 or 12 h. The resultant derivative mixture was vigorously vortex-mixed 
and subjected to UPLC/ESI/MS.  
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For the biological samples, 100 µL of SBA solution in anhydrous acetonitrile was 
added to the pretreated brain and plasma samples residues. After vigorous vortex-
mixing, mixture was incubated using the optimized conditions, i.e. 60ºC for 2 h, 
and injected for UPLC/ESI/MS analysis. 
5.2.8.2 UPLC/MS instrumentation and conditions 
In this study, a Q-TRAP® 3200 LC/MS/MS system (Applied Biosystems) coupled 
to UPLC was used to achieve higher sensitivity. In this case, both UPLC and MS 
systems were controlled by Analyst® 1.4.2 software. The optimization of the 
compound- and source-dependent MS parameters for the full scan experiments of 
the steroids was performed as described in section 5.2.6.1 using ESI/MS in 
negative mode. Product ion scanning (PIS) experiments was also performed to 
optimize the parameters. Multiple reaction monitoring (MRM) experiment was 
performed to profile the endogenous steroids in rat plasma samples. The parent 
ions of [M+183]– were scanned in quadrupole 1 (Q1), fragmented in the collision 
cell and the products ions were full scanned out of quadrupole 3 (Q3). The 
transition of [M+183]– to 157 or 201 was used in the MRM experiments. To verify 
that all peaks presented in the spectrum came from the same compound, extracted 
ion chromatograms at the masses presented were selected and their retention time 
and peak shape were checked. The analysis of a blank was used to demonstrate 
possible interferences from the mobile phase. The first 1 min of the solvent were 
discarded using the built-in divert valve controlled by the Analyst® software. All 
data were acquired at unit resolution.  
The mobile phases consisted of Milli-Q water (solvent A) and acetonitrile (solvent 
B) both containing 1 mM ammonium acetate. The elution conditions were: linear 
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gradient of 5 to 95% solvent B (0-20.00 min), isocratic at 95% solvent B (20.00-
20.50 min) and isocratic at 5% solvent B (20.50-23.00 min). The flow rate was 0.6 
mL/min and the back pressure was approximately 8600 psi at the initial mobile 
phase condition. The injection mode was partial loop with needle overfill and the 
injection volume was 5 µL. The column heater and sample manager were set at 40 
and 4ºC, respectively. Each wash cycle consisted of 1000 µL of weak washing 
solvent (acetonitrile/methanol/water 40:30:30 v/v) and 1000 µL of strong washing 
solvent (acetonitrile/DMSO 90:10 v/v).  
5.2.8.3 Calibration curves 
Stock steroid mixtures at the concentration of 0.1, 0.5, 1, 5, 10, 50, 100, 500 and 
1000 ng/mL for each steroid were prepared in 6% albumin. Each steroid mixture 
was spiked with a constant amount (100 ng, 100 µL of 1 µg/mL stock solution) of 
IS and then passed through a SPE column, The eluted steroids were derivatized as 
described above. Calibration curves were generated for the range of 0.05–1000 
ng/mL concentration using the peak area ratios calculated against the peak area of 
IS. Each data point represented an average of three replicates. The calibration 
curve was generated using Analyst® software by plotting the peak area ratios (test 
steroids/IS) against theoretical concentrations of each steroid. Accuracies were 
measured based on the expected and experimentally determined concentrations 
obtained for all the analytes using the Analyst® software.  
5.2.9 GC/EI/MS analysis of steroid-HFBA derivatives 
5.2.9.1 Derivatization of steroids with HFBA 
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HFBA has been widely used for the derivatization of steroids for the GC/MS 
analysis in biological samples [401, 403, 586-591]. In the present study, the 
samples were spiked with 1 µg of IS, pretreated using the protocol described 
above, and the extracts were derivatized with HFBA as previously described [401, 
403, 587] with minor modification. Briefly, 1 mL of anhydrous acetone were 
added into the sample residue, and evaporated completely under stream of nitrogen 
using TurboVap® LV evaporator (Caliper life sciences, Hopkinton, MA, USA). 
This step may help to remove the possible residue of the moisture. After that, 50 
µL of HFBA and 200 µL of anhydrous acetone were added and the vial was closed 
with a PFTE-coated screw cap. The reaction mixture was vortex-mixed for 30 s 
and incubated at 60ºC for 60 min. The excess derivatizing reagent was evaporated 
off to dryness under a gentle stream of nitrogen at 40°C and HFBA derivatives 
were reconstituted in 20 µL of GC-grade hexane. The sample was transferred to 
autosampler vials equipped with deactivated glass insert, and 2 µL was injected 
into GC/MS system. For the standard steroids, 10 µL of stock solution (1 mg/mL 
in methanol) for each steroid was added into a reaction vial and dried under stream 
of nitrogen before the derivatization reaction.  
5.2.9.2 GC/MS 
The derivatized steroids extracted from the biological samples were injected into a 
Shimadzu QP-2010 GC/EI/MS system (Shimadzu Corporation, Japan) equipped 
with a DB-5MS thin-film capillary column (30 m × 250 µm i.d., 0.25 µm film; 
J&W Scientific, Agilent Technologies, CA, USA) and an AOC-20i auto injector 
(Shimadzu Corporation, Japan).   
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The GC/MS configuration and condition parameters are summarized in Table 5-4. 
Briefly, injection (2µL) was performed in the splitless mode at 280ºC (2 min of 
splitless injection time). An additional 100 kPa pressure was used to assist the 
sample injection during the sampling time. The ion source and interface 
temperatures were set to 200 and 280ºC, respectively. The GC column oven was 
initially maintained at 60ºC for 2 min, and then ramped from 60 to 220ºC at 
20ºC/min with hold time 2 min, 220 to 300 °C at 3 °C/min (hold time 2 min), 
followed by a 5 min isocratic cool down to 60ºC and an additional 3 min 
equilibration time. The carrier gas, high-purity helium, was maintained at a 
constant flow rate of 1 mL/min during the analysis.  
Table 5-4  GC/MS configuration and condition parameters 
Parameters  Settings 
GC  
Injection temperature (ºC) 280 
Injection mode  Splitless 
Injection volume (µL) 2 
Sampling time (min) 2 
Flow control mode Linear velocity 
Pressure  (kPa) 57.4 
Total flow (mL/min) 50 
Column flow (mL/min) 1 
Linear velocity (cm/s) 36.5 
Purge flow (mL/min) 3 
Split ratio  Auto 
High pressure injection (kPa) 100 
  
GC/MS interface and MS  
Ion source temperature (ºC) 200 
Interface temperature (ºC) 280 
Solvent cut time (min) 5 
Detector gain mode + 0.3v relative to tuning value 
Acquisition mode  SIM 
The samples were firstly qualitatively scanned using full scan mode in the mass 
range of m/z 50-700. For quantitation, the mass spectrometer was operated in the 
selected ion monitoring (SIM) mode. Both full scan and SIM experiments were 
performed in EI ionization mode with an electron energy of 0.3kV plus the 
detector voltage generated in the corresponding tuning file to improve the 
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sensitivity. All the chromatograms were acquired and processed using 
GCMSsolution software (Shimadzu, Japan). Peaks detected with the total ion 
chromatogram (TIC) were identified by comparison of their mass spectra and 
retention times with the tested reference compounds. Peaks with S/N values lower 
than 10 were not accepted for the quantitation. The S/N values were based on the 
masses chosen by the software for quantitation. Peak areas were calculated using 
selected quantitation masses for each analyte and IS. For the specificity, a sample 
was deemed positive for a particular compound if both target and reference ions 
present simultaneously in the range within 0.5% of the relative retention times of 
the reference compound in the spiked samples at 1 µg/mL level. Furthermore, the 
relative abundances of the ions in the sample should be within 50% of that of the 
ions of the reference compound in the spiked sample. 
5.2.9.3 Linearity, LOD and LOQ, carry-over effect and precision 
For the linearity study, stock steroid mixtures were prepared at the concentrations 
of 0.08, 0.4, 0.8, 4, 8, 40, 80 and 400 ng/mL for each steroid in 6% albumin. Each 
sample was spiked with a constant amount (100 ng, 100 µL of 1 µg/mL stock 
solution) of IS and then passed through a SPE column, and the eluted steroids were 
derivatized as described above. Calibration curves were generated for the 
concentration range of 0.8–800 ng/mL using the GC/MS peak area ratios 
calculated against the peak area of IS. Each data point represented an average of 
three replicates. The calibration curve was obtained by plotting the peak area ratios 
(test steroids/IS) against theoretical concentrations of each steroid. A calibration 
curve was prepared and generated for each batch of the biological sample analysis 
to minimize the inter-batch variation. The limit of detection (LOD) and limit of 
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quantitation (LOQ) for each steroid was estimated according to a S/N ratio of 3 
and 10, respectively. The carry-over effect was evaluated by comparing the 
integrated peak areas of steroids obtained from the consecutive analyses of the 
calibrant at the highest concentration (800 ng/mL) versus those of the blank sample 
(hexane).  
For the repeatability study, QC standard steroid mixtures at the concentrations of 1 
and 10 ng/mL for each steroid were prepared in 6% albumin and spiked with a 
constant amount (100 ng, 100 µL of 1 µg/mL stock solution) of IS. The samples 
were analyzed in triplicate to examine the intra-day precision. The GC/MS peak 
area ratios for each steroid were calculated against those of IS, and used to monitor 
the variations of the response for individual steroid.  
5.2.10 Data collection, processing and statistical analysis 
For LC/MS methods, all the data were collected and processed using Analyst® 
software. For GC/MS, GCMSsolution software was used for the data collection 
and processing. Data were expressed as mean ± SD, except otherwise indicated. 
All data were analyzed using SPSS 16.0 (SPSS, Inc., Chicago, IL, USA), while the 
figures were generated using GraphPad Prism 4.0 (GraphPad Inc., San Diego, CA). 
Statistical comparisons for multiple groups were performed using a one-way 
analysis of variance (ANOVA) followed by Student’s Newman-Keuls test. 
Differences between two groups were analyzed using unpaired Student’s t-test 
with unequal variances assumed. Statistical significance was set as P < 0.05.  
5.3 RESULTS 
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5.3.1 Extraction recovery of steroids from biological samples by liquid 
extraction (LE) and SPE 
In this experiment, the recoveries of the intact steroids extracted from the control 
samples prepared in 6% albumin or steroid-free brain homogenates were 
determined using UV detector. The sensitivity of the UV method is crucial. As 
steroid molecules do not contain any strong UV chromophores, the detection 
wavelength used is mostly directed by the parameters of UV detectors used. In 
previously published HPLC methods with UV detection, wavelengths ranging 
from 200 to 220 nm were applied. In this study, UV detector was set at 210 and 
247 nm in dual monitoring mode. Our results showed that the sensitivity satisfied 
the requirements for the recovery study, as steroids could be detected by UV 
detector at 1 µg/mL level. Pregnenolone-16α-carbonitrile was used as IS, as it is a 
stable compound that does not occur naturally, and it does not coelute with or 
interfere with the detection of other steroidal analytes.  
LE is among the commonly used techniques for the extraction of analytes from 
biological samples. The widely used solvent extraction-partitioning methods for 
the extraction of lipids from animal tissues have been well-established by Folch et 
al. [592] and Bligh and Dyer [459]. These methods were based on the ability of 
chloroform-methanol mixtures to form a monophasic system with the water in the 
tissue which will then disrupt the membrane structures and remove the lipid from 
the tissues. In addition to these two methods, various other solvent systems and 
techniques have been used for the extraction of steroids from tissue and cells of 
animal origins. The solvents most frequently used include highly polar solvents 
such as chloroform-methanol mixture [459, 592], methanol [401], ethanol and 
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acetone [593], etc. Although chloroform-methanol mixture was a good solvent for 
the extraction of non-polar steroids, it gave a low yield of total steroids due to its 
poor extraction of polar steroids. Due to the high polarity, aqueous methanol and 
ethanol were not effective to extract all of the non-polar steroids. The extraction 
method involved sequential extraction by continuous mixing with methanol, 
methanol/benzene (1:1) and benzene may result in the good recovery of non-polar 
and polar steroids. However, the high toxicity of benzene needs to taken into 
account before deciding to use extraction schemes based upon this solvent.  
SPE is an extraction method that uses a solid phase and a liquid phase to isolate 
one or more types of analytes from a solution. It is an increasingly useful sample 
preparation technique and has been extensively exploited recently. SPE is a rapid 
and more efficient approach that can be used for analyte extraction, sample 
concentration and clean up, as well as solvent exchange, etc. With SPE, many of 
the problems associated with LE can be prevented, such as incomplete phase 
separations, less-than-quantitative recoveries, and disposal of large quantities of 
organic solvents. SPE provides improved selectivity and specificity, higher 
recovery, greater precision and reduced interferences compared to LE. SPE has 
been widely used in the extraction of steroids from complicated biological samples 
[350, 401, 416]. Different cartridges  such as AMPREP C18 minicolumns [350, 
401], Oasis HLB [402, 594] and Strata X cartridges [416] have been reported.  
In this thesis, the samples collected from animals were pre-treated with Strata X 
cartridge from Phenomenex (Torrance, CA, USA). Our results showed that protein 
precipitation resulted in the recovery of 77.1 ± 5.1 for 17β-estradiol in 6% 
albumin, while SPE obtained better recovery (Table 5-5). Unreasonable recoveries 
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for 21-deoxycortisol, for example 247.4 ± 14.0%, were observed, while the reason 
remains unknown.  
Table 5-5 Recoveries (%) of 17β-estradiol and 21-Deoxycortisol from 6% albumin by SPE 
using various washing (in rows) and eluting solvents (in columns) 
 Methanol Acetonitrile Ethyl acetate Isopropanol 
17β-Estradiol     
H2O 88.9 ± 15.2 91.2 ± 80.0 93.9 ± 7.5 105.0 ± 6.4 
5% Methanol 92.8 ± 5.6 52.2 ± 44.9 86.2 ± 48.9 111.5 ± 1.8 
10% Methanol 83.7 ± 22.0 108.2 ± 7.9 74.6 ± 11.8 119.0 ± 15.9 
20% Methanol 112.5 ± 23.7 150.8 ± 7.9 88.9 ± 15.1 127.5 ± 31.0 
     
21-Deoxycortisol     
H2O 112.0 ± 12.5 147.1 ± 20.7 100.4 ± 10.6 135.9 ± 19.6 
5% Methanol 100.9 ± 5.8 153.2 ± 25.6 109.2 ± 20.2 99.5 ± 25.6 
10% Methanol 121.4 ± 30.0 136.4 ± 9.3 109.1 ± 9.2 112.7 ± 11.9 
20% Methanol 126.6 ± 21.7 130.0 ± 2.5 247.4 ± 14.0 124.6 ± 28.0 
In addition, the combination of 5% methanol in water as washing and methanol as 
elution solvent gave better recoveries of both tested standard steroids. Although we 
did not examine the recovery of sulfated steroids, 40% methanol in water has been 
widely used for the elution of these compounds. In our study, we did not aim at the 
determination of sulfated steroids. As such, the elution of sulfated steroids was still 
involved in the SPE procedures to avoid the possibility of the interference due to 
the sulfated steroids during the subsequent derivatization process. The optimized 
solvents as outlined in Table 5-6 were finally used to extract non-sulfated steroids 
from plasma and brain. 
Table 5-6  SPE for the extraction of sulfated and neutral steroids from brain and plasma samples 
 Solvents Volumes 
Condition Methanol 4 mL 
Equilibration H2O 4 mL 
Washing 10% methanol 4 mL 
Elution of sulfated steroids 40% methanol 4 mL 
Elution of neutral steroids Methanol 4 mL 
 
5.3.2 UPLC/ESI/MS and UPLC/APPI/MS analysis of intact non-derivatized 
steroids 
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The optimized compound- and source- dependent MS parameters used for ESI and 
APPI analyses are summarized in Table 5-7 - Table 5-8, indicates the preferences 
for positive and negative ionization of each steroid. methanol and water were used 
as the mobile phase in both ESI and APPI experiments. The intensity of each 
steroid at the concentration of 1 μg/mL obtained using Q1 mode was monitored 
and compared.  
Table 5-7  Optimized MS parameters used for the detection of endogenous steroids using ESI or 
APPI sources  
Parameters (units) ESI APPI 
Curtain gas (psi) 20 20 
IonSpray or PhotoSpray voltage (V) +5500 / -4500 +/-1200 
Temperature (ºC) 500 350 
Gas 1 (psi) 30 30 
Gas 2 (psi) 50 50 
Declustering potential (V) +/-70 -60 
Entrance potential (V) +/-10 -10 
   
Collision energy (V) +/-50 +/-30 
Collision cell exit potential (V) +/-1 +/-3 
Scan dwelling time (ms) 300 300 
   
Dopant flow rate (μL/min) / 20 
Mobile phase flow rates (mL/min) 0.2 0.1 
With ESI, protonated [M+H]+ or deprotonated [M-H]- ions were formed for all 
tested steroids, using the positive or negative ionization mode, respectively. APPI 
resulted in the same molecular ions for each steroid, except that PREG and 
pregnanolone formed [M]+ ions with positive APPI. 
Table 5-8  IonSpray voltage used for each intact steroids in ESI and APPI studies 
 ESI (v) APPI (v) 
PREG -4500 +1200 
Pregnanolone +5500 +1200 
PROG +5500 -1200 
21-Hydroxyprogesterone -4500 -1200 
17α-Hydroxypregnenolone -4500 -1200 
17α-Hydroxyprogesterone -4500 -1200 
21-Deoxycortisol -4500 -1200 
Cortisol -4500 -1200 
DHEA +5500 -1200 
Androstenedione -4500 +1200 
Estrone -4500 -1200 
17α-Estradiol   -4500 -1200 
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Allopregnane-3,20-dione +5500 +1200 
3α-OH-DHP -4500 -1200 
Androstanolone +5500 +1200 
Corticosterone -4500 -1200 
17β-Estradiol -4500 -1200 
 
5.3.3 UPLC/APPI/MS vs UPLC/ESI/MS 
The LC and MS parameters were optimized independently for ESI and APPI using 
intact steroids, and ESI using steroid-HA derivatives. The optimized parameters 
were applied in the analysis of steroid compounds using ESI or APPI source. The 
intensities obtained from LC/MS Q1 mode with steroids at 1 μg/mL were 



















Figure 5-3 Comparison of ESI and APPI analysis of intact steroids and HA-steroid derivatives 
using full scan mode 
 
Our results showed that APPI generates higher sensitivities for most of the steroids 
than ESI, with a ratio factor ranging 1-11.36, except for PREG (0.82), PROG 
(0.31), androstenedione (0.28), allopregnane-3,20-dione (0.63) and androstanolone 
(0.29).  
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In previous studies, excellent sensitivity had been reported for steroid analysis 
using APPI [409, 595-597]. However, Leinonen et al. compared ESI, APCI  and 
APPI for steroid analysis and found that ESI was the best method, although APCI 
and APPI also exhibit good specificity without matrix interference [411]. Our 
results suggested that APPI is more suitable for the analysis of most steroids than 
ESI, although ESI also produced good signals for a small part of the tested 
compounds. 
5.3.4 UPLC/ESI/MS analysis of steroid-HA derivatives  
5.3.4.1 Derivatization of steroids with HA 
The derivatization of steroids with HA was reported previously [393, 419, 585]. 
Liu et al. performed the reaction by heating the mixture of steroids and HA at 60 or 
70 °C in 70% methanol for 3 h [393, 419], while another study utilized the 
protocol of heating the mixture of steroids and HA in water at 90 °C for 30 min 
[585]. Steroid-HA derivatives were reported to be extracted by LE using MTBE 
[585] or C18 SPE columns [393, 419]. In this study, the dried residues purified by 
SPE were re-dissolved for derivatization with 300 µL of an aqueous 
hydroxylamine hydrochloride solution (1.5 M). The tubes were vortex-mixed and 
incubated in an oven (Binder, Crown Scientific, NSW, Australia) at 90 °C for 60 
min. The reaction mixture was added to 1 mL of MTBE, vortex-mixed for 15 min, 
and centrifuged at 13,000 rpm for 30 min. The supernatant containing the 
derivatives were collected and evaporated, and the residue was reconstituted with 
50 µL of methanol-water (50:50, v/v), and the samples were analyzed on the 
LC/ESI/MS instrument [585]. In addition, it was reported that the incubation by 
heating at 60°C for 3 h gave no or incomplete derivatization of the 11-oxo group 
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and of oxo groups hindered by two adjacent hydroxyl groups [419]. In our study, 
to ensure the completion of the derivatization of steroids, the reaction was carried 
out in 100 µL of pyridine at 60°C for 1 h using 10 mg of reagent. In addition, the 
reaction was also performed in an ultrasonic water bath at 60 °C for 1 h.  
5.3.4.2 UPLC/MS analysis of steroid-HA derivatives 
In this study, the carbonyl but not hydroxyl groups of the steroids were derivatized 
using HA to enhance the ESI efficiency and detection sensitivity. After 
derivatization, the carbonyl group was oximated with HA to introduce a nitrogen-
containing group (Figure 5-4), which is very sensitive to positive ESI. The 
generation of these characteristic and intense ions along with their retention 
behavior provided the basis for identification and quantitation of steroids in 
























































Figure 5-4  Reaction of carbonyl-groups (a), steroids 21-hydroxyprogesterone (b), 
androstanolone (c) estrone (d) with derivatizing reagent HA and reaction procedures 
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As each carbonyl group is replaced by one nitrogen-containing group, steroids with 
one carbonyl group formed one derivative, detected as [M+16]+. However, for 
steroids with two carbonyl groups, two derivatives, i.e. [M+16]+ and [M+31]+ were 
detected. Figure 5-5 shows typical selected ion profiles of steroids obtained in a 





Figure 5-5 Chromatograms of steroid-HA adducts for steroids 21-hydroxyprogesterone (a), 








The oximated carbonyls of the fully derivatized steroids yielded a mixture of syn- 
and anti isomeric oximes [598], thus generating chromatographic doublets in some 
cases as shown for 21-hydroxyprogesterone, androstanolone and estrone. 
Interestingly, estrone did not show twin-peaks as the isomers were not separated 
chromatographically. The isomer peaks are theoretically not possible to be 
avoided, as the isomers can always be formed due to the lone pair electrons with 
the nitrogen. Although syn- and anti-isomers did not form in a consistent 
proportion, quantitation based on both peaks could be performed. In certain 
instances (notably trace analyses), the observation of characteristic twin derivatives 
may be diagnostically useful. However, for the steroids with two carbonyl-groups, 
the reaction seemed not to be completed, as some steroids showed both mono- and 
di-substituted HA adducts (Figure 5-5 a). Therefore, the use of catalyst like 
pyridine, longer incubation time, ultrasonication and microwave heating were 
attempted to accelerate reaction of both the carbonyl-groups with the HA 
completely. However, similar results were observed (data not shown). Therefore, 
the doublet derivatives for each steroid with two carbonyl-groups, together with 
the twin-peak for each derivative, rendered the chromatogram more complex for 
interpretation. 
5.3.5 UPLC/ESI/MS analysis of steroid-SBA derivatives 
5.3.5.1 Derivatization of steroid with SBA 
The reaction of SBA with the hydroxyl-group of example steroids (DHEA AND 
17β-estradiol) are shown in Figure 5-6. The derivatization conditions including the 
incubation temperature and time were optimized and presented in Figure 5-7. Our 
results showed that the intensities of the derivatives increased with the incubation 
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temperature (Figure 5-7 A) up to 70ºC when incubated for 2 h. The intensities of 
derivatives reached a plateau after incubation at 70ºC for 2 h, while started to 
decline slowly after that point of time (Figure 5-7 B). This phenomenon might be 
due to the degradation of the derivatives at high temperature. Therefore, to 
minimize the possible degradation, incubation at 60ºC for 2 h was used for the 






















































Figure 5-6 Chemical structures of derivatizing reagent SBA and the reactions with hydroxyl 
group (a), DHEA (b) and 17β-estradiol (c) 









































Figure 5-7  Optimization of incubation temperature for the derivatization of DHEA, 17β-
estradiol and 17α-estradiol with SBA individually in anhydrous acetonitrile for 2 h 
(A); Optimization of incubation time for the derivatization of DHEA, 17β-estradiol 
and 17α-estradiol with SBA individually in anhydrous acetonitrile at 70ºC (B). 
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Table 5-9  UPLC/ESI/MS/MS parameters used for identifications of steroid-SBA derivatives in MRM detection mode 
Steroids MW -OH Groups Theoretically possible MW Observed ions (m/z) Retention time (min) Alcoholic Phenolic Mono- Di- Tri- Parent Daughter 
PREG 316.5 1 0 500.7 / / 499 157 8.13 
Pregnanolone 318.5 1 0 502.7 / / 501 157 8.34 
Progesterone PROG 314.5 0 0 / / / / / / 
21-Hydroxyprogesterone 330.5 1 0 514.6 / / 513 201 6.70 
17α-Hydroxypregnenolone  332.5 2 0 516.7 700.8 / 515 157 7.12 
17α-Hydroxyprogesterone  330.5 1 0 514.6 / / 513 157 12.69 
21-Deoxycortisol  346.5 2 0 530.6 714.8 / 529 157 5.34 
Cortisol 362.5 3 0 546.6 730.8 915.0 545 201 5.55 
DHEA 288.4 1 0 472.6 / / 471 157 6.95 
Androstenedione  286.4 0 0 / / / / / / 
Estrone  270.4 0 1 454.5 / / 453 157 13.93 
17α-Estradiol 272.4 1 1 456.6 640.7 / 455 157 5.63 
Allopregnane-3,20-dione  316.5 0 0 / / / / / / 
3α-OH-DHP  318.5 1 0 502.7 / / 501 157 8.19 
Androstanolone 290.4 1 0 474.6 / / 473 157 7.05 
Corticosterone 346.5 2 0 530.6 714.8 / 529 201 5.99 
17β-Estradiol 272.4 0 1 456.6 / / 455 157 5.98 
Cholesterol 386.7 1 0 570.7 / / 569 157 15.39 
Pregnenolone-16α-carbonitrile (IS) 341.5 1 0 425.5 / / 524 157 7.19 
The specific ion pair transitions were used together with the retention time for identification in the MRM mode of the steroid-SBA derivatives. SBA, 2-sulfobenzoic acid 
cyclic anhydride; /, not applicable. 
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5.3.5.2 UPLC/MS analysis of steroid-SBA derivatives 
The optimized MS parameters for the detection of steroid-SB derivatives are 
summarized in Table 5-10. The MRM chromatogram obtained for 13 pairs of 
parent-product ions is shown in Figure 5-8.  
Table 5-10 Optimized MS parameters for the detection of endogenous steroids and 
pregnenolone-16α-carbonitrile (IS) 
Parameters (units) Values 
Curtain gas (psi) 20 
IonSpray voltage (V) -4500 
Temperature (ºC) 500 
Gas 1 (psi) 30 
Gas 2 (psi) 50 
Declustering potential V) -70 
Entrance potential (V) -10 
  
Collision energy (V) -50 
Collision cell exit potential (V) -1 
Scan dwelling time (ms) 300 
 
 
Figure 5-8  Chromatograms of the steroid-SBA adducts for the mixture of the tested steroids (1 






Figure 5-9  Chromatograms of the steroid-SBA adducts extracted from 1 mL of LH rat plasma. 
The arrows indicate where the steroid-HA derivatives are expected to elute.  
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Our results showed that the calibration curves for each steroid at the concentration 
of 0.1-1000ng/mL were poor, with the correlation efficiency R2 ranging from 0.6 
to 0.8 (data not shown). The poor correlation between the ionization response and 
concentration might be due to the interference of the excess residue of derivatizing 
reagent SBA, which was not removed in this study. In addition, excess SBA was 
found to cause severe ion source contamination, which required regular clean up of 
the MS system. A preliminary experiment using 1 mL of LH rat plasma was 
performed and presented in Figure 5-9. Similar results were obtained when we 
analyzed whole brain homogenate (~1.5 g) of LH rats (data not shown). Our results 
found that only a few steroids (PREG, corticosterone) could be detected using this 
method in the biological samples obtained from rats. Considering the poor linearity 
and unsatisfactory sensitivity, it may be unsuitable for the determination of steroids 
in biological samples especially those from mice. 
5.3.6 GC/EI/MS analysis of steroid-HFBA derivatives 
5.3.6.1 Derivatization of steroids with HFBA and GC/MS analysis of 
derivatives 
In this study, HFBA was used to derivatize the hydroxyl group (Figure 5-10) of 
steroids to enhance their volatility as well as detection sensitivity. 
























Figure 5-10 Reaction of HFBA with the hydroxyl groups and steroid 17β-estradiol 
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Figure 5-11 Chromatogram obtained from rat plasma spiked with 100 ng/mL of each steroid in 
scan mode using GC/EI/MS for epitestosterone (1); 17α-estradiol (2); androsterone 
(3); 17β-estradiol (4); estriol (5); androstenedione (6); DHEA (7); estrone (8); 
androstanolone (9); 3α-OH-DHP (10); pregnanolone (11); PROG (12); PREG (13); 
allopregnane-3,20-dione (14); corticosterone (15); 21-hydroxyprogesterone (16); 
pregnenolone-16α-carbonitrile (IS, 17); cholesterol (18).  
 
The HFBA derivatives of steroid were shown to be stable at temperature of 60 °C 
used in the previous study [590]. The generation of these characteristic and intense 
ions along with retention behavior provided the basis for identification and 
quantitation of steroids in biological matrices. The target and reference ions were 
used together with the retention time for identification in the SIM mode of the 
steroid-HFBA derivatives, while the target ions were used for quantification. 
Figure 5-11 shows a typical selected ion profile of steroids and IS obtained in a 
single GC run. Identified steroids were quantified using two-ion SIM as shown in 





















Table 5-11 GC/MS parameters and validation for the steroid analysis using SIM detection  
Steroids derivatized with HFBA Target ion Reference ion Retention time (min) R2 
Precision (%) LOQ LOD 
1 ng/mL 10 ng/mL (ng/mL) (ng/mL) 
Epitestosterone 680 467 18.56 0.9981 78 7 1.5 0.5 
17α-Estradiol 664 451 18.80 0.9974 10 2 3.3 1.0 
Androsterone 486 442 19.04 0.9965 5 4 1. 3 0.4 
17β-Estradiol  664 451 20.21 0.9971 34 6 5.0 1.5 
Estriol 235 663 20.81 0.9931 59 8 48.0 14.4 
Androstenedione 482 467 20.83 0.9948 65 2 2.7 0.8 
DHEA 270 255 20.91 0.9987 40 7 13.3 4.0 
Estrone 466 422 21.28 0.9972 36 6 29.2 8.8 
Androstanolone 414 486 21.97 0.9991 4 3 1.7 0.5 
3α-OH-DHP 496 514 22.34 0.9989 6 4 4.0 1.2 
Pregnanolone 496 514 22.59 0.9985 7 5 8.0 2.4 
PROG 510 495 24.50 0.9984 1 2 6.7 2.0 
PREG 298 283 24.51 0.9988 6 7 6.7 2.0 
Allopregnane-3,20-dione 231 298 27.02 0.9964 6 3 80.0 24.0 
Corticosterone 705 720 27.48 0.9973 12 13 33.3 10.0 
21-Hydroxyprogesterone  722 707 28.09 0.9997 17 15 32.0 9.6 
Cholesterol 368 369 33.08 0.9974 11 9 2.0 0.6 
Pregnenolone-16α-carbonitrile (IS) 323 308 32.07 / / / / / 
/: not applicable
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5.3.6.2 Quantitation of steroids 
The first stage of this study was to screen for a wide range of pure steroid 
compounds. For this purpose, derivatives of pure steroid standards were used to 
adjust sample injection, temperature, and pressure conditions of the GC for their 
optimum resolution as HFBA derivatives. The HFBA derivative of each steroid 
was individually analyzed for their mass spectrometric behavior. Diagnostic ions 
for each compound were chosen from their mass spectra according to their high 
relative abundance and selectivity, excluding those that might originate from 
overlapping elutions of steroid derivatives. Utilization of these diagnostic ions 
facilitated SIM experiments of endogenous brain steroids at increased sensitivity. 
The ion of higher relative abundance was chosen as the target ion for quantitation 
while the second ion as a qualifier to aid in identification.These ions are also listed 
for the non-biological steroid (pregnenolone-16α-carbonitrile) that was used in this 
study as IS for quantitation. Identification of steroids was based on comparison 
with the retention time and diagnostic ions of standards. This initial screen 
monitored 18 steroids simultaneously in a single run, as indicated in Figure 5-11. 
5.3.6.3 Linearity, LOD and LOQ, carry-over effect and precision 
The linearity of the calibration curve for each steroid was listed in Table 5-11. Our 
results indicated good correlation between the mass spectrometric response and 
concentrations of steroid within the range of 0.4-400 ng/mL. Also shown in Table 
5-11 were the intra-day precision, as well as the LOD and LOQ for each steroid. 
No carry-over contamination was observed between consecutive injections. The 
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intra-day variation was not examined as all the samples used for the comparison 
purpose could be finished in one batch.  
5.4 DISCUSSION 
Both LC/MS and GC/MS have been widely used for the determination of steroids 
in biological samples. Normally, derivatization procedures are used to improve the 
ionization efficiency of steroids due to the lack of functional groups with steroid 
that can be easily ionized. In this study, LC/APPI/MS analysis was first examined 
and compared with LC/ESI/MS to examine the feasibility of analyzing intact 
steroids to avoid the comparatively more tedious derivatization procedures. In 
addition, derivatizing reagents aiming at either carbonyl- or hydroxyl- group was 
used to generate the HA and SBA derivatives, respectively, for LC/ESI/MS 
analysis. Moreover, GC/EI/MS determination of steroid-HFBA derivatives were 
investigated.  
5.4.1 Extraction of steroids 
Steroids consist of an essentially non-polar lipophilic 
cyclopentanoperhydrophenanthrene nucleus modified on the periphery of the 
nucleus or on the side chain by the addition of polar hydrophilic groups. During 
metabolism, steroids become more hydrophilic by esterification (conjugation) with 
glucuronic or sulphuric acid. Despite these polar groups, the relative non-polarity 
of steroids means that they are soluble in organic solvents to varying degrees and 
thus can be extracted from aqueous media by an organic solvent or solvent mixture 
of suitable polarity. Steroids secreted in vivo are carried in the bloodstream bound 
to plasma proteins, especially globulins or albumin. While globulins usually have 
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high binding affinity for steroids, its binding capacity is low. On the other hand,  
albumin has low affinity but high capacity for a wide variety of steroids. Some 
steroids are incorporated as an integral part of plasma lipoproteins, and these 
lipoproteins may in turn form part of the structures of cells and tissues from which 
steroids may need to be extracted. The presence of the steroid binding proteins and 
their interaction with the steroid of interest is an important consideration when 
deciding how best to develop a method for the analysis of a particular steroid.  
SPE has steadily gained acceptance within the analytical techniques and is now 
rapidly replacing traditional LE as the sample preparation technique. In this study, 
a previously reported protocol with minor modification was used [401]. The 
present study employed methanolic extraction of steroids from plasma or brain 
followed by SPE to separate free steroids and steroid sulfates completely before 
the MS-based analyses.  
Methanol-based solvent mixtures [394, 401] were most widely used to precipitate 
proteins and extract steroids from biological samples before the SPE clean-up. In 
this study, acidified methanol with 1% of acetic acid was used to break steroids 
from their binding proteins and precipitate the proteins and lipids after 
centrifugation. Using this protocol, Liere et al. obtained almost 100% recovery of 
added deuterated steroids into the methanolic brain extract [401]. During the 
evaporation of methanolic extract in our preliminary experiment, however, acetic 
acid was found not be removed via evaporation by high flow of nitrogen at 50ºC 
for 3 h. Therefore, freeze-drying was used instead of blow-drying by nitrogen as 
the former was found to be more efficient. Steroid conjugates were not analyzed in 
the present study. Therefore, after loading the reconstituted methanolic extract onto 
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the SPE column, methanol/water (40:60) was added to remove the sulfated steroids 
from the free steroids. In terms of SPE, the recovery of 17β-estradiol and 21-
deoxycortisol were found to be 92.8 ± 5.6 and 100.9 ± 5.8, respectively. 
5.4.2 MS-based analysis of steroids 
The general goal of this study was to explore the metabolic profiling of free 
steroids in complex biological samples. As mentioned above, GC/MS is the most 
popular method for both free and conjugated steroids after hydrolysis, liquid 
extraction and derivatization. To maximize sensitivity, free steroids are often 
measured separately after extraction and derivatization. While such methods are 
well developed, they are time consuming and challenged by some problems such 
as the possible thermal decomposition of derivatives during analysis. Hence, the 
development of more rapid and straightforward methods that requires less sample 
preparation procedures is of great interest. In the initial stage of the study, we 
aimed at developing analytical methods that are free from laborious sample 
preparation procedures such HPLC fractionation and derivatization.  
Compare to GC/MS, LC/MS provides several advantages for steroid analysis, such 
as allowing the direct detection of intact steroid without hydrolysis and 
derivatization steps, reducing the analysis time, and decreasing the use of 
hazardous reagents. Furthermore, LC/MS allows the determination of thermally 
labile compounds. However, our extensive literature review found that although 
ESI [595, 599], APCI [600] or APPI [596, 597] has been used for the analysis of 
steroids, there were some limitations associated with each of them. ESI was mainly 
used to measure the anabolic steroids in horse urine, with higher concentration and 
more sample amount available, but may not be sufficiently sensitive for the 
 194 
analysis of endogenous steroids [393, 408]. APCI is more suitable than ESI for the 
analysis of neutral compounds like steroids and is not as susceptible to matrix 
suppression. However, it often suffers from high background and therefore does 
not always provide the high sensitivity required in the analysis of endogenous 
steroids [409].  
The recently introduced APPI is a novel ionization method for LC/MS, which is 
especially more suitable for less polar compounds [601, 602]. APPI is initiated by 
10 ev photons emitted from a krypton discharge lamp. In dopant assisted APPI, the 
photons first ionize a dopant, a substance of ionization energy below the energy of 
photons, which is present in larger amounts than the analytes [601]. Once formed, 
the dopant molecular ions can then react with the solvent through proton transfer or  
with analytes through charge exchange in case the ionization energies of the 
analytes are below that of the dopant [603]. Therefore, the route of ionization and 
thus the selectivity of the method can be affected by the choice of solvent and 
dopant [603, 604]. The selectivity toward photoactive analytes in better with APPI 
and the amount of background is significantly lower than with APCI. Therefore, 
better sensitivity is usually obtained with APPI than with APCI [412, 601]. APPI 
has also been found less susceptible to matrix effects than ESI or APCI [605-607]. 
APPI has been utilized in the analysis of polar as well as non-polar analytes and it 
has been shown better universality with greater structural diversity than ESI and 
APCI [603, 608, 609], especially for non-polar and low-molecular mass 
compounds that cannot be analyzed efficiently by the other two methods [412, 609, 
610], including steroids [409, 596, 597, 601, 611]. Guo et al. successfully 
developed and validated a method using APPI method, with excellent LODs of 1-
10 pg/mL for 12 steroids and simple sampler preparation in human serum [597]. 
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However, that study was performed on an API-5000 triple-quadrupole mass 
spectrometer, which is much more sensitive than our Q-TRAP. Indeed, the 
previous reports on the ionization efficiency of APPI, ESI and APCI for steroids 
were contradictory. Kauppila et al. [409] reported that APPI was superior in 
sensitivity for all the steroids tested including estradiol and DHEA than APCI, 
while Leinonen et al. [411] found ESI gave them the best signals.  
In this study, the applicability of ESI and APPI for the detection of the free 
anabolic steroids was examined and compared. Our results suggested that APPI 
was sensitive for the analysis of more underivatized steroids than ESI. However, 
our preliminary experiment on the analysis sensitivity of APPI analysis suggested 
that our APPI source equipped on an API Q-TRAP mass spectrometer may not be 
able to detect trace amount of endogenous steroids in biological samples. 
Therefore, derivatization of steroids using proper reagent to improve the sensitivity 
became necessary. HA has been used to derivatize the carbonyl group of steroids 
improve the ESI sensitivity [393, 421]. Our results showed that steroid-HA 
derivatives obtained 1.4-108 times higher intensity than with intact steroids using 
ESI method. Nonetheless, the formation of cis- and trans- isomeric oxime 
derivatives became a challenge, as the isomers were separated chromatographically 
by UPLC and therefore increased the apparent complexity of mixture analysis. In 
certain instances (notably trace analyses), the observation of characteristic twin 
derivatives may however be diagnostically useful. Interestingly, a recent paper on 
the analysis of testosterone and DHEA after derivatization with HA using 
UPLC/MS/MS was reported [421]. This study showed baseline separation of the 
testosterone isomers but no discernable separation of the cis- and trans-DHT 
species.   
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Compared with positive ESI/MS, negative ESI/MS is expected to provide greater 
sensitivity, as the background noise is relatively lower using this mode. In this 
study, SBA was successfully used as a derivatizing reagent for the analysis of 
steroids containing hydroxyl group. We developed a reaction solvent system using 
anhydrous acetonitrile, as chloroform and pyridine did not result in the derivatives. 
However, the poor linearity of the developed method prevented it to be used for the 
analysis of steroids in biological samples. A further SPE clean-up step to remove 
the excess SBA reagent may help to improve the linearity and make it possible to 
detect some steroids in the biological samples. However, this extra clean-up step 
can be cumbersome and time-consuming.  
Most non-conjugated steroids are amenable to gas phase analysis after suitable 
chemical modification like derivatization. For GC/MS analysis, the general reason 
for employing a derivatization procedure is to permit or optimize mass 
spectrometric analysis, such as conferment of volatility and improvement of 
stability. A derivatization procedure may be defined as a microchemical reaction of 
predictable consequence that retains the essential structural feature of the analytes. 
Thus, conversion of an alcohol to an ether is a simple example of a derivatization. 
The method developed by Liere et al. [401] using HFBA has been widely used in 
the measurement of endogenous steroids in biological samples such as human 
brain [350] and rat plasma and brain [394, 403]. Therefore, this well-established 
assay may provide a reliable and accurate platform for the profiling and 
determination of steroids in the biological samples. However, this method requires 
elaborate sample preparation especially HPLC fractionation [401]. Therefore, we 
avoided this step to simplify the sample preparation procedures. Based on our 
results, GC/MS method was still advantageous compared to various LC/MS based 
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analytical methods, due to its higher sensitivity, better resolution and specificity. 
Unfortunately, our results showed that the sensitivity of this method was not 
sufficiently high to quantitate the endogenous steroids in complex biological 
samples using this method, although we have successfully developed and validated 
it in our laboratorywith comparable LOD and LOQ with other previous study 
[401]. In addition, we found that the HPLC fractionation procedure is still 
necessary for the steroid analysis using GC/MS method. Moreover, some 
biological samples used in this study were limited in the amounts, such as plasma 
(around 0.6 mL) and brain (around 400 mg) obtained from mouse models. These 
limited samples did not allow us to profile the steroids using multiple analytical 
approaches.  
In this chapter, we discussed several MS-based approaches in measuring 
endogenous steroids. Although none of the described methods could be applied 
directly to our steroid experiments in vivo, our study generated pertinent 
information that are useful for the bioanalysis of endogenous steroids in biological 
systems. In addition, with the progression of MS technologies which could provide 
us higher sensitivity, it would be interesting and promising to profile the 
endogenous steroids using MS approaches in complex biological samples.  
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CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 ACHIEVEMENTS AND CONCLUSIONS 
In this thesis, we aimed at investigating the non-targeted metabolic and targeted 
steroidal biomarker profiling of aging and AD using both in vivo and in vitro 
models.  
We performed the metabolic profiling experiments and discovered marker 
metabolites associated with aging and AD using GC/MS-based metabonomics and 
multivariate data analysis. In this study, both C57BL/6J mouse (1-month vs 5-
month) and LH rat (2-month vs 2-year) models were analyzed using GC/MS to 
identify the small molecule metabolites related to aging. In addition, both young 
and aged LH rats were treated with LA, and the resultant metabolic profiles were 
investigated and compared to elucidate the effects of the pharmacological 
intervention on aging. To identify the marker metabolites of AD, the metabolic 
profiles of two transgenic AD mouse models, TASTPM and p25-induced mice, 
were examined and compared to those of the wild type mice (C57BL/6J). 
Moreover, an in vitro cortical neuron cell model was further investigated to 
elucidate the changes in metabolic profiles related to aging and glutamate-
treatment, which may be implicated in the pathogenesis of AD. Our study 
demonstrated clear differences in metabolic profiles associated with aging and AD 
in both the in vivo and in vitro models. A number of metabolites were found to be 
associated with aging and AD, with different metabolites observed between the 
different aging and AD animal models. Moreover, LA treatment also lead to 
pertinent changes of metabolite profiles in LH rats. 
 199 
On the other hand, we determined the steroid levels in aging and AD models, as 
well as developed and compared various MS-based analytical techniques for the 
profiling of endogenous steroids in biological samples. The brain and plasma 
samples obtained from animal models were investigated for the endogenous 
steroids using EIA. We found that some endogenous steroids, such as DHEA and 
corticosterone, in brain and plasma of mouse and rat models were changed 
consistently with aging and AD.  
Our results suggested that global metabolic changes were associated with aging 
and AD in the metabolism pathways of TCA cycle, sugar, fatty acid and amino 
acid, etc. Some marker metabolites such as myo-inositol and cholesterol identified 
in our study were consistent with the previous reports. The metabolic difference 
among various animal models may indicate the presence of inter-species variation. 
Our results suggested that the identified small molecule marker metabolites might 
be promising biomarkers for the diagnosis of AD, which may subsequently 
accelerate the preclinical R&D in pharmaceutical industry. LA treatment may be 
beneficial to aging or even reverse the aging process in LH rats. To the best of our 
knowledge, this is the most comprehensive metabolic profiling study of aging and 
AD involving various biological samples obtained from a variety of models. In 
addition, this is also the first study that investigated the metabolic profiling 
associated with aging in cortical neuron cells and LH rats, as well as the metabolic 
profiling of AD in TASTPM mice, p25-induced mice and glutamate-treated 
cortical neuron cells. Our findings may be helpful in the better understanding of 
the global metabolic profiling associated with aging and AD in these models. The 
MS-based methods examined in our laboratory did not provide us a practical assay 
for the profiling of steroids in biological samples due to either the relatively poor 
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specificity or sensitivity. The problems encountered in the bioanalysis of steroids 
in biological samples were presented and discussed. However, it is still promising 
to develop the MS-based platform for the profiling of steroids using newly 
emerged MS technologies in the future.  
In our study, we discovered some potential metabolite and steroid biomarkers for 
aging and AD using GC/EI/MS platform and multivariate data analysis. These 
markers are still needed to be further validated in the future, particularly by 
quantitation using authentic standards. Our results also suggested that a group of 
biomarkers rather than a single one could be used for the differentiation of aging 
and AD. These biomarkers, if used for disease diagnosis or drug evaluation, should 
change linearly with disease progression and correlate closely with established 
clinico-pathological parameters of the disease. It is unlikely that any single 
biomarker would fulfill all these requirements. More likely, a group of biomarkers 
will be needed for the early diagnosis and similarly for evaluation of disease 
progression for therapeutic trials. For example, the combination of more detailed 
clinical assessments encompassing specific cognitive and neuro-physiological 
testing, in addition to imaging, biochemical and genomic profiling, is likely to be 
needed [612]. Although outside the scope of this thesis, it is noteworthy that 
metabonomics should ideally form part of systems biology-based strategy for the 
study of organisms integrated with other “-omics” technologies such as genomics 
and proteomics [552-554]. 
6.2 FUTURE DIRECTIONS 
Although substantial results have been generated from our study, there remained 
some areas, which need to be improved or addressed in future studies: 
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1. Regarding the data acquisition platform, NMR, GC/MS and LC/MS(/MS) 
are the prevalent techniques at present. None of them, including GC/EI/MS 
that was used in our study, is a perfect technique that could meet all the 
requirements of metabonomics in measuring metabolites globally. To date, 
it has not been possible to accurately determine the levels of all metabolites 
simultaneously, because of the substantial chemical and physical 
heterogeneity of the metabolome. In our lab, some new instruments, 
including UPLC/QTOF/MS (Waters) and GC×GC/TOFMS (LECO) are 
available recently. Therefore, a complementary platform, especially 
UPLC/QTOF/MS, could be used to expand the metabolic space that can be 
profiled;  
2. It is advisable to accurately quantitate the confirmatively identified 
biomarkers using LC/MS/MS method in the future study;  
3. Older C57 mice than 5-month of age should be included to mimic the aging 
process of this species;  
4. The sample sizes involved in some experiments of this thesis were 
comparatively small, which should be scaled-up in the future study;  
5. Both a training set and a test set should be included to examine the 
specificity and sensitivity of the markers;  
6. Due to the possible inter-species variability, a clinical trial should be 
performed to examine the biomarkers in healthy aged subjects and AD 
patients, although human trials in AD are difficult, costly and time-
consuming due to the slow disease course, insidious onset and patient-to-
patient variability;  
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7. Due to the emergence of “targeted metabonomics”, such as “steroidomics 
in the brain” [582], it is interesting develop an assay with greater specificity 
and sensitivity for the profiling of endogenous steroids in biological 
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